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ABSTRACT 
 
SYNTHESIS AND CHARACTERIZATION OF STAR BLOCK 
COPOLYMER FOR CONTROLLED DRUG DELIVERY 
 
Amphiphilic multiarm block copolymers of hydrophobic poly(methyl 
methacrylate) core and hydrophilic poly(acrylic acid) corona has been synthesized, 
characterized and proposed for an anticancer drug that is 5 Florouracil (5FU). 3 arm, 4 
arm and 6 arm PMMA-b-PtBA (poly(methyl methacrylate-block-poly(tertiary butyl 
acrylate)) copolymers with molecular weights from 18 kDa to 80 kDa were synthesized 
by Atomic Transfer Radical Polymerization and reacted into PMMA-b-PAA 
(poly(methyl methacrylate-block-poly(acrylic acid)) by hydrolysis of tBA chains. 
Optimum molecular weight and hydrophobic core ratio was determined by evaluation of 
critical micelle concentrations and maximum loading capacities with pyrene. Loading 
method was selected among simple equilibrium, solvent deposition, salting out and 
dialysis methods. Dialysis method yielded the highest loading contents of model drug 
indomethacin.  Optimum loading conditions in terms of  temperature, duration, pH and 
polymer concentration were determined with anticancer drug 5FU. 4 arm PMMA-b-
PAA with molecular weight 18000 Da and hydrophobic core ratio 0.27 was proposed 
for controlled delivery of 5FU. Optimum loading conditions were determined as 15°C 
in acidic aqueous medium with pH 1.0-1.5 and loading interval as 4 hours. Minimum 
polymer concentration was estimated to be 2000 mg/L for an optimum loading. Drug 
loaded particles were characterized by FTIR, TGA, DTG and DSC. 5FU loaded 
PMMA-b-PAA samples with drug contents about 14-20 % were investigated by a 
continuous operation where a diffusion cell was employed to monitor release profiles. 
Controlled release of 5FU with zero order release kinetics for 18 days was provided by 
4 arm PMMA-b-PAA. Biodegradation of loaded particles were monitored through 
particle size analysis by Dynamic Light Scattering and Atomic Force Microscopy. 
 
 
 
 
 
 v
ÖZET 
 
KONTROLLÜ İLAÇ AKTARIMI İÇİN YILDIZ BLOK KOPOLİMER 
SENTEZİ VE KARAKTERİZE EDİLMESİ 
 
Hidrofobik poli(metil metakrilat) merkez etrafında hidrofilik poli(akrilik asit) 
çeperden oluşan amfifilik yıldız blok kopolimerler sentezlendi ve kanser ilacı 5 
Florourasil taşıyıcısı olarak kullanılmak üzere karakterize edildi. 18 kDa-80 kDa 
molekül ağırlığı aralığında 3-kollu, 4-kollu ve 6-kollu PMMA-b-PtBA (poli(metil 
metakrilat)-blok-poli(tersiyer bütil akrilat) kopolimerleri Atomik Transfer Radikal 
Polimerizasyon tekniğiyle sentezlendi ve tBA kollar hidroliz reaksiyonuyla akrilik asite 
dönüştürüldü. Kritik misel konsantrasyonları ve maksimum piren yüklenme kapasiteleri 
değerlendirilerek optimum molekül ağırlığı ve hidrofobik merkez oranı belirlendi. 
Model ilaç olarak kullanılan indometazinle yapılan deneylerde en yüksek yükleme 
miktarı diyaliz yöntemiyle elde edildi. Diyaliz yöntemiyle optimum yükleme 
koşullarının belirlenmesinde model ilaç olarak kanser ilacı 5-florourasil kullanıldı. 18 
kDa molekül ağırlığı ve 0.25 hidrofobik merkez oranına sahip 4-kollu PMMA-b-PAA 
kopolimerin kontrollü 5FU salımı için optimum yükleme koşulları 15°C’de, 1.0-1.5 pH 
aralığında sulu çözelti içinde, yükleme süresi 4 saat ve minimum polimer 
konsantrasyonu 2 g/L olmak üzere belirlendi. İlaç yüklü polimer numuneleri FTIR, 
TGA, DTG ve DSC ile karakterize edildi. 5FU yüklenme miktarları 14-20% olan 
PMMA-b-PAA numuneler difüzyon hücresine yerleştirildi ve salınan ilaç miktarları 
UV-spektroskopi yöntemiyle belirlendi.  4-kollu PMMA-b-PAA kopolimeriyle 18 gün 
süresince kontrollü salım sağlandı. İlaç yüklü polimerlerin biyolojik parçalanma 
özellikleri Dinamik Işık Saçılımı ve Atomik Güç Mikroskopi yöntemleriyle belirlenen 
parçacık büyüklükleri bazında incelendi.   
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CHAPTER 1 
 
INTRODUCTION 
 
Water soluble amphiphilic polymer particles are good candidates for drug 
delivery with their thermodynamic and kinetic stabilities, high drug loading capacities 
and low critical micelle concentrations. Their structures with hydrophobic cores and 
hydrophilic coronas provide beneficial properties such as elimination of additional 
surfactants in drug formulations, protection of drug from premature degradation and 
opportunities for controlled and targeted delivery (Leroux and Ranger, 2002; Nishiyama 
and Kataoka, 2006).  
One of the best candidates for delivery of hydrophobic drugs is star polymers 
which are branched polymer chains around a multifunctional core. The number of the 
active sites of the core molecule of a unimolecular polymeric carrier determines the 
number of arms. They may be classified as dendrimers, symmetrical star block 
copolymers and miktoarm block copolymers where each arm is another type of  
polymer chain (Deng et al., 2007; Tunca et al., 2002). Synthesis of miktoarm star 
polymers requires sophisticated initiators whose active sites show different reactivities 
with different monomer species. 
Dendrimers are the most famous star shaped polymers introduced by Tomalia’s 
and Freche’s studies in 1980’s. Polyamidoamine (PAMAM) is the most widely studied 
dendrimer for biomedical applications and is reported to be stable, biodegradable and 
nontoxic under certain conditions (Svenson and Tomalia, 2005; Patri et al., 2005; 
Tomalia et al., 2006). Dendritic structures including all star shaped polymers can be 
synthesized by two techniques as shown in Figure 1.1. These may be explained as 
achieving the synthesis around a core and repeating the procedure for addition of 
branches several times (divergent method) or, simply producing the branched chains 
and attaching them around an initiator which has various active sites (convergent 
method).  
PAMAM is produced by divergent synthesis while dentritic structures of block 
copolymers of polyethyleneoxide (PEO), mostly studied by Fréchet and coworkers 
(Tomalia and Fréchet, 2005; Grayson and Fréchet, 2001, Gillies and Fréchet, 2004), are 
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synthesized by convergent methods. But the synthesis of dendrimers are hard to control 
in either cases and the reaction yields are low. Hence star block copolymers constitute a 
good alternative with the possibility of using controlled polymerization techniques.  
 
 
 
 
Figure 1.1.  Schematic presentation of divergent and convergent synthesis 
(Source: Tomalia et al., 2006). 
 
 
Star block copolymers are the most versatile type of dendritic structures with the 
numerous possibilities of synthesis, modifications and applications. They can be sorted 
according to number of arms and distribution of polymers that constitutes the star 
shaped polymer as summarized in Figure 1.2 (Haddleton et al., 1997; Ganguly, 2002; 
Kilian, 2004; Yin et al., 2005; Chu et al., 2004; Ishizu and Uchida, 1999). Amphiphilic 
structure is often produced by block copolymers constituting hydrophilic and 
hydrophobic polymer blocks in numerous shapes, built by both convergent and 
divergent techniques Such block copolymers have recently drawn significant attention 
with their perfect solubilizing properties (Kilian, 2004). Their potential in drug delivery 
area has also been widely studied, especially in gene delivery, and delivery of 
chemotherapeutic agents (Gaucher et al., 2005; Kakizawa and Kataoka, 2002).  
 
 
Divergent Growth 
Convergent Growth 
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Figure 1.2. Schematic representation of simple AB graft, AnBn, and (AB)n star-block 
copolymers. (Source: Ishuzu and Uchida, 1999) 
 
 
Star block copolymers form polymeric micelles where interior spaces of 
polymeric structure constitute a reservoir for the drug. Hydrophobic cores and 
hydrophilic coronas are particularly favoured to solubilize hydrophobic drugs. The 
substance can be stocked in the particles by hydrophobic-hydrophobic interactions, 
diffusion or conjugation (Marion et al., 1999; Chytil et al., 2006). Star block copolymers 
have also been proposed as good candidates for smart drug delivery systems like pH 
sensitive, thermosensitive or targeted drug delivery. Generally polyethylene glycols, 
polylactides and block copolymers of poly ethylene oxides have been used for drug 
delivery studies for they are approved biodegradable and biocompatible polymers. 
Polystyrene has also been widely investigated for core-and-shell type unimolecular 
polymer structures. In the last decade, acrylic block copolymers have gained attention 
for their extremely low critical micelle concentrations, amphiphilic properties and 
relative ease of controlled polymerization techniques.  
ATRP (Atom Transfer Radical Polymerization) is a beneficial controlled 
polymerization technique for it allows shorter reaction times at high reaction 
temperatures and yields acceptable polydispersities (Krishnan and Srinivasan, 2004). 
Block copolymers synthesized by controlled polymerization techniques can be designed 
as linear, branched or star shaped unimolecular structures. The linear block copolymers 
may act as surfactants in aqueous media and produce polymeric micelles with low 
Simple AB Graft Copolymer 
 
 
 
 
A2B2 Star-Block Copolymer 
 
 
 
 
(AB)4 Star-Block Copolymer 
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critical micelle concentrations (Gaucher et al., 2005). The critical micelle concentrations 
of star block copolymers are even lower. Block copolymer systems, linear or star 
shaped, have been widely studied for their loading capacities with various hydrophobic 
drugs and have shown versatile characteristics in terms of drug loading, drug release 
performance, critical micelle concentrations and cytotoxicity. Each parameter has been 
claimed to depend on molecular weight, arm length, composition and concentration of 
the polymer, drug type, dosage and preparation method. Therefore, polymer architecture 
is quite important when the material is to be used as a drug carrier for controlled 
delivery. Whether they are used for oral, intravenous or transdermal drug delivery, drug 
loading capacity, release kinetics, particle stability and compatibility are all related with 
polymer architecture as well as molecular weight and type of polymer (Qiu and Bae, 
2006). 
 Controlled and sustained delivery profiles are not only desired to provide 
constant plasma levels of the drug after administration. With polymeric particles that are 
capable of sustained and/or controlled drug delivery, enhanced permeability and 
retention characteristics of cancerous tumors can be expected to serve for the wellbeing 
of the patient. This expectancy can be explained by increased drug levels in tumors by 
passive diffusion. Polymeric micelles have been reported to show prolonged circulation 
times after intravenous administration and minimum accumulation in liver. Besides 
drug distribution is reported to be higher in tumors due to perivascular accumulation of 
macromolecules in tumor tissues with reduced drug levels in general (Sahoo and 
Labhasetwar, 2003). 
Especially for amphiphilic systems, properties of the core material such as 
hydrophobicity and size of the core are known to be important parameters that 
determine the performance of polymer in specific applications. It has been reported that 
hydrophobic core block-length determines stability and loading performance as well as 
release kinetics. Drug loading performance of the polymer synthesized is expected to 
increase with increasing molecular weight of hydrophobic core. On the other hand, high 
molecular weight PMMA cores were not desired for they don’t produce biodegradable 
polymeric materials. Therefore an ideal polymeric micelle for drug delivery purposes 
must comprise a PMMA core at a molecular weight of oligomer level where PMMA 
core has to have 10-100 repeating units (Allen et al., 1999) and the resulting polymer 
should not be greater than 50000 Da in molecular weight (Bontha et al., 2006; 
Nishiyama and Kataoka, 2006). 
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In our study main purpose is to synthesize biocompatible and biodegradable 
amphiphilic nanoparticles that can be effectively loaded by an anticancer drug and tend 
to accumulate in solid tumors by avoiding reticuloendothelial system. For this reason 
polymeric micelles with particles sizes less than 100 nm, made of hydrophobic PMMA 
core and hydrophilic PAA shell have been synthesized and characterized. Considering 
all the approaches and requirements summarized above, an ideal carrier was tried to be 
selected among various star block copolymers (# arm PMMA-b-PAA) with different 
number of arms, molecular weights and hydrophobic core ratios. The star block 
copolymers PMMA-b-PAA were synthesized by atomic transfer radical polymerization 
(ATRP) technique through a two-stage reaction and hydrolysis. The polymers 
synthesized were investigated in terms of their critical micelle concentrations, 
maximum loading capacities and drug loading efficiencies. 4 arm PMMA-b-PAA with 
molecular weight about 20 kDa and hydrophobic core ratio of 0.25 is proposed as an 
ideal drug carrier for parenteral administration and controlled delivery of a widely used 
anticancer drug, 5 Fluorouracyl. 
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CHAPTER 2 
 
LITERATURE REVIEW 
 
2.1. Atomic Transfer Radical Polymerization 
 
Star polymers have drawn attention as one of the most promising materials for 
biomedical applications. They can be tailored for specific purposes providing many 
opportunities in synthesis (selection of initiators, monomers, catalysts, reaction media, 
etc.) through the use of controlled polymerization techniques.  
The controlled polymerization methods used for the synthesis of block 
copolymers from vinyl monomers can be listed as ROP (Ring Opening Polymerization), 
SFRP (Stable Free Radical Polymerization) and ATRP (Atomic Transfer Radical 
Polymerization) can be employed in various combinations (Tunca et al., 2002; Celik et 
al., 2003; Erdoğan et al., 2004) ATRP is a beneficial controlled polymerization 
technique for it allows shorter reaction times at high reaction temperatures and yields 
acceptable polydispersities (Krishnan and Srinivasan, 2004; Brar and Saini, 2007). 
Since the initiation is fast and termination is negligible for controlled polymerization 
techniques, ratio of dead chains are as small as 10% compared to conventional radical 
polymerization. Another important advantage is possibility of elimination of catalysts 
used in controlled polymerization while initiator residues inevitably remain in final 
polymer in radical polymerization (Braunecker and Matyjaszewski, 2007). 
Major advantage of ATRP among radical polymerization techniques is 
availability of reagents which are procurable commercial chemicals such as alkyl 
halides, transition metals and various ligands. Another important advantage ATRP 
provides is the precise control over polymerization reaction. Zhao claims that ATRP 
reaction has almost linear kinetics which paves the way for high reaction yields (Zhao et 
al, 2001).  Polymerization rate mainly depends on initiator concentration and ratio of 
activator to deactivator concentration as in Equation 2.1. 
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Rp is the rate of polymerization, Kp is the propagation constant,  [M] is the 
monomer concentration, and [R·] is the concentrtation of organic radicals generated 
from alkyl halide initiator (RX). KATRP is the ratio of activation constant to deactivation 
constant (=Ka/Kd). LmMet+n is a transition metal complex that cleaves the alkyl halogen 
bond of RX and genertes the organic radical species besides the metal halide complex 
having a higher oxidation state notated as LmMet+(n+1)X.  The organic radicals (R·) may 
either propogate or terminate after they are generated but termination at this stage is 
generally negligible for ATRP reactions (Braunecker and Matyjaszewski, 2007).. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.1 Schematic presentation of atom transfer radical polymerization where Ka is 
rate constant of activation, Kd is rate constant of deactivation and Kp is the 
rate constant of propagation (Source: Ibrahim, 2006).   
 
 
Both kinetics and yield of ATRP reactions can be controlled by two major 
factors; considerably high rate of initiation and persistent radical effect which means 
continuous activity of catalyst through reaction. For a successful ATRP reaction, 
termination of the living polymers must be kept at a minimum level. Termination occurs 
as an undesired reaction between the radical species (RMn·) which appear as active 
species in Figure 2.1. The number of radical species is kept low as the reaction 
equilibrium favors the deactivated (dormant species) side and at low concentration of 
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radical species a minimum termination occurs. Hence, the kinetic behavior of the 
reaction mechanism is vitally important to produce a polymer with controlled molecular 
weight and polydispersity. A fast initiation and rapid reversible deactivation is 
necessary for uniform growth of polymer chains and narrow molecular weight 
distributions. An equilibrium between propagating radicals (or active species) and 
dormant species can be provided by selection of appropriate catalyst and ligand that 
minimizes termination. Therefore it is a critical issue to create an efficient ligand and 
catalyst system for a specific polymer. (Coessens et al., 2001; Ibrahim, 2006)  
ATRP of vinyl monomers require three components: an organo-halide type 
initiator, a catalyst which is salt of a transition metal in lower oxidation state and a 
ligand which is generally an amine compound. ATRP reactions can be mediated by 
various metals such as Ti (Group 4), Mo (Group 6), Re (Group 7), Fe, Ru, Os (Group 
8), Rh, Co (Group 9), Ni, Pd (Group 10) and Cu (Group 11) which is the most efficient. 
Generally used ligands are nitrogen based compounds which can be listed as bidentate 
bipyridine, pyridine imine, tridentate diethylenetriamine, tetradentate tris[2-aminoethyl] 
amine, tetraazacyclotetradecane, etc. (Malinowska et al., 2005; Braunecker and 
Matyjaszewski, 2007). The homogeneity and distribution of reactants is another 
important issue and can be acquired by the ligand. 2,2 bipyridine derivatives or linear 
amines are used as ligands to increase the solubility of the catalyst and accelerate 
copper mediated ATRP reactions. PMDETA (N,N,N’,N”,N”-pentamethyl 
diethylenetriamine) as a ligand was also reported to prove the living character of the 
polymerization and as the most suitable ligand for ATRP of all functional acrylates and 
methacrylates. Type of solvent used as reaction media is effective on solubility of the 
catalyst  (Yin et al., 2005; Ibrahim, 2006).  
ATRP reaction can be used for the both convergent and divergent synthesis of 
star block copolymers. Several molecules with various numbers of active sites can be 
used to initiate reaction. AB and ABC types of block copolymers of a group of 
monomers involving styrene, vinyl pyridine, acrylates and methacrylates can be 
produced by ATRP reactions starting from bromo-macromolecules. (Sun et al., 2005)  
Active sites generally constitute brominated or chlorinated endgroups. Phenolic 
ester based initiators or tetra-, hexa-, octa- functional initiators based  on calyx[n]arene 
cores have been proposed for activation in order to be used in ATRP reactions.  
Multisulfonyl chlorides and brominated D-glucose molecules have also been offered. 
Chlorinated siloxane, brominated phosphazene molecules may well provide multiarm 
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initiators for ATRP. Finally, multifunctional initiators brominated by bromoisobutyryl 
bromide have successfully been used as initiators for ATRP yielding low 
polydispersities. Divinyl benzene is the most widely used initiator in convergent 
approach where polymerized arms are connected to each other to form a unimolecular 
starlike molecule by a difunctional linker which constitutes the very center of the 
molecule.  
ATRP is a robust technique for functional methacrylates. Acrylic acid is an 
exceptional acrylic monomer that is not easily polymerized by ATRP, because carboxyl 
groups of acrylic acid interacts with the catalyst. Use of a precursor like tertiary butyl 
acrylate is preferred for synthesis of poly(acrylic acid). In that case PtBA is synthesized 
through ATRP, at 60-90°C by using CuBr as catalyst in the presence of a ligand which 
may be PMDETA or a specific bipyridine. About 25(v)% solvent would better be added 
to help dissociation of catalyst.  PtBA can then be reacted to poly(acrylic acid) 
(Coessens et al., 2001). 
 
2.2. Biodegradable Polymers Used for Drug Delivery 
 
Smart drug carriers are one of the most attractive research subjects of our era 
since medicine and medical technologies has been developing so fast parallel to 
increasing demand of quality in healthcare. One of the most problematic therapies are 
protein administration and cancer chemotherapy which require controlled doses 
intravenously applied. Most neoplastic anticancer drugs are hydrophobic and require 
use of a dissolving agent such as surfactants or specific buffer compositions to be 
applied.  
Especially in chemotherapy, the greatest problems may be counted as short half-
life of chemotherapeutic agent, side effects and toxicity besides drug resistance 
(Manocha and Margaritis, 2008). Because of those problems cancer therapy requires 
high doses which increases undesired side effects tremendously. Hence, development of 
controlled drug delivery systems have been a challenge for several decades. 
Unfortunately an optimized drug delivery system has not been settled yet and so many 
researches with biodegradable, biocompatible materials such as chitosan, poly(ethylene 
glycol), poly lactides, polyamidoamine and poly(ethyleneoxide) dendrimers has been 
going on. In order to obtain an enhanced solubility and controlled delivery of the drug, 
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commercial liposomes are coupled with anticancer drugs but their use is not a 
responsive solution due to their poor stability and possible toxicity over critical doses 
(Qui and Bae, 2006).  
Polymeric nanoparticles and especially block copolymers are proposed for their 
low critical micelle concentrations. A low CMC provides a better stability and 
solubilization of hydrophobic drugs in aqueous media with very low polymer 
concentrations when compared to liposomes and conventional surfactants (Rösler et al., 
2001; Allen et al., 1999; Tao and Uhrich, 2006; Jones et al., 2008). Theoretical studies 
on micelle formation of block copolymers focus on CMC since it indicates a measure 
on aggregation number or number of chains that form a micelle structure. Conventional 
characterization of block copolymer micelles are known as X-ray scattering, neutron 
scattering and light scattering techniques. Structure of polymeric micelles can be 
determined by SAXS (small angle x-ray scattering) of SANS (small angle neutron 
scattering). Turbidity can be employed for polymers with high molecular weights. 
Sedimentation and viscometric studies can also be useful  for caharacterization of 
micelle forming polymeric structures. (Gast, 1997) 
Micelle formation performance of polymeric micelles are generally estimated by 
combination of light scattering and determination of CMC by fluorescence 
spectroscopy. TEM might be used to confirm structures of micelles in addition to those 
two techniques. Dynamic Light Scattering (DLS) is a very common method to 
determine hydrodynamic radius of small particles. DLS correlates intensity fluctuations 
with the scattered light and z-average diffusion coefficient of the scatterers and 
calculates hydrodynamic from Stokes-Einstein equation given as Equation 2.2. (Candau 
and Otterwill, 1998). 
 
D
Tkr Bh πη6=  (2.2)
 
where kB is Boltzmann constant, T is temperature, η is solvent viscosity and D is z-
average diffusion coefficient. 
Fluorescence methods can be used to determine loading capacities besides CMC 
or CAC by using a fluorophore instead of drug (Zhang et al., 2007). The major problem 
that emerges with polymeric micelles is optimization of loading conditions to maximize 
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drug loading efficiencies, because although polymeric micelles have been reported to 
have very high loading capacities (Leroux and Ranger, 2002) block copolymers of 
biodegradable polymers generally exhibit low drug loading performances. 
Loading a polymeric nanoparticle with a chemically active drug can be possible 
by both chemical conjugation and physical adsorption/absorption. Physical adsorption 
has advantages over conjugation for the sake of simplicity of release mechanism, and 
less sensitivity to changing medium conditions. In this case loading is provided by drug-
hydrophobic core interaction which also determines the release characteristics based on 
diffusion. Both loading and release performances are affected by solvent used as 
medium, concentration and duration of operation (Qui and Bae, 2006). 
As the criteria for evaluating performance of a polymeric drug carrier, properties 
such as critical micelle concentration, maximum loading capacity, stability and 
biodegradability has to be considered besides drug release characteristics of the 
material. The method of loading has been a critical issue which affects all these 
properties of the loaded particles. According to that, the efficiency is directly dependent 
on the physical and chemical structure of the polymeric carrier, the drug or selected 
medium for loading. Several loading methods can be listed as simple equilibrium, co-
precipitation, dialysis, solvent deposition and salting-out methods (Gaucher et al., 2005; 
Lukyanov and Torchilin, 2004; Allen et al., 1999). 
Direct solution or simple equilibrium method is recommended for highly soluble 
amphiphilic copolymers. For acrylic star block copolymers, neutralization and heating 
treatment may be necessary for solubilizing the polymer in aqueous medium (Burguiere 
et al., 2003). Hardly soluble block copolymers can be micellized by dialysis method by 
use of a water miscible solvent or oil in water emulsion (solvent deposition) methods. 
But these methods require a very careful selection of the solvent for it significantly 
affects the yield of drug loading. Table 2.1 summarizes studies on drug loading 
performances of several biodegradable homopolymers and block copolymers, 
comparing drug loading capacities (as % drug contents) according to loading methods 
employed. Drug loading capacities are generally expressed in terms of drug loading 
contents (% DLC)  and drug loading efficiencies (% DLE) whose definitions are given 
in Equations 2.3 and 2.4. mdrug the is amount of drug loaded by carrier particle and 
mparticle is the total weight of drug loaded particle in Equation 2.3. In Equation 2.4, 
(mdrug)actual is amount of drug that was actually loaded and (mdrug)theoretical is the amount 
of drug initially introduced to be loaded by the drug carrier. 
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Table 2.1. Literature survey for drug loading performances of various biocompatible  
homopolymers or block copolymers. 
 
Polymer 
(MW) Drug Loading Method DLC % Reference 
PEG dendrimers 
(>3500) Indomethacin Coprecipitation 11 
 
Liu et al., 
2000 
PCL-PHPMA 
(25000-35000) Indomethacin Dialysis 5-12 
 
Lele and Leroux 
2002 
PEG 
(5000, 17000) 
Indomethacin 
Ketoprofen 
Piroxicam 
Coprecipitation 
0.7 
0.4 
1.7 
 
Djordjevic et al., 
2003 
PLA-PEG 
(6000-60000) 
5-FU 
Paclitaxel Dialysis 0.1-2.7  
 
Jie et al., 
2005 
PEG-b-PTMC 
(20000-70000) Dexamethasone 
Single Emulsion 
Salting Out 
2-14 
12-16  
 
Zhang et al., 
2006 
PLA/PLGA 
(16000, 100000, 
200000) 
Doclataxel Solvent deposition method <1 
 
Musumeci et al., 
2006 
PCL-PEO 
(10000-30000) at-Retionic acid 
Coprecipitation in 
water 0.2-0.9  
 
Quaglia et al.,  
2006 
PHPMA 
(15000-35000) Doxorubicin Conjugation 4-7  
 
Chytil et al.,  
2006 
PEG-PDLLA-
OSM 
(3000-4000) 
Paclitaxel 
Solid dispersion 
pH induced 
micellization 
6.4 
7.6 
 
Shim et al., 
2006 
PEO-b-PMA 
(25000) Cysplatin 
Single Emulsion 
(incubation at 
37ºC) 
22 
 
Bontha et al.,  
2006 
PLLA-b-
PDMAEMA 
(20000-200000) 
Chlorambucil Film casting 5 
 
Yuan et al.,  
2007 
PNIPAAm-PMMA 
(80000) 
Prednison 
acetate Dialysis 11 
 
Wei et al.,  
2007 
MPEG-PCL 
(18600-30500) Docetaxel Nanoprecipitation 19.4 
 
Zheng et al., 
2009 
 
100% ×=
particle
drug
m
m
DLC  (2.3)
 
( )
( ) 100% ×=
ltheoreticadrug
actualdrug
m
m
DLE  (2.4)
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The drugs used as model drugs are anticancer and  anti-inflammatory drugs with 
hydrophobic character which require aid to be dissolved in aqueous media for 
administration. A suitable carrier is expected to have a good solubilizing performance 
for administration as well as keeping plasma levels of drug after administration. 
Therefore designing smart biodegradable polymeric particles with high loading 
capacities and good stabilities for controlled delivery of specific drugs is a huge 
research area where so many approaches are proposed but very few materials could 
have been commercialized to be used for drug delivery. 
Water soluble amphiphilic polymer particles with hydrophobic cores and 
hydrophilic branches allow solubilization of hydrophobic drugs in aqueous media with 
no addition of other chemicals such as surfactants. A number of biodegradable, 
biocompatible polymeric micelles with sustained delivery characteristics have been 
proposed for both parenteral and transdermal delivery of various drugs, especially the 
ones that cannot be administered by oral route. Dendritic materials like PAMAM 
(polyamidoamine) dendrimers (Svenson and Tomalia, 2005; Cheng and Xu, 2008; 
Asthana et al., 2005; Aulenta et al., 2003) and commercial Eudragit suspensions 
(methyl methacrylate and methyl methacrylic acid copolymers) (Castelli et al., 2003; 
Eerikäinen et al., 2004) have been studied in terms of encapsulation and controlled 
release performance of anti-inflammatory drugs. Polycaprolactam, poly lactic acid, 
polyvinyl pyrolidone and polyethylene glycol have been the most famous biodegradable 
polymers proposed for drug delivery (Breitenbach et al., 2000; Kang and Leroux, 2004; 
Yang et al., 2007; Bartolozzi et al., 2007). But biodegradable polylactide nanospheres 
were generally reported to indicate  relatively low loading capacities  (less than 5w%) 
(Klose et al., 2008; Kang et al.,2008; Castelli et al., 1997) and a burst effect due to 
relatively high loading of drug (Musumeci et al., 2006). Star shaped PEG micelles 
which were commonly  loaded by co-precipitation method also yielded low loading 
capacities with anti-inflammatory drugs (Djordevic et al., 2003). 
Frechet proposes pH sensitive poly ethylene oxide block copolymers as drug 
carriers for cancer therapy  because tumors have slightly more acidic media compared 
to normal metabolism (Gillies and Frechet, 2004). Diblock copolymers of t-butyl 
methacrylate and 2-(diethylamino)ethyl methacrylate were also reported to show pH 
sensitivity (Mao et al., 2005). Doxorubicin loaded  poly(ethylene oxide):poly(b-benzyl 
L-aspartate) micelles were reported to have thermosensitivity properties, besides small 
diameters and a low critical micelle concentrations (Marion et al., 1999). 
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Nondegradable N-(2-Hydroxypropyl)methacrylamide copolymers and  biodegradable 
poly(ethyleneglycol) multiblock copolymers were designed as water-soluble carriers of 
anticancer drug doxorubicin and  the drug release of the conjugates was observed to be 
faster under mildly acidic conditions (Chytil et al., 2006; Ulbrich et al., 2003).  Some 
commercial polymeric micelles (Pluronic and polyethylene glycol–
distearoylphosphatidyl ethanolamine) were tried for the solubilization of several poorly 
water-soluble anticancer drugs and it was reported that, polymeric micelles were highly 
stable up to particle size of 100 nm and the loading capacities changed according to 
polymer and drug type (Sezgin et al., 2006).  
Poly (trimethylene carbonate)–poly(ethylene glycol)–poly(trimethylene 
carbonate) nanoparticles were studied for the controlled release of methotrexate (a, 
hydrophobic, anticancer drug) but the loading capacities were relatively low (Zhang and 
Zhuo, 2005a). 
Nanospheres prepared by solvent displacement method using polylactic acids 
(PLA) at different molecular weight and polylactic-co-glycolic acid (PLGA) were 
studied for their drug loading and drug release performances with the drug doclataxel. 
Poly(d,l-lactide-co-glycolide) was studied for a controlled release of another anti-cancer 
drug, paclitaxel (Kang et al., 2004). The biodegradable nanospheres also showed 
relatively low loading capacity, and a burst effect prior to sustained release profiles 
(Musumeci et al., 2006). 
Effect of crosslinking was investigated on block ionomer complexes of poly 
(ethylene oxide)-b-poly(methacrylic acid) copolymers which constituted hydrophilic 
nanospheres of core-shell morphology. It was reported that crosslinked 
polymethacrylate cores exhibited pH dependent swelling behavior and cisplatin, a 
potent chemotherapeutic agent, was incorporated into the ionic core of the micelles with 
remarkably high efficiency (22% w/w). The drug-loaded micelles were stable in 
aqueous dispersions exhibiting no aggregation or precipitation for a prolonged period of 
time. Slow release of platinum complexes was observed in sustained manner from the 
cisplatin-loaded cross-linked micelles (Bontha et al., 2006). An overview of the studies 
suggest that loading capacities of block copolymers with acrylic blocks are much higher 
than conventional biodegradable polymers. PEG carriers grafted or copolymerized with 
block or branched polymers involving phenolic or acrylic groups exhibited improved 
loading and solubilizing capacities exceeding 10w% (Sant et al., 2005; Liu et al., 2000). 
PCL (Lele and Leroux, 2002; SanMiguel et al., 2008), PVP (Sairam et al., 2007), and 
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PEO (Bontha et al., 2006) polymers  showed superior drug loading performances when 
compared to other polymeric carriers when copolymerized with acrylic polymers.   
The selection of acrylic star block copolymers as anticancer drug carriers also 
depend on their reported advantages over many of other biomaterials. They have 
extremely low critical micelle concentrations, can be designed and synthesized in a 
controlled manner with low polydispersities and can be modified for specific purposes. 
Poly (methyl methacrylate)-block poly(t-butyl acrylate) copolymers yield stable 
amphiphilic  polymeric nanoparticles with very high stability in aqueous media. Their 
ease of precisely controlled molecular weights, number of arms and hydrophobic core 
ratios is an opportunity for optimization of those for physical drug loading for a specific 
drug. It has been reported that hydrophobic core block-length determines stability and 
loading performance as well as release kinetics. Hence, drug loading performance is 
expected to increase with increasing molecular weight of hydrophobic core. On the 
other hand, high molecular weight PMMA cores were not desired for the difficulty of 
biodegradation as molecular weight increases. Hence an ideal polymeric micelle for 
drug delivery purposes must consist of a PMMA core at a molecular weight of oligomer 
level where PMMA core has to have maximum 10-100 repeating units (Allen et al. 
1999) and the resulting polymer should not be greater than 50000 Da in molecular 
weight (Nishiyama and Katakoa 2006, Bontha et al. 2006). An ideal drug carrier should 
have a size less than 200 nm (preferably 10-100 nm) and should remain in bloodstream  
for long time for a successful biodistribution. But it should not accumulate within the 
liver, kidneys or lungs. This accumulation phenomenon called as “glomerular 
excretion” can be avoided by water-soluble polymeric carriers (with 42-50 kDa 
molecular weights) despite their elongated durations in blood circulation system. On the 
contrary, they tend to accumulate in tumors (Nishiyama and Kataoka, 2006). 
Poly methyl methacrylate is known as a non-degradable biocompatible polymer 
widely used as joints for bone repairing and in dental applications. It has also been 
reported as a drug release agent and has been listed among biocompatible core materials 
to form amphiphilic block copolymers to serve as drug carriers (Brannon-Peppas, 1997; 
Ning et al., 2002). Poly methyl methacrylate grafted chitosan particles were reported to 
be nontoxic and blood-compatible (Radhakumary et al., 2005). A four arm star 
copolymer of poly acrylic acid arms with pentaerythritol core was investigated as a 
dental filler and was found that cytotoxicity depended on molecular weight and dose 
(Xie et al., 2006).  
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Poly (acrylic acid) is the most suitable and common hydrophilic acrylic polymer  
used in medicine and food chemistry. PtBA completely hydrolyses to produce poly 
acrylic acid which is an approved food and drug ingredient and a conventional 
controlled drug delivery agent (Burguiere et al., 2003; Brannon Peppas, 1997).  
Polymeric micelle produced from a PMMA core and PAA shell synthesized by 
hydrolysis of PMMA-b-PtBA has been reported to have acceptable solubilizing 
performance of silver particles (Ishizu et al., 2005). In fact, many studies are available 
on synthesis and characterization of acrylic block copolymers by controlled 
polymerization techniques but studies that focus on solubilization performance are 
rather few (Narrainen et al., 2002; Even et al., 2003; Limer et al., 2006).  
 
2.3.  Delivery of Anticancer Drugs with Biodegradable Particles  
 
Cancer as one of the major issues in medicine still occupies a great deal of 
research in hope of improving chemotherapy and radiotherapy. Therapeutic difficulties 
of these applications mainly originate from the nature of disease that has the ability to 
modify its surrounding for its growing and proliferation. Drug resistance and lack of 
selectively toxic anticancer agents are other issues that make cancer treatment difficult 
and risky.  Drug resistance or chemotherapy resistance means the low uptake of drug by 
solid tumors which require either increasing doses or enhancing diffusion through 
cancerous tissues. Increased doses cause detrimental side effects which may sometimes 
be fatal. Therefore invention of smart drug carriers or targeting mechanisms constitutes 
an extremely important part of cancer research. For designing a system that aims a 
chemotherapy with increased influence on tumors or/and cancer cells and minimized 
contact with healthy cells, it has to be considered how cancer grows. 
Cancer starts in mutated single cells which replicate at higher rates than normal 
cells. Cancerous cells occupy most nutrients and oxygen in their environment and 
replace normal cells by growing faster than them. The growth continues until tumor 
reaches to its diffusion limited maximal size which claims a steady state. At this state, 
the nutrients and oxygen occupied by cancerous cells at the surface cannot diffuse 
through solid tumor and reach to the core where cell death begins. At this maximal size 
which is about 2 mm3 number of proliferated cells is about the same as the ones that die 
due to lack of nutrients. For further growing, cancerous tissue organizes vascularization 
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which provides more nutrients and oxygen by formation of new vessels. This 
phenomena is called as angiogenesis. Next and most dangerous activity of cancerous 
cells is transportation through blood or nymph vessels and cause formation of new 
tumors as shown in Figure 2.2. Different approaches for site specific chemotherapy 
have been proposed to prevent formation and proliferation of cancerous cells for 
different stages of tumor formation. (Brannon-Peppas and Blanchette, 2004; Manocha 
and Margaritis, 2008) They may be listed as follows: 
1.  Avoiding reticuloendothelial system: Reticuloendothelial system is defense 
mechanism of metabolism for the clearance of alien particles and microorganisms from 
the body. Alienated particles are filtered through liver, spleens and lungs and are 
sequestered by macrophages. If a particle designed for specific drug delivery purpose 
have the size, morphology and surface characteristics that avoid being eliminated by the 
reticuloendothelial system, it may remain in circulatory system until it degrades and 
rather accumulates in solid tumors. These particles should have a particle size less than 
100 nm and hydrophilic surface.  
 
 
 
Figure 2.2.  Stages in tumor development: (A) healthy cells—nutrient rich, normal 
replication rate; (B) peripheral cancerous tissues bathe in nutrients, higher 
replication rate, gradient decrease in nutrient supply from periphery to 
core; (C) necrotic core—very low to no nutrient supply, interstitial 
pressure decreases from core to periphery; (D) tumor reaches diffusion-
limited maximum size (2 mm3), cells break off from primary tumor; (E) 
cancer cells invades into local tissues; (F) angiogenesis; and (G) 
metastasis via blood and lymph vessels. (Manocha and Margaritis, 2008)    
 
 
2.  Enhanced permeability and retention: Ensembled cancerous cells have been 
observed to have enhanced permeability due to vascularization around the tumor 
formation. Although it allows overfeeding of cancerous tissues, in classical 
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chemotherapy this is thought to be the reason for the effectiveness of toxic drugs on 
cancerous tissues rather than healthy cells although it may not work for every case. 
Retention is another property observed in solid tumors due to poor lymphatic drainage.  
3. Tumor specific targeting: Since cancer cells need overfeeding, particular 
antigens within their medium are overexpressed. Folic acid is the most famous protein 
observed at extended amounts in tumors. Folate receptors are expected to tend to cancer 
cells which allow tumor targeting. 
4.  Prodrugs: Prodrugs are complexes that have been designed to activate only 
after reaching tumors. For this purpose specific linkers and ligands are used. Toxic drug 
is conjugated by a linker that is usually broken by peptidase or acidic medium that are 
peculiar to environments of cancerous cells. But the mechanism may not work properly 
in any case for  in vivo conditions may vary from person to person and are hard to 
predetermine. 
5. Targeting through angiogenesis: Instead of overexpressed antigens, some 
angiogenesis stimulating molecules can be targeted to get into tumors. The molecules 
that have this capability are vascular endothelial growth factor, basic fibroplast growth 
factor, platelet-derived growth factor, and some metalloproteinases which indicate 
suspicious vascularization. To prevent angiogenesis and in turn avoid feeding of 
cancerous cells can be possible by limiting endothelial proliferation, introducing 
angiogenesis inhibitors, avoiding angiogenesis stimulatory factors. Both are possible to 
prevent angiogenesis or use angiogenesis as a selective route to deliver toxic drugs to 
cancerous sites. 
5FU is a hydrophobic neoplastic anticancer drug which is widely used in breast, 
colon, pancreas and eye cancer (Pascu et al., 2003). To prevent side effects, decrease 
drug resistance, provide elongated influence in circulatory system and a controlled 
delivery, various nanocarriers were investigated in terms of 5FU loading and release 
performance as listed in Table 2.2. With poly(lactide-co-glycolide) 3.8 % drug content 
could be achieved (McCarron and Hall, 2008). Entrapment of 5FU by crosslinking 
during loading was studied with acrylic copolymers but loading with 
adsorption/absorption yielded better drug loading efficiency which depended on drug 
concentration (Babu et al., 2006).  
One way of minimizing toxic side effects of 5FU was proposed as preparation of 
polymer-5FU conjugates. Sulfated polysaccharides have been proposed for 5FU 
conjugation although the release properties were not desirable for cancer therapy.  
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Table 2.2 Drug Loading Contents (DLC) and Drug Loading Efficiencies (DLE) of 
several biomaterials loaded with anti-cancer drug 5-FU. 
 
Material MW (kDa) 
Loading 
Method 
DLE* 
% 
DLC* 
% Reference 
PAMAM 
dendrimer 5-20 Conjugation - <1 
 
Zhuo et al, 1998 
 
PVP hydrogel 
network 10-18 Conjugation - <1 
 
Liu & Rimmer, 
2002 
PLGA 
microsphere 40-75 
Solvent 
Evaporation 50 <1 
 
Gupte & Ciftci, 
2004 
PLA-b-PEG 
nanoparticles 8-60 
Solvent 
Evaporation 10-50 <2 
 
Jie et al, 2005 
 
PDTC-b-PEG-
b-PDTC 74-13 Dialysis 17-7 4-2 
 
Zhang & Zhuo, 
2005b 
PLA  
fibers 100-200 Wet Spinning 75-90 10 
 
Gao et al, 2007 
 
Chitosan/PAsp 
nanoparticles 18/5 Absorption 10-35 10-28 
 
Zheng et al, 
2007 
Chitosan 55-550 Crosslinking 28-66 - 
 
Yang & Hon, 
2009 
Chitosan/PEG 
microparticles 300 
Phase 
Inversion 70 <1 
 
Lin & Fu, 2009 
 
Porphyran 
LMW 
Porphyran 
250 
5 Conjugation 
80 
60 
4-7 
18 
 
Zhang et al, 
2010 
     * DLC and DLE are defined by Equations 2.3 and 2.4. 
  
The conjugates showed fast initial releases reaching almost equilibrium within 
the first 10 hours with relatively higher rates of release in basic media while it is known 
that the medium is slightly acidic in cancerous regions (Zhang et al., 2009).  Zhuo et al 
achieved controlled release profiles over seven days of periods by dendrimer conjugates 
of 5FU (Zhuo et al., 1999). Another succesfull attempt is 5FU conjugates with poly(N-
vinyl pyrrolidone) derivatives which provide quite slow release profiles (Liu and 
Rimmer, 2002). The main disadvantage in this application is that minute amounts of 
drug can be introduced by conjugation due to great difference in molecular weights of 
drug and conjugated polymer.  
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Polyorganophosphazene microparticles were loaded with indomethacin and 5FU 
by solvent evaporation technique yielding very high loading contents up to 50%. But 
the microparticles delivered loaded drug very fast (Gudasi et al., 2006). 
 Chitosan is another biomaterial proposed for controlled 5FU delivery (Yang et 
al., 2009). Some studies with hydroxyapetite and chitosan yield insignificant 5FU 
loading contents less then 1% although they have been proposed as controlled delivery 
agents (Dodova et al., 2009; Santos et al., 2009). Lin et al. studied crosslinking of 
chitosan / polyethylene glycol microparticles to provide  controlled release of 5FU and 
Jain improved release profiles with incorporation of hyaluronic acid in chitosan 
particles. But drug loading capacities were still poor and 50% of the loaded drug was 
released in the first 12 hours (Lin and Fu, 2009; Jain and Jain, 2008).  Zheng et al. 
attained high loading drug contents (20-30%) by using hydrophilic particles of chitosan 
and polyaspartic acid salt and they could obtain controlled release from particles 
through glutaraldehyde crosslinking (Zheng et al., 2007). 
Acrylamide methyl methacrylate copolymers of core and shell type were also 
loaded to yield high 5FU contents (5-15%) by in situ polymerization of monomers. The 
release rates were proposed to depend on degree of crosslinking via N,N’-methylene 
bisacrylamide and 5FU contents of loaded microparticles (Babu et al., 2006). 5FU 
loaded nanoparticles (30 nm) of poly(γ-benzyl-L-glutamate) (PBLG) as and 
poly(ethylene glycol) (PEG) exhibited very high loading capacity about 27% by dialysis 
method. But 40% of loaded content was released in two hours (Li et al., 2008). 
5FU loading to PLGA particles is commonly achieved by precipitation/solvent 
evaporation techniques. Main problem reported about drug delivery performance of 
PLGA is the burst effect which means sudden release of loaded drug due to fast 
degradation (Gupte and Ciftci, 2004). Poly(L-lactic acid) microfibres were loaded with 
5FU achieving high loading capacities (10%) by wet-spinning method but burst effect 
remains as a challenging problem (Gao et al., 2007). 
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CHAPTER 3 
 
THEORY 
 
3.3. Theoretical Models for Drug Release  
 
Practical use of controlled drug release systems require well-defined kinetic 
behavior that provides administration of a specific drug at an optimum level through 
release process. Tailored materials proposed for drug delivery are investigated in terms 
of capacity and length of release in the search of accomplishing a controlled release 
behavior. Controlled release of drugs from nanoparticles that were administered into 
circulatory system is required to provide safe and efficient plasma levels of the drug.  
Controlled release systems by using biodegradable particles can be categorized 
as reservoir systems, matrix systems, chemically controlled systems and swelling 
particles. Although it is difficult to make certain distinctions between release profiles of 
those systems, each system exhibits characteristic release properties in parallel to 
physical and structural conditions they occupy.  
Reservoir and matrix systems are commonly expected to be diffusion derived 
systems. An ideal reservoir system can be defined as a sorce of drug, covered with a 
permeable membrane that provides a constant release. This ideal case can be expressed 
by zero order release kinetics. Another ideal case is bioerodible particles that 
disintegrate with a constant rate and converge to first order release kinetics. On the 
other hand, when the only release mechanism is diffusion through a membrane Fick’s 
diffusion equation (Equation 3.1) applies (Langer and Peppas, 1981; Crank, 1975).  
 
 
dx
dcDK
dx
dcDJ i −=−=  (3.1)
 
 
where J is flux of active ingredient, D is diffusivity of the active ingredient in the rate 
controlling membrane, and dci/dx is the concentration gradient of the substance in the 
membrane. Equation 3.1 can be written substituting concentration gradients between 
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solutions on the two sides of the membrane with introduction of K, ratio of 
concentration in the membrane to the concentration in the solution named as partition 
coefficient. KD can also be expressed as permeability of the membrane, P. 
 Fickian diffusion through a rate controlling membrane is the most general form 
of release mechanism in reservoir type drug release systems. Fickian diffusion through 
spherical particles is commonly expressed as in Equation 3.2, by transient diffusion 
equation which is used to find diffusion coefficient through polymeric particles: 
 
 
⎟⎠
⎞⎜⎝
⎛
∂
∂
∂
∂=∂
∂
r
qr
rr
D
t
q 2
2  (3.2)
 
 
Equation 3.2 shows the change in amount of substance released from spherical particles, 
where q represents amount of substance transferred through particle, r is distance from 
the center of the sphere and D is diffusion coefficient. This equation assumes constant 
diffusion coefficient and the case is valid at low concentrations considering the 
following initial and boundary conditions (Crank, 1975; Klose et al. 2008) : 
 
at 0t = , Mq =  
 
for 0t >  and at pRR = , tMq =  
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Integration of Equation 3.2 with the boundary conditions given by Equation 3.3 ends in 
Equation 3.4 for spherical particles and that can be simplified as in Equation 3.5 by 
reducing the series to the first term (n=1). Equation 3.6 is a further simplified form to be 
used for calculation of diffusivity from initial slope of Mt/M versus t1/2 graph. 
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However, release kinetics observed in most of the systems that depend on 
diffusion are preferably modeled by zero order or first order kinetics. Zero order 
kinetics considers release systems where release rate remains constant and is 
independent of the instantaneous drug content of the reservoir. First order release 
kinetics generally indicate proportionality of release rate to drug content of reservoir. 
These ideal and extreme conditions can be expressed by the simple mathematical 
equations given by Equations 3.7-3.9. But it shoul be reminded that most of the actual 
drug release system, a correspondence with theoretical models can merely be obtained 
in the first one third interval of total release period. (Ritger and Peppas, 1987; Ho and 
Sirkar, 1992; Heng et al. 2001; Prabakaran et al. 2003).  
 
Zero Order ;  
 
tkMM
oto
=−  (3.7)
 
First Order;   
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Fickian Diffusion model;  
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Ritger-Peppas model; 
 
nt kt
M
tM =)(  (3.10)
 
Ritger and Peppas stated by Equation 3.10 provides a far more general definition 
of release system with any value of n, covering t-1/2 release systems. Value of n 
determined by Ritger-Peppas model virtually shows the diffusion characteristics of the 
system. For the cases where n=0.5, cartesian system of mass transfer is said to be 
Fickian and the transfer is completely diffusion driven. When the diffusion occurs 
through spherical particles n is expected to be 0.43 to be considered Fickian. An n value 
between 0.5 and 1 indicates anomalous behavior which may be explained by existance 
of a release profile driven by both diffusion and another release mechanism. Any 
deviation from predetermined power of theoretical kinetic model can be caused by other 
physical aspects of the system like swelling, relaxation or erosion of the particles 
(Lowman and Peppas, 1999).  
 
3.2. Description of the System 
 
Drug release profile of loaded PMMA-b-PAA nanoparticles were estimated by a 
continuous release process which took place in a diffusion cell that is schematically 
shown in Figure 3.1. Loaded particles were placed in donor compartment and released 
amount of drug that passed through a semipermeable membrane was continuously 
monitored from the stream  passing through receptor compartment. 
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Figure 3.1. Schematic representation of the diffusion cell where drug release occurs. 
 
 
Since both compartments are well mixed, the mass transfer resistance is assumed 
to be the resistance of membrane that separated the two compartments. Therefore 
overall mass transfer coefficient occurs to be the permeation of the membrane and 
Equation 3.13 which is derived from Equation 3.1 is used to determine drug 
concentration in donor compartment starting from drug concentration measured from 
receptor compartment.  
 
 
  
(3.13)
 
M=CrVr (3.14)
 
 
where M is amount of drug that is transferred by diffusion through membrane and 
defined as in Equation 3.14, Cd is concentration of drug in donor compartment, Cr is 
concentration of drug in receptor compartment, Vr is volume of receptor compartment, 
A is area of diffusion and  P is permeability (Lowman and Peppas, 1999). 
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For the volume of receptor (Vr) is constant; 
)( rd CCAPt
M −=
d
d
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(Conc: Cr) 
 PBS flow 
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Substituting Cr= Y(t) and Cd= X(t) : 
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In Equation 3.18, both concentration functions in donor and receptor 
compartments are time dependent. Y(t), namely drug concentration in receptor 
compartment can be experimentally determined and is to be dependent on drug 
concentration in donor compartment. Therefore a mathematical expression that 
represents drug release profile from polymeric nanoparticles is required for an ultimate 
analysis of drug release behavior of drug loaded particles. It can be managed by 
analytial solution of Equation 3.18 assuming X(t)=kntn, expecting that drug release from 
particles will be explained by one of the well-known mechanisms which can be 
summarized as zero order kinetics (n=0) or Fickian diffusion (n=0.5) or first order 
kinetics (n=1). 
Solution of the first order linear differential equation given by Equation 3.18 is 
as follows: 
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Integrating Equation 3.23 by using “integration by parts”: ∫∫ −= vduuvudv ,   
u = tn  ,  du = ntn-1dt , κ
κtev =  , dv = eκtdt   (where 
rV
AP=κ ) 
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u = tn-2  ,  du = (n-2)tn-3dt , κ
κtev =  , dv = eκtdt    
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Equation 3.28 is verified by analytical solution of integration in the form 
∫ dxxe mA  where A is defined as bx  provided that b is a constant (Tuma, 1987). 
Converting concentration of drug in receptor compartment which is a function of 
time given in Equation 3.27 to amount of released drug shown in Equation 3.28, it will 
be possible to compare theoretical amount of released drug with experimental data that 
represented the amount of drug released from polymer particles within donor 
compartment, permeated to receptor compartment through membrane and measured 
continuously by UV-spectrophotometry. Once again, concentration variation of drug in 
receptor compartment is denoted by Y(t), and in donor compartment by X(t). Mt 
represents the cumulative amount of drug continuously released from the system and 
determined by summation of instantaneous amounts at certain time intervals determined 
by UV-spectrophotometry. F is volumetric flow rate of  buffer solution passing through 
receptor compartment. 
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Equation 3.29 is an alternating series which converges and can be reduced to the 
first five terms as in Equation 3.30.  
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where Cn and C are integral constants. 
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3.3. Permeation through Membrane  
 
In order to define the system schematically described in Figure 3.1 by a 
mathematical model, permeability of the membrane that separates two compartments of 
the diffusion cell has to be known. Permeability is estimated by performing an 
experiment where a known concentration of drug solution not loaded to any carrier has 
been placed in donor compartment, passed through the membrane and monitored versus 
time. 
Assumptions related to this experiment performed in the diffusion cell are: 
• Initial drug concentration is constant. 
• Solutions in both compartments are homogeneous. 
• Permeation is unidirectional in normal direction to the membrane. 
• Perfect sink conditions are provided. 
Then  Equation 3.16 can be reconsidered for these conditions where Cd is 
constant and known. Integrating Equation 3.16 for boundary conditions that are Cr=0 at 
t=0, and Cr=Cr(t)  at t=t: 
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CHAPTER 4 
 
MATERIALS AND METHODS 
 
4.1. Materials 
 
Pentaerythritol (PENTA) (Aldrich, 98%) and dipentaerythritol (diPENTA) 
(Charmor, 96%) was dried at 180 ºC for 3 hours and cooled under nitrogen. 1,3,5-
trihydroxybenzene was dried at 110 ºC and cooled under nitrogen. 2-bromoisobutyryl 
bromide (Fluka, 97%), triethylamine (TEA) (Riedel-de-Haen, 99%) and 4-
dimethylaminopyridine (DMAP) (Fluka, 99%) were used as received. Tertiary butyl 
acrylate (tBA) (Aldrich, 99%) and methyl methacrylate (MMA) (Aldrich, 99%) were 
passed through basic alumina columns for removal of stabilizers. N,N,N’,N”,N”-
pentamethyl diethylenetriamine (PMDETA) (Aldrich, 99%) was distilled over NaOH 
before use. Tetrahydrofuran (THF) (J.T. Baker, 99.8%) was dried and distilled over 
LiAlH4. The other solvents, namely ethanol, methanol, n-hexane, diethyl ether and 
dichloromethane were purified by conventional procedures. CuBr (Aldrich, 99.999%) 
and anisole (Aldrich, 99%) was used without further purification. Other solvents such 
as dimethyl formamid, dichloromethane, ethanol and methanol were at reagent grade. 
Trifluoroacetic acid (TFAA) (Aldrich, 99%) was used for hydrolysis. Pyrene (Fluka, 
99%) was employed as the fluorescent probe. Indomethacin (Fluka, 99%) and 5 
Fluorouracil (5FU) (Aldrich, 99%) were used as model drugs. Standard PBS (phosphate 
buffer solution) at pH value 7.4 was prepared by dissolving 8 g NaCl, 0.2 g KCl, 1.44 g 
Na2HPO4 and 0.24 g KH2PO4 in 1 L deionized water. 
 
4.2. Synthesis of Initiators  
 
Brominated 1,3,5-trihydroxybenzene so called 1,3,5-(2-bromo-2-methyl 
propionate) benzene was synthesized from 1.73 gr 1,3,5-trihydroxybenzene in THF 
(tetrahydrofuran). 1 gr DMAP (dimethyl amino pyridine) was dissolved in 130 ml THF, 
and 1,3,5-trihydroxybenzene was added. 6.7 ml TEA (triethyleneamine) was dissolved 
 31
in 30 ml THF and added under nitrogen. Then 6 ml 2-BIB (2-bromoisobutyryl bromide) 
was added dropwise at 0˚C in 20 minutes. Afterwards addition of reactants, reaction 
vessel was stirred at room temperature overnight. The product was filtered, THF was 
evaporated, the powder was dissolved in Cl2CH2, washed with water twice, washed with 
5% sodium bicarbonate solution to remove unreacted 2-bromoisobutyryl bromide, 
Cl2CH2 phase was seperated, dried over MgSO4, and finally vacuum dried. For further 
purification brominated 1,3,5-trihydroxybenzene is dissolved in 150 ml Cl2CH2, washed 
with 50 ml 1% NaOH solution and water, dried over MgSO4, then vacuum dried, 
dissolved in diethyl acetate and recrystallized in 20% ethyl acetate-80% hexane 
solution.  
Brominated pentaerythritol so called pentaerythritol tetrakis (2-
bromoisobutyrate) was synthesized from 1.09 gr pentaerythritol in THF. 1 gr DMAP 
was dissolved in 130 ml THF, and pentaerythritol was added. 6.7 ml TEA was dissolved 
in 30 ml THF and added under nitrogen. Then 6 ml 2-BIB was added dropwise at 0˚C. 
The reaction vessel was warmed up to room temperature and stirred under nitrogen 
overnight. The product was filtered, THF was evaporated, the powder was dissolved in 
Cl2CH2, washed with water twice, washed with 5w% sodium bicarbonate aqueous 
solution to remove unreacted 2-bromoisobutyryl bromide. Cl2CH2 phase was separated 
and dried over MgSO4 and finally vacuum dried. For further purification, the initiator 
was dissolved in Cl2CH2, washed with 1w% NaOH solution and deionized water, dried 
over MgSO4, vacuum dried and recrystallized in diethyl ether.  
 Brominated dipentaerythritol so called di-pentaerythritol hexakis (2-
bromoisobutyrate) was synthesized from 1.35 gr pentaerythritol in THF as described 
above. For further purification brominated pentaerythritol is dissolved in Cl2CH2, 
washed with 1% NaOH solution and water, dried over MgSO4, vacuum dried and 
recrystallized in diethyl ether. 
 
4.3. Synthesis of Macroinitiators  
 
 Multiarm PMMA macroinitiators were synthesized from 10 ml of methyl 
methacrylate. Monomer was diluted with anisole at 1:1 volumetric ratio. For the 
polymerization reaction, 78.1 µL ligand (PMDETA) and 0.037 gr catalyst (CuCl) was 
introduced. Initial molar ratio of monomer/initiator was 250 for each arm. The reactants 
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were purified from oxygen by degassing through three freeze-thaw cycles. Freezing and 
thawing process was performed on a vacuum line schematically shown in Figure 4.1.  
Then reactants eliminated from dissolved O2 and moisture were reacted for 10-12 
minutes at 70 ºC as shown in Figure 4.2. The product was passed through neutral 
activated alumina column, vacuum dried, diluted in tetrahydrofuran and precipitated in 
hexane for purification. 
 
 
Figure 4.1. Experimental set up for degassing the reactants prior to ATRP reaction 
 
 
4.4. Synthesis of  Multiarm PMMA-b-PAA Copolymers 
 
For polymerization of tBA to synthesize PMMA-b-PtBA from PMMA 
macroinitiator, 7 ml of tBA was used as monomer and diluted with anisole at 1:1 
volumetric ratio. 196 µL ligand (PMDETA) and 0.015 gr catalyst (CuBr) was 
introduced. Initial molar ratio of monomer/initiator was 600 for each arm. The reactants 
were degassed through three freeze-thaw cycles then reacted for 4-12 hours at 90 ºC. 
The product was passed through neutral activated alumina column, vacuum dried, 
diluted in tetrahydrofuran and precipitated in methanol-water mixture to eliminate 
residual monomer. 
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Figure 4.2. Fotographs of experimental setup for ATRP synthesis of star block 
copolymers (a) vacuum line for degassing, (b) freeze-thaw process and (c) 
reaction carried in oil-bath. 
 
 
The polymer sample was dissolved in dichloromethane, dried over Na2SO4, 
filtered and vacuum dried. PMMA-b-PtBA samples were hydrolized with trifluoroacetic 
acid. The polymer synthesized was dissolved in 10 ml distilled dichloromethane and 2 
ml of trifluoroacetic acid was added. Reaction was completed by 24 hours of stirring at 
room temperature.  
 
4.5. Characterization 
 
Molecular weights of the star block copolymer were determined by Gel 
Permeation Chromatography (GPC). GPC analysis were achieved with an Agilent 
model 1100 instrument equipped with a pump, refractive-index, UV detectors and four 
Waters Styragel columns (HR 5E, HR 4E, HR 3, and HR 2). THF was the eluent stream 
passing with a flow rate of 0.3 mL/min at 30 °C. Toluene was used as an internal 
 b  c 
 a 
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standard. The molecular weights of the polymers were calculated on the basis of linear 
PMMA standards (Polymer Laboratories).  
Chemical structures of the initiator (pentaerythritol tetrakis (2-
bromoisobutyrate)), macroinitiator (PMMA) and the star block copolymer (PMMA-b-
PtBA) were determined by Bruker NMR spectrometer (250 MHz for 1H-NMR). 1H-
NMR and 13C-NMR analysis of hydrolyzed copolymer was achieved by Varian 400-
MR spectrometer. The efficiency of the hydrolysis reaction was confirmed by Fourier 
Transform Infrared Spectroscopy.  
Loaded particles were characterized by Differential Scanning Calorimetry 
(DSC-50 Shimadzu), Thermal Gravimetric Analysis and Differential Thermal 
Gravimetry (Seteram Labsys) in addition to Fourier Transform Infrared 
Spectrophotometry (Shimadzu FTIR 8400 S).  
 
4.6. Maximum Loading Capacity 
 
Pyrene stock solutions and polymer solutions with constant concentrations were 
prepared. Each sample of 4 ml included 20 µL ethanol. Pyrene aliquots were taken into 
test tubes at twelve different dozes which vary between 2.5x10-7 M and 30x10-7 M. 
After vacuum drying for 4 h at 25 °C, polymer solutions at determined polymer 
concentration were transferred into pyrene containing tubes and were kept at 4 °C, dark 
medium for 16 hours being stirred. Then 750 μL samples were centrifuged with 1500 
rpm for 10 minutes. Centrifuged samples were scanned in fluorescent 
spectrophotometer to determine maximum capacity of pyrene loading. Fluorescent 
measurements were performed at Varioskan Flash microplate reader. Emission spectra 
in 360-450 nm interal were recorded with excitation at 330 nm wavelength and 
intensities at 393 nm were recorded versus increasing pyrene concentrations.  
Experiment is performed at two diferent polymer concentrations  which were 
200 mg/L and 500 mg/L. Change in intensity of pyrene loaded polymer samples with 
increasing pyrene concentrations were compared to blank pyrene solutions that took the 
same treatment as the pyrene loaded polymer solution samples. Blank solutions 
contained the same pyrene concentrations of the polymer solutions. 
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4.7. Critical Micelle Concentration 
 
Pyrene was dissolved in chloroform and diluted to 2x10-5 mg/ml. 10 μL aliquots 
were taken into test tubes which were dried under vacuum for 4 hours at 25°C. 20 mg 
polymer sample was dissolved in 1 ml alcohol to obtain a stock solution. Then aliquots 
taken from stock solutions were diluted to 5 ml to obtain different polymer 
concentrations from 0.015 mg/L to 1500 mg/L. Then 5 ml polymer solutions were 
transferred into pyrene containing test tubes. Each tube had a pyrene concentration of 
2x10-7 M. The tubes were kept at 4 °C for 16 hours being stirred at a dark medium. 750 
μL samples were drawn for fluorescence measurements. The samples were centrifuged 
at 1500 rpm for 10 min before fluorescence measurements. Fluorescence measurements 
were performed at Varioskan Flash microplate reader. Excitation spectra were obtained  
in 300-360 nm interval keeping the emission wavelength at 393 nm. Bandwidth was 
kept 5 nm and stepsize was 3 nm during all scans. Critical micelle concentration was 
determined from emmision intensity ratios of the excitation bands at 336 nm and 333 
nm (I336/I333) versus polymer concentration on logarithmic scale. CMC determined from 
shifts in excitation spectra was verified by I1/I3 ratio changes in emmission spectra and 
also by UV-spectroscopy at 266 nm. 
 
4.8. Drug Loading 
 
Drug loading was achieved by several methods for comparison. The methods 
applied to load multiarm star block copolymer samples with the model drugs 
indomethacin and 5-FU were performed as follows: 
1. Simple equilibrium method: The polymer and drug were simply added into 
buffer saline solution under agitation and filtered. 
2. Co-precipitation: The drug and the polymer were dissolved in appropriate 
solvents. Polymer and drug solutions were mixed and kept for 30-60 min. (The solution 
may be dispersed by ultrasonic treatment.) Then the homogeneous solution was added 
into suitable  nonsolvent (that was generally a nonpolar solvent like hexane, diethyl 
ether or a mixture of the two) drop by drop under agitation. The polymer precipitate is 
filtered and vacuum dried. 
 36
3. Dialysis: The polymer and drug are dissolved in appropriate solvents and 
kept for 30-60 minutes. (The solution may be dispersed by ultrasonic treatment.) Then 5 
ml of water is added drop wise into the solution, and poured into dialysis bag. The 
polymer+drug solution is dialyzed against 2 L of water for 24 hours and the medium is 
freshened in 12 hours. The ingredients after 24 hours is freeze-dried for determination 
of drug loading efficiency.  
4. Solvent deposition method (Coacervation): The polymer and drug are 
dissolved in appropriate solvents. The organic phase is poured into water phase (water 
or PBS). Solvent is evaporated under vacuum or  polymer is micellized in water 
medium and drug is separately dissolved in solvent. Then the drug solution is poured 
into micelle and solvent is evaporated under vacuum. Then the solution is centrifuged 
(or filtered) several times to remove precipitates. 
5. Salting-out method: The polymer and drug are dissolved in appropriate 
solvents. Then the solvent is evaporated. The film formed is hydrated in buffer solution, 
and the micelle is formed with intensive shaking. Excess drug precipitates and is 
removed by filtration. 
 Drug loading conditions were optimized in terms of type of medium, 
temperature, loading interval and polymer concentration. For the selection of loading 
medium, 20 mg polymer samples was introduced to equal amount of drug in water, 
ethanol, 1% acetic acid, dimethyl sulfoxide and dimethyl formamide. In each 
experiment polymer sample was dissolved in 0.25 ml ethanol then diluted to specific 
concentration with solvent of interest in which 20 mg of drug was previously dissolved. 
All loading experiments were performed at room temperature for 2 hours. After loading, 
loaded sample was washed off excess drug by dialysis method and freze dried. Drug 
content of each sample was determined from spectrophotometric analysis of dialysis 
media. Dialysis was performed in 100 ml portions of distilled water and medium was 
refreshed at every one hour period. Concentrations of 100 ml dialysis media was 
followed until ultimate purification of loaded polymer samples from excess drug which 
took 12-18 hours depending on type of solvent.  
 After selection of medium, optimum temperature of loading medium and 
duration of loading was determined through trials performed at three temperatures, 
25°C, 15ºC and 5ºC. Polymer samples of 10 mg were dissolved in 0.25 ml ethanol, 
mixed with equal amount of drug dissolved in selected loading medium in water bath 
kept at specific temperature. Drug content of samples were monitored versus time and 
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loading intervals to reach equilibrium besides drug loading efficiencies were 
determined.  
In order to determine effect of polymer and initial drug concentration on loading 
performance 20 mg polymer samples were dissolved in 0.5 ml of ethanol and 20 mg 
drug portions were dissolved in 1.5 ml 1 % HCl. Polymer solutions were diluted with 
distilled water to have  concentrations of  500 mg/L, 2000 mg/L or 3500 mg/L. After 
addition of drug into polymer solutions, loading was achieved at 15 °C under stirring in 
4 hours. The solutions were transferred into dialysis tubes which were placed in 1 L of 
water. The dialysis media were refreshed at 5th and 12th hours. Further dialysis in 100 
ml of water for 1 hour was employed for checking by UV-spectroscopy to understand 
whether samples were completely washed off excess drug or not.  The drug content of 
the samples were estimated by subtracting the amount of excess drug washed out by 
dialysis from the initial content.  
Quantities of excess drug were determined by measuring absorbance of certain 
volume of dialysis media by UV-Vis Spectrophotometry (Perkin Elmer) at 266 nm for 
5FU.  
 
4.9. Drug Release 
 
Drug release profiles were obtained by a continuous process which involved a 
diffusion cell as in Figure 4.3 and a flow cell attached to a UV-Vis Spectrophotometer. 
5 mg of drug loaded polymer sample was dissolved in 1 ml PBS within donor 
compartment of diffusion cell which was kept at 37 Cº through experiment. Fresh buffer 
was passed through the diffusion cell with a 0.025 ml/min flowrate by using a syrince 
pump. The donor and acceptor compartments of the diffusion cell were separated by 
cellulosic membrane with 12000-14000 MWCO. UV-absorbance data of the dowstream 
passing through the diffusion cell and then a flow cell placed within spectrophotometer 
were simultaneously recorded with respect to time. Absorbance data was converted to 
concentration values of the drug by using Beer’s law. Calibration curve of 5FU in PBS 
was used to determine released amount of drug by multiplying instantaneous 
concentration (mg/ml) data collected at 1 minute intervals by volumetric flowrate 
(ml/min).   
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Figure 4.3. (a) Flow-through dissolution apparatus used to measure free drug flux 
arising from a nanoparticulate suspension held separated from a dissolution 
chamber by a semi-permeable membrane (Source: McCarron and Hall, 
2008). (b) Photograph of the diffusion cell used in drug release studies. 
 
4.10. Biodegradation 
 
Particle size analysis by dynamic light scattering was achieved by Zetasizer 
(3000 HSA, Malvern). Polymer samples were prepared by dissolving polymer in limited 
amount of alcohol then diluting to 2 mg/ml with PBS. Each sample was filtered through 
0.2 µm teflon membrane prior to measurement (n=4). Biodegradion of polymer samples 
at different polymer concentrations (1,2,4,6 and 8 mg/ml) were also investigated. 
Loading ability of biodegraded polymer samples were detected by UV-
spectrophotometer after they were loaded with pyrene as described in section 4.6. 
The results were also compared to particle size analysis of AFM micrographs 
(Digital Instruments MMAFM-2/1700EXL). Freeze dried polymer samples were 
dissolved in deionized water at a concentration of 5 mg/L and kept in thermoshaker at 
37ºC for degradation. 5 ml samples taken daily were filtered through 0.45 µm teflon 
membrane and dripped on glass supports.  Each sample was immediately frozen at -
20ºC, freeze dried  (Telstar, Cryodos)  for 48 hours and kept at dessicator for 
dehumidification for 24 hours. AFM  images were obtained by tapping mode. 
nanoparticle 
suspension 
solvent 
dissolution 
chamber 
semipermeable 
membrane (a) 
b 
(b) 
 39
CHAPTER 5 
 
RESULTS AND DISCUSSION 
 
5.1. Synthesis of Initiators 
 
Initiators with three, four and six brominated active sites were synthesized in 
tetrahydrofuran and under N2 as described by Jankova et al. (Jankova et al., 2005; Even 
et al., 2003). Starting materials were 1,3,5-trihdiroxybenzene with three –OH groups, 
pentaerythritol with four –OH groups and  dipentaerythritol with six –OH groups.  
Bromination of –OH groups was achieved by  reacting with 2-bromoisobutyryl bromide 
by using a ligand. Triethyleneamine (TEA) was used as ligand for bromination of 1,3,5-
trihdiroxybenzene while dimethylaminopyridine (DMAP) was used for bromination of 
pentaerythritol and dipentaerythritol. All reactions were carried in tetrahydrofuran 
(THF) and all reactants were completely dried before reaction. The reactions shown in 
Figures 5.1, 5.2 and 5.3 were carried under nitrogen and the system was carefully 
prevented from oxygen and moisture in order to produce extremely pure brominated 
products. Reaction conversions were simply calculated from molar conversion of 
starting material as shown by Equation 5.1 where n is number of moles, MW is 
molecular weight and w is weight of reactants and products, and given in Table 5.1. 
 
 
100100(%) ×=×=
rr
pp
r
p
MWw
MWw
n
n
Conversion  (5.1)
 
 
Table 5.1. Conversions of bromination reactions of starting materials to synthesize 
initiator molecules with 3, 4 and 6 brominated active sites. 
 
Reactant MW (Da) 
Wreactant
(gr) Product 
MW 
(Da) 
Wproduct 
(gr) 
Conversion  
(%) 
THB 162 1.73 THB-Br 499 5.04 94.5 
PENTA 136 1.09 PENTA-Br 572 3.50 76.3 
diPENTA 254 1.35 diPENTA-Br 956 3.42 67.3 
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Figure 5.1. Schematic presentation of bromination reaction of 1,3,5-trihydroxybenzene 
to synthesize 1,3,5- (2-bromo-2-methyl propionate) benzene 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.2. Schematic presentation of bromination reaction of pentaerythritol to 
synthesize pentaerythritol tetrakis (2-bromoisobutyrate). 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.3. Schematic presentation of bromination reaction of di-pentaerythritol to 
synthesize di-pentaerythritol hexakis (2-bromoisobutyrate) 
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Bromo-initiators, namely 1,3,5- (2-bromo-2-methyl propionate) benzene with 
three active sites, pentaerythritol tetrakis (2-bromoisobutyrate) with four active sites and 
dipentaerythritol hexakis (2-bromoisobutyrate) were compared with starting materials 
by thermal analysis. The change in thermal behavior of materials as shown in Figures 
5.4-5.6 confirmed that bromination reactions were completed. 
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Figure 5.4. TGA overlay of (a) unreacted 1,3,5-trihydroxybenzene and (b) 1,3,5- (2-
bromo-2-methyl propionate) benzene. 
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Figure 5.5. TGA overlay of (a)  unreacted pentaerythritol and (b) synthesized 
pentaerythritol tetrakis (2-bromoisobutyrate). 
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Figure 5.6. TGA overlay of (a)  unreacted di-pentaerythritol and (b) synthesized di-
pentaerythritol hexakis (2-bromoisobutyrate). 
 
 
1H-NMR spectra of each sample was evaluated to determine purity of the 
products. Purity of the initiators were determined by comparing the specific peak areas 
obtained from 1H-NMR spectrum to the stoichiometric ratios of types of hydrogen 
groups observed in molecular structure.  
Brominated and purified 1,3,5-trihydroxybenzene has two types of hydrogen 
groups, one belonging to the benzene ring and the other to the methyl groups of added 
isopropyl bromide arms, which were notated as a and  b respectively in Figure 5.7. As 
can be calculated from the molecular structure, the ratio of these two types of hydrogen 
atoms are 3/18 (=1/6) in number for the molecule has three CH and six CH3 groups. The 
characteristic peak of CH appears at 2.04-2.06 ppm interval and has a peak area of 
58.381 while signals of the 2-bromopropanoate groups [COO(CH3)2Br] are 6.95-6.97 
ppm with a total peak area of 7.912. The ratio of the integrals (areas) of the peaks was 
determined as 1/7.37 which corresponds to a 82% purity. 
 
 
 
 
 
 
 
 
(a) (b) 
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Figure 5.7. 1H-NMR spectrum of 1,3,5- (2-bromo-2-methyl propionate) benzene. 
 
 
H-NMR spectrum of brominated pentaerythritol provided two peaks that belong 
to C(CH2)4 and bromopropanoate groups 4[COOC(CH3)2Br] at 4.31 and 1.92 ppm with 
peak areas of 7.912 and  32.793 respectively (Figure 5.8). Comparing the ratio of the 
peak areas to the stoichiometric H ratio (8/24) it was determined that 99% purity was 
obtained after purification although the purity of the synthesized material had been 
determined as 64.7% before purification. 
Brominated dipentaerythritol, on the other hand, could be purified to 100% 
purity according to the signals that appear as follows: 2[C(CH2)3] at 4.28 ppm, 
O(CH2)2 at 3,58 and 6[COOC(CH3)Br] at 1.92 ppm with the peak areas of 13.688, 4.57 
and 41.645 (Figure 5.9).  
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Figure 5.8. 1H-NMR spectrum of pentaerythritol tetrakis (2-bromoisobutyrate). 
 
 
5.2. Synthesis of  PMMA-b-PAA Polymers  
 
Synthesis of PMMA-b-PAA block copolymers constitutes of two stage ATRP 
reaction to produce PMMA-b-PtBA copolymer and hydrolysis of PMMA-b-PtBA to 
react tertiary butyl acrylate groups into acrylic acid. ATRP synthesis of 3 arm, 4 arm 
and 6 arm PMMA initiators is the first stage of the polymerization reaction and are 
shown in Figures 5.10-5.12.   
For the ATRP synthesis of PMMA macroinitiators from  the bromo-initiators 
synthesized and purified previously, CuCl was used as catalyst in stoichiometric ratio. 
PMDETA was  used in 10% excess to increase solubility of catalyst and provide 
persistent radical  effect of the catalyst.  
Dilution of monomer with an appropriate solvent that was anisole was employed 
to keep concentration of active species as high as possible throughout reaction. This was 
also expected to minimize termination reactions via coupling of active species. A third 
advanage of addition of a strong solvent was  further solubilization of catalyst as well. 
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Figure 5.9. 1H-NMR spectrum of di-pentaerythritol hexakis (2-bromoisobutyrate). 
 
 
Amount of monomer, methyl methacrylate (MMA) to be reacted was 
determined as a result of trials achieved by various M/Io (monomer to initiator molar 
ratio) values between 100 and 250. Since CuCl is a very effective catalyst when 
combined with MMA, reaction is quite fast still depending on initial monomer ratio as 
shown by Equation 2.1. When M/Io ratio was as high as 250, ATRP reaction at 60°C 
yielded macroinitiators having desired molecular weights (<5000 Da) within 10-12 
minutes. High rate of reaction provided a very low polydispersity, on the other hand 
reaction conversions were as low as 3-5% (Table 5.2). Although the conversions were 
too low to propose they can be improved and still provide acceptible polydispersities by 
an optimization study of reaction conditions (temperature, time, M/Io ratio) to obtain  
reaction conversions. In this study low conversions were tolerated since minimum 
molecular weight distribution of the macroinitiator was extremely important at this 
stage of synthesis in order to prevent side reactions at the second stage of synthesis. 
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Figure 5.10. ATRP synthesis of 3 arm PMMA from 1,3,5- (2-bromo-2-methyl 
propionate) benzene. 
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Figure 5.11. ATRP synthesis of 4 arm PMMA from pentaerythritol tetrakis (2-
bromoisobutyrate). 
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Figure 5.12. ATRP synthesis of 6 arm PMMA from di-pentaerythritol hexakis (2-
promoisobutyrate). 
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Figure 5.13.  1H-NMR spectrum of 3 arm PMMA. 
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Figure 5.14. 1H-NMR spectrum of 4 arm PMMA. 
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Figure 5.15.  1H-NMR spectrum of 6 arm PMMA. 
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The chemical structure of each macroinitiator synthesized was analized by 1H-
NMR and given by Figures 5.13-5.15. 1H -NMR spectrum of PMMA  is δ: 0.8–1.0 ppm 
(3H, CH3), 1.7 ppm (2H, CH2), 3.6 ppm (3H, COOCH3), 7.25 ppm (H, CHCl3). 
(Malinowska et al., 2005; Ishizu et al., 2005; Nurmi et al., 2007). CH2 peak labelled 
with letter ‘b’ in Figures 5.13-5.15 depicts a number of shifts within the range 1.35-2.3 
ppm probably due to molecular interactions between chains. Areas of related peaks of H 
groups belonging to PMMA have been consistent with molecular structures. 
Molecular weights of PMMA and PMMA-b-PtBA copolymers were determined 
by Gel Permeation Chromotography (Figures 5.16-5.18). For performing the second 
stages of polymerization reactions that are presented schematically by Figures 5.19-5.21 
experimental molecular weight of PMMA initiator was used to determine quantity of 
PMMA initiator to be reacted with certain volume of tBA. Stoichiometric ratio of 
monomer to initiator (M/I1) determines rate of reaction (as mentioned in Chapter 3), 
final molecular weight of copolymer and also polydispersity. The reaction conditions 
and conversions are tabulated in Table 5.2 for the samples of 3 arm, 4 arm and 6 arm 
PMMA-b-PAA polymers having molecular weights as follows; 3 arm PMMA(MW: 
5600 Da)-b-PtBA (MW: 22000 Da), 4 arm PMMA(MW: 4700 Da)-b-PtBA 
(MW:27000 Da), 6 arm PMMA(MW: 8100 Da)-b-PtBA (MW:77000 Da, 45000 Da and 
18000 Da). 
Figure 5.16. GPC profiles of 3 arm PMMA macroinitiator and the 3 arm star PMMA-b-
PtBA copolymer having molecular weights of 5600 Da and 22000Da. 
 
 53
 
Figure 5.17. GPC profiles of 4 arm PMMA macroinitiator and the 3 arm star PMMA-b-
PtBA copolymer having molecular weights of 4700 Da and 27000 Da. 
 
 
 
 
Figure 5.18. GPC profiles of 6 arm PMMA macroinitiator and the 3 arm star PMMA-b-
PtBA copolymer having molecular weights of 8000 Da and 77000 Da. 
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Table 5.2. Reaction conditions and conversions of PMMA-b-PAA synthesis by 2 stage 
ATRP polymerization and hydrolysis reactions. 
 
 PMMA-b-PtBA 3.1 PMMA-b-PtBA 4.1 PMMA-b-PtBA 6.1 
Initiator (Io) 
1,3,5- (2-bromo-2-
methyl propionate) 
benzene 
Pentaerythritol tetrakis 
(2-Bromoisobutyrate) 
Dipentaerythritol 
hexakis (2-
Bromoisobutyrate) 
Monomer MMA (10 ml) MMA (10 ml) MMA (10 ml) 
Mo/Io 750 1000 1500 
Solvent Anisole (1:1 Vm/Vs) Anisole (1:1 Vm/Vs)* Anisole (1:1 Vm/Vs) 
Catalyst CuCl (3x Io) CuCl (4x Io) CuCl (6x Io) 
Ligand PMDETA (3x Io) PMDETA (4x Io) PMDETA (6x Io) 
Reaction T (ºC) 60 60 60 
Reaction time (min) 12 12  12  
MW (Da) 5600  4700  8100 Da 
PI 1.09 1.14 1.15 
Weight of product (gr) 0.25  0.34 0.32  
Cp (%) 2.0 2.9 2.6 
    
Initiator (Iı) 3- arm PMMA-Br  (MW 5600 Da) 
4 arm PMMA-Br 
(MW 4700) 
6- arm PMMA-Br 
(MW 8100) 
Monomer 4 ml tBA 4 ml tBA 5 ml tBA 
Solvent Anisole (1:1 Vm/Vs) Anisole (1:1 Vm/Vs) Anisole (1:1 Vm/Vs) 
Mo/Iı 1500 2500 3000 
Catalyst CuBr (3.3x Iı) CuBr (4.4x Iı) CuBr (6.6x Iı) 
Ligand PMDETA (33x Iı) PMDETA (44x Iı) PMDETA (66x Iı) 
Reaction T (ºC) 90ºC 90ºC 90ºC 
Reaction time (h) 5  6 17  
MW (Da) 22000 27000 770008000 
PI 1.22 1.16 1.83 
Weight of product (gr) 0.44 0.44 0.78 
Weight of product  
after hydrolysis (gr) 0.22  0.25 0.41 
Cp (%) 10.0 11.0 24.0 
Ch (%) 62.0 80.0 84.0 
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where Cp is molar conversion of polymerization, Ch is molar conversion of hydrolysis 
reaction, wp is net weight of polymer synthesized, wi is weight of initiator used and wm 
is the initial weight of monomer incorporated in Equation 5.1. In Equation 5.2., nAA is 
number of moles of acrylic acid produced and ntBA is number of moles of tBA that 
reacted with TFAA during the hydrolysis reaction. 
Chemical structure of the synthesized PMMA-b-PtBA block copolymers were 
investigated by  1H-NMR. 1H-NMR spectrum of PMMA-b-PtBA is δ: 1.4 ppm (9H, 
COOC(CH3)3), 1.7 ppm (2H, CH2 of PMMA and PtBA), 2.4 ppm (H, CH of PtBA), 3.6 
ppm (3H, COOCH3 of PMMA), 6.9 ppm (9H, COOC(CH3)3 of tBA), 7.25 ppm (s; H, 
CHCl3) (Malinowska et al., 2005; Ishizu et al., 2005; Nurmi et al., 2007). CH2   It was 
observed that residual tBA monomer remained besides specific peaks of PMMA and 
PtBA blocks in 1H-NMR spectra of copolymers given by Figures 5.22-5.24.  
Multiarm PMMA-b-PAA molecules were produced by hydrolysis reaction 
(Figure 5.25). The residual monomer observed in 1H-NMR analysis of PMMA-b-PtBA 
was eliminated during hydrolysis reaction since the polymer was reacted with 
trifluoroacetic acid in dichloromethane. Amphiphilic PMMA-b-PAA copolymer 
produces a solid precipitate which separates from reaction medium. 1H and 13C-NMR 
analysis showed that monomer residue was eliminated through hydrolysis reaction 
(Figure 5.26).   
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Figure 5.19. ATRP synthesis of 3 arm PMMA-b-PtBA from 3 arm PMMA 
macroinitiator. 
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Figure 5.20. ATRP synthesis of 4 arm PMMA-b-PtBA from 4 arm PMMA 
macroinitiator. 
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Figure 5.23.  1H-NMR spectrum of 4 arm PMMA-b-PtBA. 
      8          7          6          5          4          3          2           1          0   ppm     
O 
O 
O 
O 
O 
O 
O 
O 
n
Br 
O O 
O 
n
a
b
c
O O 
m
e
d 
O O 
b
d d 
Br 
O O 
Br 
 
O 
O 
O 
m 
m 
n 
n 
O O 
Br 
O 
m 
 
O 
 61
 
 
 
 
 
 
 
Br 
O
O 
O 
O 
O 
O 
O O
O 
O O 
O 
O 
n
n 
n 
m 
Br 
b 
O
O
n
O
O
n
a 
O 
O
O 
O 
O 
O 
O 
O 
O
O
m 
O 
O 
O 
c 
nO
O
O
b 
d
d 
O 
O 
m 
O 
m
d 
a 
b 
d 
e 
c 
CdCl3 
tBA
Figure 5.24.  1H-NMR spectrum of 6 arm PMMA-PtBA. 
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Figure  5.25.   Chemical structure of 4 arm PMMA-b-PAA synthesized by hydrolysis of 
4 arm PMMA-b-PtBA. 
 
 
Peaks of H groups and C atoms of PMMA and PAA chains of 4 arm PMMA-b-
PAA  labeled on NMR spectra given in Figure 5.26 have been defined on molecular 
structure depicted in Figure 5.25.  CH2 groups of hydrophobic PMMA and hydrophilic 
PAA labeled with the letter ‘b’ appeared as two distinct peaks  about 1.6 and 1.8 ppm.  
1H-NMR spectrum given in 5.25-a showed that CH3 peak belonging to tBA almost 
disappeared after hydrolysis. 
13C-NMR spectrum explains the structure of amphiphilic molecule more clearly. 
C peak of CH3 groups from both PtBA and residual tBA are not observed as in Figure 
5.26.b. The only unexpected peak that was not consistent with molecular structure of 
PMMA-b-PAA copolymer was the peak observed at 159 ppm. This peak indicates  
presence of (-COOC-) structure due to crosslinking of acrylic acid chains. Since the 
peak is small degree of crosslinking is expected to be low and can be more accurately 
determined by FTIR analysis. 
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(a) 
 
 
 
(b) 
 
Figure 5.26.  (a) 1H-NMR spectrum of 4 arm PMMA-b-PAA  (b) 13C-NMR spectrum of 
6 arm PMMA-b-PAA. 
 
 
 
 
DCM 
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Efficiency of hydrolysis reaction was also examined by FTIR spectra of block 
copolymers before and after hydrolysis (Figure 5.27-5.29). Peaks of each sample were 
investigated  and named with repect to Table 5.3 (Silverstein et al., 2005; Storey et al., 
2005; Ishizu et al., 2005; Wei et al., 2007; Yu et al., 2007; Kang et al., 2006; Yu et al, 
2004; Yin et al., 2006) 
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Figure 5.27. FTIR spectra of (a) 3 arm PMMA-b-PtBA with 5600 Da PMMA core and 
total molecular weight of 22000 Da, (b) 3 arm PMMA-b-PAA produced by 
hydrolysis. 
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Figure 5.28. FTIR spectra of (a) 4 arm PMMA-b-PtBA with 7000 Da PMMA core and 
total molecular weight of 30000 Da, (b) 4 arm PMMA-b-PAA produced by 
hydrolysis. 
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Figure 5.29. FTIR spectra of (a) 6 arm PMMA-b-PtBA with 8100 Da PMMA core and 
total molecular weight of 77000 Da, (b) 6 arm PMMA-b-PAA produced by 
hydrolysis. 
 
 
 
Table 5.3. Specific FTIR peaks related to PMMA-b-PtBA copolymers. 
 
Wavenumber (cm-1) Band Monomer 
752 CH vibration of C-CH3 Methyl methacrylate 
990 CH vibration of O-CH3 Methyl methacrylate 
1150 C-O stretching tert-Butyl acrylate 
1168 COO ester stretching Acrylic acid 
1260 C-O stretching Acrylic acid 
1400 Stretching vibration of C(CH3)3 tert-Butyl acrylate 
1440-1460 Symmetric stretching of COO- Acrylic acid 
1570 Asymmetric stretching of COO- Acrylic acid 
1715 Carboxyl peak Acrylic acid 
1730 C=O stretching All acrylic monomers 
2800-3200 OH Acrylic acid 
2925 C-H asymmetric stretching of methyl groups tert-Butyl acrylate 
 
 
 
 
 
 
 
 
(a) 
(b) 
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5.3. Maximum Loading Capacity 
 
Maximum loading capacities of seven polymers were compared to select the 
ideal hydrophobic drug carrier. In that manner number of arms, total molecular weights 
and hydrophobic core ratios were the main issues for comparison. Table 5.4 gives a list 
of seven block copolymers synthesized with different number of arms, molecular 
weights and hydrophobic core ratios. 
 In order to determine maximum loading capacities, pyrene was used as 
fluorescent probe and pyrene loading capacity of polymer samples were determined by 
fluorescent method. Pyrene is a highly hydrophobic substance whose chemical structure 
is as in Figure 5.30 and is used as an indicator for loading capacity of polymers  with 
hydrophobic drugs. 
 
 
Figure 5.30. Chemical structure of pyrene. 
 
 
Table 5.4. List of polymers compared for maximum loading capacity. 
Sample Number 
of Arms 
MW of  PMMA 
core (Da) 
MW of PMMA-b-
PtBA form (Da) 
Hydrophobic 
Core Ratio (%) 
PMMA-b-PAA 3.1 3 5600 22000 25.2 
PMMA-b-PAA 4.1 4 4700 27000 17.4 
PMMA-b-PAA 4.2 4 7000 30000 23.3 
PMMA-b-PAA 4.3 4 7000 17000 41.2 
PMMA-b-PAA 6.1 6 8000 77000 10.1 
PMMA-b-PAA 6.2 6 8000 45000 18.0 
PMMA-b-PAA 6.3 6 8000 18000 46.0 
 
 
Determination of maximum loading capacity was performed by loading certain 
concentrations of polymer samples by various pyrene concentrations in aqueous 
medium. After elimination of unloaded quantity of pyrene by centrifugation, loading 
capacity was determined from fluorescence emission intensity of pyrene at 393 nm. 
Loading capacities were determined at two polymer concentrations which were 500 
mg/L and 200 mg/L.  
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A sample graph for change in emission intensities of  4 arm PMMA-b-PAA with 
4700 Da PMMA core and 27000 Da total molecular weight at different pyrene 
concentrations excited at 330 nm is given in Figure 5.31. Figures 5.32 and 5.33 show 
the variations of emission intensities (at 393 nm) of 3 arm, 4 arm and 6 arm PMMA-b-
PAA samples with respect to pyrene concentration at a polymer concentration of 500 
mg/L. Maximum loading capacity is observed to increase with increasing hydrophobic 
core ratio. 4 arm and 6 arm PMMA-b-PAA samples exhibit better loading capacities 
when compared to 3 arm PMMA-b-PAA.    
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Figure 5.31. Emission spectra of  PMMA-b-PAA 4.1 loaded at different pyrene 
concentrations designated in different colors. 
 68
0
50
100
150
200
250
300
350
0 5 10 15 20 25 30 35
Pyrene concentration (10-7 M)
I 3
93
 (R
FU
)
PMMA-b-PAA 4.3 PMMA-b-PAA 4.2
PMMA-b-PAA 4.1 PMMA-b-PAA 3.1
blank
 
Figure 5.32. Variation of emission intensities of  3 arm and 4 arm PMMA-b-PAA 
samples loaded at 500 mg/L polymer concentration with respect to pyrene 
concentration. 
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Figure 5.33. Variation of emission intensities of  6 arm PMMA-b-PAA samples loaded 
at 500 mg/L polymer concentration with respect to pyrene concentration. 
 
 
Figures 5.34 and 5.35 show the variations of emission intensities (at 393 nm) of 
3 arm, 4 arm and 6 arm PMMA-b-PAA samples with respect to pyrene concentration at 
a polymer concentration of 200 mg/L. Maximum loading capacities of 3 arm, 4 arm and 
6 arm PMMA-b-PAA samples at both concentrations of  500 mg/L and 200 mg/L are 
listed in Table 5.5. Maximum loading capacities in terms of emission intensity at 393 
nm given in relative fluorescence units were achieved at and above pyrene 
concentrations of 20 ×10-7 M.  
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Figure 5.34. Variation of emission intensities of  3 arm and 4 arm PMMA-b-PAA 
samples loaded at 200 mg/L polymer concentration with respect to pyrene 
concentration. 
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Figure 5.35.  Variation of emission intensities of  6 arm PMMA-b-PAA samples loaded 
at 200 mg/L polymer concentration with respect to pyrene concentration. 
 
 
 Table 5.5 shows that highest loading capacities were attained by highest 
hydrophobic core ratios at 500 mg/L polymer concentration. 4 arm and 6 arm PMMA-
b-PAA samples with similar hydrophobic core ratios exhibit comparable maximum 
loading capacities at that polymer concentration. But  when system is diluted to a 200 
mg/L polymer concentrations, it was observed that maximum loading capacities of 4- 
arm PMMA-b-PAA were higher than that of 6 arm PMMA-b-PAA with similar 
hydrophobic core ratios.  
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 At lower polymer concentration it was also observed that hydrophobic core ratio 
is not the only criteria that improves maximum loading capacity. At relatively dilute 
systems importance of stability of the polymer emerges. Although hydrophobic core 
ratio determines the loading capacity of the polymer, it reduces the stability of the 
polymer when it exceeds an optimum value. Therefore an ideal multiarm PMMA-b-
PAA to be used as an hydrophobic drug carrier is estimated to have 4 arms and a a 
hydrophobic core ratio about 0.25. 
 
 
Table 5.5. Maximum loading capacities of 3 arm, 4 arm and 6 arm PMMA-b-PAA 
samples loaded at different polymer concentrations. 
 
 
 
Sample 
 
MWPMMA / 
MWPMMA-b-PAA 
(Da) 
Max. Loading 
Capacity  
(500 mg/L) 
(I 393) 
Max. Loading 
Capacity  
(200 mg/L) 
(I 393) 
 
fc 
  
PMMA-b-PAA 3.1 5600/22000 154.11 60.56 0.26 
PMMA-b-PAA 4.1 4700/27000 150.43 59.05 0.17 
PMMA-b-PAA 4.2 7000/30000 216.97 139.54 0.23 
PMMA-b-PAA 4.3 7000/17000 301.80 132.12 0.41 
PMMA-b-PAA 6.1 8100/77000 106.825 53.84 0.11 
PMMA-b-PAA 6.2 8100/45000 198.53 53.09 0.18 
PMMA-b-PAA 6.3 8100/18000 344.41 117.30 0.45 
 
 
5.4. Critical Micelle Concentration 
 
Critical micelle concentration is a very important characteristics of micelle 
forming polymers for drug transportation systems.  Critical micelle concentration is a 
minimum concentration that polymer forms a micelle and is able to carry a hydrophobic 
drug in aqueous medium and are generally determined by pyrene fluorescence methods.  
Critical micelle concentrations (CMC) of PMMA-b-PAA samples loaded with pyrene at 
different polymer concentrations could have been analyzed by evaluation of both 
emission and excitation spectra. Emission spectra were obtained for an excitation 
wavelength of 330 nm, and excitation spectra were obtained for an emission wavelength 
of 393 nm. Variation of excitation spectra for a pyrene loaded 4 arm PMMA-b-PAA 
sample with 5000 Da PMMA and 45000 Da total molecular weight with respect to 
polymer concentration is shown in Figure 5.36.  Pyrene loading was performed by 
mixing polymer solutions at different concentrations with constant amount of pyrene at 
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4°C for 16 hours. Emission intensities (393 nm) of the samples were followed during 
loading to make sure equilibrium is reached within 16 hours. Pyrene concentration was 
2×10-7 M to prevent excimer formation which leads erroneous results in fluorescence 
measurements. 
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Figure 5.36. Excitation spectra of  pyrene loaded 4 arm PMMA-b-PAA samples (MW: 
5000/45000 Da) at polymer concentrations designated in different colors. 
 
 
Critical micelle concentrations were determined from changes in  I336/I333 ratio 
with increasing polymer concentrations as in method given by Lele and coworkers (Lele 
et al., 2002)  The blue shift in I336 band of excitation spectra of pyrene indicates the 
change in excitation behavior of the probe due to loading. Figure 5.37 shows this 
change in  I336/I333 ratio for 4 arm PMMA-b-PAA sample (MW: 5000/45000 Da). CMC 
is accepted to be the polymer concentration where initial constant I336/I333 line intersects 
the increasing slope emerged due to loading. Sketches of I336/I333 ratio versus polymer 
concentration of other PMMA-b-PtBA samples that were investigated for comparison 
are given in Appendix A.  
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Figure 5.37. Determination of CMC from shifts in I336 band in excitation spectra (n=2). 
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Figure 5.38. Determination of CMC from I1/I3 ratios in emission spectra (n=2). 
 
 
CMC of the 4 arm PMMA-b-PAA sample has also been determined from the 
ratio of first and third emission bands (I1/I3) versus polymer concentration in mg/L as in 
Figure 5.38. Intensities of the first and third bands of pyrene correspond to fluorescence 
emissions at 372 nm and 385 nm wavelengths (LópezDíaz and Velázquez, 2007; Zhang 
et al., 2007; Aguiar et al., 2003). Distinct  I1 and I3 bands were observed more clearly as 
in Figure 5.39 when pyrene was dissolved in chloroform. The drop in I1/I3 ratio 
designates a change in pyrene’s location due to loading and CMC is supposed to be 
intersection of horizontal and steep slopes of initial constant and increasing I1/I3 values 
on non-logarithmic scale. 
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Figure 5.39. I1 and I3 bands at 372 nm and 385 nm on emission spectrum of pyrene in 
chloroform (excited at 330 nm). 
 
 
As a final approach, pyrene loaded PMMA-b-PAA sample was analyzed by UV-
spectrophotometry and absorbance spectra of pyrene solubilized by certain 
concentrations of polymer  were measured. Change in absorbance spectra increasing 
with polymer concentration was observed as in Figure 5.40. An increase in UV-
absorbance at 266 was observed after 10 mg/L polymer concentration on Figure 5.41 
which verifies CMC obtained by fluorescence spectroscopy. 
 
 
 
Figure 5.40. UV-Absorbance spectra of  pyrene loaded 4 arm PMMA-b-PAA samples 
(MW: 5000/45000 Da) at polymer concentrations designated in different 
colors. 
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Figure 5.41. Determination of CMC from change in UV-absorbance A266 with respect to 
polymer concentration (n=2). 
 
 
Comparison of CMC values listed in Table 5.6 suggests that a hydrophobic core 
ratio at 0.25 provides improved stability indicated by minimum critical micelle 
concentrations. Another characteristics that affect stability in terms of CMC is 
molecular weight. It was observed that increasing molecular weight of block copolymer 
increases stability but it has to be reminded that increased molecular weights reduce 
loading capacity of multiarm PMMA-b-PAA copolymers and increased molecular 
weight of PMMA core would prevent degradation of polymer particles. 
 
 
Table 5.6. Critical micelle concentrations of 3 arm, 4 arm and 6 arm PMMA-b-PAA 
samples having various molecular weight and hydrophobic core ratios. 
 
 
Sample 
MWPMMA / 
MWPMMA-b-PAA 
(Da) 
 
CMC 
(mg/L) 
 
fc 
PMMA-b-PAA 3.1 5600/22000 5 0.26 
PMMA-b-PAA 4.1 4700/27000 10 0.17 
PMMA-b-PAA 4.2 7000/30000 5 0.23 
PMMA-b-PAA 4.4 6400/33000 10 0.19 
PMMA-b-PAA 4.5 5000/45000 10 0.11 
PMMA-b-PAA 6.1 8100/77000 10 0.11 
PMMA-b-PAA 6.2 8100/45000 20 0.18 
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5.5. Drug Loading  
 
5.5.1 Determination of Optimum Drug Loading Method 
 
 Drug loading methods were listed as simple equilibrium, co-precipitation, 
dialysis, solvent deposition and salting out methods which have been described in 
Chapter 2.2. PMMA-b-PAA copolymers cannot form micelles by direct mixing with 
water. A micellization technique has to be applied during loading which follows 
dissolution of drug and polymer samples in appropriate solvents. Polymer samples can 
be dissolved in ethanol and dimethyl sulfoxide with slight heating while dimethyl 
formamide readily dissolves the polymer. After dissolution of polymer and drug, they 
have to be mixed at definite loading conditions that consist of type of loading medium, 
polymer and drug concentrations, temperature and duration of the process. Before an 
analysis of effectiveness of those parameters, the most efficient loading technique has to 
be determined. 
Model drug used for selection of loading method was indomethacin. 
Indomethacin is an anti-enflammatory drug that is slightly soluble in aqueous medium. 
The chemical structure is shown in Figure 5.42. 
  
 
 
 
 
 
 
 
 
 
Figure 5.42. Chemical structure of indomethacin. 
 
 
In order to make a comparison among loading methods listed above, 
indomethacin was loaded to 4 arm PMMA-b-PAA (MW: 7000/30000 Da) which has 
exhibited the highest maximum loading capacity with pyrene at a polymer concentration 
H3C      O 
CH2COOH 
CH3 
C        O 
N 
Cl 
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of 200 mg/L. Reaction conditions and conversions of 4 arm  PMMA-b-PAA (MW: 
7000/30000 Da) synthesis are given in Table 5.7 for information.  
Co-precipitation is not a suitable method for loading acrylic block copolymers 
for an appropriate nonsolvent, like diethyl ether for PEG derivatives (Djordevic et al. 
2003), does not exist. Therefore PMMA-b-PAA samples were loaded by  other three 
techniques and drug loading efficiencies were determined by UV-spectrophotometer.  
 
 
Table 5.7. Reaction conditions and conversions of synthesis and hydrolysis reactions of 
4 arm PMMA-b-PAA (7000/30000). 
 
 4 arm PMMA-Br 4 arm PMMA-b-PtBA 
4- arm PMMA-
PAA 
Initiator (I) Pentaerythritol tetrakis (2-Bromoisobutyrate) 
4 arm PMMA-Br 
(MW 7000 Da) 
Reactants:  
Trifluoro acetic 
acid + 4 arm 
PMMA-b-PtBA 
Mo/I 1000 2300 - 
Solvent Anisole (1:1 Vm/Vs)* Anisole (1:1 Vm/Vs)* Dichloromethane 
Catalyst CuCl (4×I) CuBr (4.4×I) - 
Ligand PMDETA (4×I) PMDETA (40×I) - 
Reaction Temperature 70ºC 90ºC 25ºC 
Reaction time 10 min 12 hours 24 hours 
MW experimental 7000 Da (PI: 1.135) 30000 Da (PI: 1.12) - 
Molar Conversion 3.75 % 14.15 % 91.7 % 
Weight of product    0.42 gr 1.014 gr 0.638 gr 
  *Volumetric solvent to monomer ratio. 
 
 
For loading 4 arm PMMA-b-PAA samples with indomethacin by dialysis 
method both polymer and drug was dissolved in dimethylformamide and excess drug 
was eliminated by dialysis in 24 hours. Loading was carried for 1 hour for each sample 
at room temperature or at 4°C. Samples were freeze dried after dialysis and drug content 
of each sample was measured  by UV-spectroscopy. Absorbance of sample at 320 nm 
was compared to calibration curve of indomethacin given in Figure 5.43. Drug content 
of loaded micelle solutions were calculated by using Equation 5.4 that was obtained 
from regression formula given by Figure 5.42 (MWindomethacin=357.8). 
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Figure 5.43. Calibration curve of indomethacin dissolved in dimethylformamide. 
 
 
Cindomethacin (mg/ml) = 0.055 × A320    (5.4)
 
 
Dialysis method not only yields high drug loading efficiencies but also provides 
micellization of freeze dried samples of drug loaded PMMA-b-PAA. Drug loaded 
samples were easily dissolved and formed stable dispersions when introduced to 
aqueous medium. When Table 5.8 was examined, it was also observed that dialysis 
method yielded superior drug contents compared to salting out and solvent deposition 
methods. 
 
 
Table 5.8. Drug loading performances of dialysis, salting out and solvent deposition 
methods. 
 
 
Method 
Solvent 
(Polymer/Drug) 
Sample Amount 
(Polymer/Drug) 
(mg) 
 
Temperature 
(°C) 
Loading 
Efficiency 
(%) 
Dialysis DMF / DMF 10 /10 25 13.4 
Dialysis DMF / DMF 10 /10 4 20.6 
Dialysis DMF / DMF 50 / 50 4 24.8 
Salting Out Water 50 / 50 25 2.5 
Salting Out PBS 50 / 50 25 5.5 
Solvent 
Deposition EtOH / DMF 10 /10 25 4.7 
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Characterization of indomethacin loaded 4 arm PMMA-b-PAA 
(MW:7000/30000 Da) was achieved by FTIR and DSC analysis given by Figures 5.44 
and 5.45. Comparison of FTIR spectra of loaded and unloaded polymer samples to that 
of model drug indomethacin shows that drug is entrapped within polymer particles since 
sharp peaks of indomethacin were repressed. However specific peaks of indomethacin 
can be distinguished.  
 
 
 
Figure 5.44. FTIR spectra of (a) indomethacin, (b) indomethacin loaded 4 arm PMMA-
b-PAA.and (c) neat polymer.  
 
 
 
Figure 5.45. DSC thermograms of (a) neat polymer and (b) indomethacin loaded 4 arm 
PMMA-b-PAA. 
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Such high loading efficiencies may indicate strong electrostatic interactions 
between polymer and drug, which is expected to affect thermal stability of polymer. 
Eerikäinen reports interaction of an acidic anti-inflammatory drug with methacrylates 
emphasizing the interactions between drug and polymer in forms of hydrogen bonds 
and electrostatic forces (Eerikäinen et al., 2004). These interactions may increase glass 
transition, melting and even degradation temperatures of the original polymer increasing 
thermal stability of the polymer.  
An interaction has been observed with DSC thermograms of our neat and drug 
loaded 4 arm PMMA-b-PAA samples given in Figure 5.45. Afterwards loading, Tg of 4 
arm PMMA-b-PAA increased from 55 ºC to 75ºC and Tm of PMMA core increased 
from 130ºC to 145ºC which designates a strong interaction between hydrophobic 
PMMA core and indomethacin. The third peak at 228ºC observed at neat polymers DSC 
thermogram belongs to PAA which was expected to melt above 200ºC. Hence Tm of 
PAA was also improved through loading for the onset of melting could not be observed 
until 250ºC. 
After approval of dialysis method as the most efficient drug loading method, the 
same procedure was repeated with anticancer drug 5 Fluorouracyl (5FU). But loading 
efficiency was very poor (less than 1 %) with both 4 arm and 6 arm PMMA-b-PAA 
samples having hydrophobic core ratios changing from 0.10 to 0.25. That may have 
arose from smaller molecular weight, or weaker electrostatic interactions related to 
chemical structure of 5FU shown in Figure 5.46. It was obvious that loading conditions 
had to be optimized for acceptable loading contents in terms of duration, temperature 
and composition of loading medium.  
 
 
 
 
 
 
 
Figure 5.46. Chemical structure of 5 Fluorouracil or 5 Fluoro-2,4-pyrimidinedione. 
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Figure 5.47. Calibration curve of 5FU dissolved in PBS (n=3). 
 
 
 C5FU (mg/ml) = 0.0165 × A266   (5.5)
 
 
Calibration curve and equation used for determination of drug concentration in 
dialysis medium are given by Figure 5.47 and Equation 5.5. Drug loading contents of 
loaded polymer samples have been determined from analysis of dialysis media and 
subtraction of removed amount of drug from initial quantity introduced. 
 
5.5.2 Determination of Optimum Duration of 5FU Loading 
 
Loading interval is an important parameter that has to be optimized considering 
other conditions such as mixing rate, temperature and composition of loading medium. 
For monitoring loading efficiency versus time a 6 arm PMMA-b-PAA 
(MW:5700/34000 Da, HCR:0.17) sample was used. In order to determine interval of 
loading to reach equilibrium,  equal quantities of drug and polymer solutions were 
mixed in distilled water with a concentration of 500 mg/L at room temperature. In 
certain time intervals a sample of specific volume was taken from solution, dialyzed 
against water and freeze dried. After weighing dry samples, drug content was 
determined by UV-spectroscopy. Drug loading contents versus sampling intervals were 
tabulated in Table 5.9.  
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Table 5.9. Drug Loading Content (DLC, %) with changing loading time for 5FU loaded 
6 arm PMMA-b-PAA (MW:5700/34000 Da) at 25°C and 500 mg/L polymer 
concentration. Loading medium is distilled water. 
 
Time of 
Loading 
(min) 
Weight 
Released 
(mg) 
Loaded 
Weight 
(mg) 
Sample 
Weight 
(mg) 
DLC 
(%) 
5 2.2511 0.2489 2.6 9.96 
10 2.2682 0.2318 2.8 9.26 
20 2.3032 0.1968 3.1 7.87 
30 2.200 0.3000 1.9 12.00 
40 2.2483 0.2517 1.9 10.07 
50 2.2302 0.2698 2.6 10.79 
60 2.1717 0.3283 2.4 13.13 
80 2.1258 0.3742 2.7 14.97 
105 2.1554 0.3446 2.9 13.78 
120 2.0241 0.4759 3.0 19.04 
150 2.1158 0.3842 3.0 15.37 
185 2.1460 0.354 2.4 14.16 
220 2.1300 0.3700 1.4 14.8 
260 2.1955 0.3045 2.8 12.8 
300 2.0987 0.4013 2.6 16.05 
360 1.8561 0.3439 1.9 17.5 
TOTAL 34.93 5.07 40.00 12.7 
 
 
Variation of drug loading contents versus time of loading in distilled water at 
25°C is shown in Figure 5.48, too. It can be suggested that loading performance reaches 
its maximum efficiency in 120 minutes and remains about the equilibrium value. 
Therefore further investigations to optimize loading conditions were performed with 4 
hours of loading intervals at room temperatures. 
The samples taken from polymer and drug solution prepared for the experiment 
to determine optimum loading interval were purified from excess drug by dialysis as 
mentioned before. Amount of excess drug was determined from UV-absorbance of 
dialysis media that has been refreshed every one hour until all excess drug was removed 
from samples. In order to optimize interval of dialysis for removal of excess drug, 5FU 
concentration of portions of dialysis medium were monitored. Figure 5.49 displays 
instantaneous amounts of drug removed by dialysis and measured every hour and total 
amount of drug released from polymer sample loaded for 120 minutes at 25°C and 500 
mg/L polymer concentration. It was estimated that at least 10 hours of dialysis was 
required to remove excess drug completely from loaded particles. 
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Figure 5.48. Variation of DLC versus time of 5FU loading for 6 arm PMMA-b-PAA   
(MW:5700/34000 Da)  at 25°C and 500 mg/L polymer concentration. 
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Figure 5.49. Instantaneous amounts of drug released within each 1 hour interval of 
dialysis (•) and total (cumulative) amount of drug removed within 
corresponding time interval of dialysis (•). 
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5.5.3 Selection of Ideal Medium for 5FU Loading 
 
For an efficient loading both polymer and drug has to be completely dissolved 
prior to mixing. Polymer samples were dissolved in ethanol and drug samples were 
dissolved in dimethyl formamide, which was a perfect solvent both for indomethacin 
and 5FU, for all loading experiments reported up to now. To select the ideal 
composition of loading medium, polymer samples were again dissolved in ethanol and 
drug samples were dissolved in the solvent investigated, at least for the experiments 
carried at 25°C. Solvents that were used as loading medium for the comparison of their 
performances in terms of drug loading content were water, ethanol, 1% acetic acid, 
dimethyl sulfoxide and dimethyl formamide. Initial polymer and drug concentrations 
were 5000 mg/L. The results are tabulated in Table 5.10 stating that 1%acetic acid and 
dimethyl formamide are the best loading media for 5FU loading to PMMA-b-PAA 
copolymers. Yield of loading is very low in ethanol and water since 5FU is slightly 
soluble in water and almost insoluble in ethanol.  
 
 
Table 5.10. Loading performance of 6 arm PMMA-b-PAA (MW: 5700/34000) at 
various loading conditions. 
 
Drug/Polymer/Solvent 
(mg/mg/ml) 
Temperature
(ºC) 
Time 
(h) 
Medium 
(Solvent) 
DLC 
(%) 
10/10/2 25 4 Water 3.6 
10/10/2 25 4 Ethanol <1 
10/10/2 25 4 1% Acetic acid 8.0 
10/10/2 25 4 DMSO 4.7 
10/10/2 25 4 DMF 7.3 
10/10/2 15 4 Water 16.9 
10/10/2 15 4 Ethanol 14.0 
10/10/2 15 4 1% Acetic acid 17.5 
10/10/2 15 4 DMSO 16.4 
10/10/2 15 4 DMF 16.4 
10/10/2 4 16 Water 20.0 
10/10/2 4 16 Ethanol 10.1 
10/10/2 4 16 1% Acetic acid 7.5 
10/10/2 4 16 DMF 17.2 
 
 
The experiment was repeated at 15°C and 4°C, too. Loading interval was kept 4 
hours for 15°C and 16 hours for 4°C. Equilibrium was reached at shorter intervals 
(between 4 and 12 hours depending on polymer concentration) at 4°C. Since stability of 
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polymer is permanent at that temperature loading intervals were preferred to be kept 
elongated.  
  For the loading experiments performed at 15°C and 4°C, drug was dissolved in 
little amount of DMF for loading experiments performed in water and ethanol. 
Otherwise loading performance would be minute due to poor dissolution of drug in 
water or ethanol. It was observed that failure of loading in water and ethanol was really 
related to dissolution performance of drug since drug loading contents in various media 
were comparable when drug was dissolved in appropriate solvent.  
But incorporation of dimethylformamide is not desired for biomaterials designed 
to be used for medical purposes. Hence, optimum drug loading medium was selected as 
1% acid solution which could also be used for dissolution of drug. Optimum loading 
temperature was obviously 15°C.  
 
5.5.4 Determination of Optimum Polymer Concentration for Loading 
 
Determination of optimum polymer concentration was achieved among three 
concentrations which were 500 mg/L, 2000mg/L and 3500 mg/L. Both drug and 
polymer sample was introduced into loading medium at the same quantities. In this 
condition the drug was in excess amount, exceeding the required amount at a great 
extent. However introduction of equal amounts of drug and polymer simplifies 
evaluation of results since drug loading contents and drug loading efficiencies shall be 
identical. Reducing initial amount of drug introduced into loading medium would 
certainly increase drug loading efficiency and has to be optimized separately to prevent 
reduction of drug loading contents. 
An amphiphilic PMMA-b-PAA copolymer with 4 arms, hydrophobic core ratio 
of 0.25 and molecular weight about 20000 Da has already been anticipated as an ideal 
drug carrier for hydrophobic drugs considering the comparison of multiarm PMMA-b-
PAA samples in terms of maximum loading capacity and CMC. Therefore a polymer 
sample, namely 4 arm PMMA-b-PAA (MW:4900/18000 HCR:0.27) has been 
synthesized to determine optimum drug loading conditions. Reaction conditions and 
conversions of three stage synthesis of the polymer sample is given by Table 5.11. 
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Table 5.11. Reaction conditions and conversions of synthesis and hydrolysis reactions 
of 4 arm PMMA-b-PAA (MW 4900/18000). 
 
 4 arm PMMA-Br 4 arm PMMA-b-
PtBA 
4- arm PMMA-b-
PAA 
Initiator (I) Pentaerythritol tetrakis (2-Bromoisobutyrate) 
4 arm PMMA-Br 
(MW 4900 Da) 
Reactants:  
Trifluoro acetic 
acid + 4 arm 
PMMA-b-PtBA 
Mo/I 1000 2300 - 
Solvent Anisole (1:1 Vm/Vs)* Anisole (1:1 Vm/Vs)* Dichloromethane 
Catalyst CuCl (4×I) CuBr (4.4×I) - 
Ligand PMDETA (4.4×I) PMDETA (40×I) - 
Reaction 
temperature 
70ºC 90ºC 25ºC 
Reaction time 12 min 4.5 hours 24 hours 
MW experimental 4900 Da (PI: 1.135) 18000 Da (PI: 1.104) - 
Molar Conversion 
% 
3.8 % 11.2 % 29.6 % 
Weight of product    0.43 gr 0.8 gr 0.3 gr 
*Volumetric solvent/ monomer ratio. 
 
 
Previously optimized loading conditions were 4 hours of loading at 15°C for 
dialysis method. Polymer samples were dissolved in small amounts of ethanol and drug 
samples were dissolved in 1% HCl to provide dissolution of drug in acidic conditions 
instead of toxic solvents. Hydrochloric acid was preferred for it is commonly used for 
drug dissolution in pharmacology.  Loading experiments were performed with two 
replicates and drug loading contents were as given in Table 5.12. Concentration of 
polymer is observed to be effective on drug loading content, but further increase in 
polymer concentration after 2000 mg/L does not increase loading capacity significantly. 
 
 
Table 5.12.  Effect of polymer concentration on drug loading performed at 15 °C, 4 
hours. 
 
Polymer 
Conc. 
(mg/L) 
Mass of 
Polymer 
(mg) 
Volume 
(ml) pH 
Drug Loading 
Content 
(%) 
500 20.0 40.0 1.968 6.4     11.3 
2000 20.0 10.0 1.431 13.6     20.6 
3500 20.0 3.0 1.213 14.8     20.7 
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Polymer samples loaded at 2000 and 3500 mg/L polymer concentrations were 
also loaded in acidic media since the drug was dissolved in 1% HCl. Loading medium 
of 2000 mg/L polymer concentration was loaded in 0.15% HCl and 3500 mg/L polymer 
concentration was loaded in 0.15% HCl  (corresponding pH values were given in Table 
5.12). 
4 arm PMMA-b-PAA samples loaded at different polymer concentrations at 
15°C and for 4 hours were analysed by FTIR to observe any change in chemical 
structure due to drug loading. FTIR spectra shown in Figure 5.50 display that 
characteristic peaks of 5FU (at 1726 and 1656 cm-1) (Gao et al., 2007) do not appear 
significantly in loaded samples. That was expected since drug is proposed to be 
entrapped  in the hydrophobic core. But a change in structure of COO- appeared due to 
chemical shift from symmetric to asymmetric bonds of C=O through loading (Ishizu et 
al, 2005). Specific bands of symmetric and asymmetric C=O bonds of carboxyl groups 
appear at wavenumbers of 1460 and 1570 cm-1, respectively. Ratio of asymmetric bond 
that appear through interaction of carboxyl group with the acidic drug 5FU to 
symmetric bond of C=O (A1570/A1460 ) is assumed a measure of loading.  A1570/A1460 
ratios listed in Table 5.13. shows that most efficient loading was performed in dimethyl 
formamide. But loading in 1% acetic acid solution was comparable.  
 
01000200030004000
Wavenumber (cm-1)
A
 (a
rb
itr
ar
y 
un
its
)
 
Figure 5.50. FTIR spectra of 4 arm PMMA-b-PAA (a) unloaded, (b) loaded at 500 
mg/L polymer concentration, (c) loaded at 2000 mg/L polymer 
concentration, (d) loaded at 3500 mg/L polymer concentration for 4 h at 
15°C  and (e) FTIR spectrum of 5FU. 
(a) 
(b) 
(c) 
(d) 
(e) 
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Table 5.13.  Ratio of asymmetric(A1570)/symmetric(A1460)  bonds of C=O of carboxyl 
groups of acrylic acid chains due to loading conditions of 4 arm PMMA-b-
PAA (MW:4900/18000). 
 
Loading 
Conditions 
Loading 
Medium* 
Polymer 
Concentration A1460 A1570 A1570/A1460 
Unloaded - - 0.494224 0.26019 0.526462 
4 h, 15°C 1 % AA 5000 mg/L 0.944267 0.860732 0.911535 
4 h, 15°C DMF 5000 mg/L 0.903261 0.906998 1.004137 
4 h, 15°C 0.5 % HCl 3500 mg/L 1.192225 0.9119 0.764872 
4 h, 15°C 0.15% HCl 2000 mg/L 1.120375 1.034097 0.922992 
16 h, 4°C 0.15% HCl 2000 mg/L 1.410556 1.279316 0.906959 
4 h, 15°C 0.05% HCl 500 mg/L 1.320948 1.025745 0.776522 
*AA: Acetic Acid, DMF: Dimethyl Formamide, HCl: Hydrochloric Acid. 
 
 
According to magnitude of change in chemical structure of carboxyl groups of 
acrylic acid (A1570/A1460 ratios),  2000 mg/L seems to be the ideal polymer 
concentration for 5FU loading into 4 arm PMMA-b-PAA samples with molecular 
weight around 20000 Da and a hydrophobic core ratio of 0.25. 
Differential scanning calorimeter thermograms of unloaded and loaded samples 
were also compared (Figure 5.51). Thermograms show that due to interaction with 5FU 
degradation temperature of 4 arm PMMA-b-PAA depicts a shift about 30°C. 
Endothermic peaks of unloaded and loaded polymer samples are listed in Table 5.14. 
 
 
Table 5.14. Endothermic peaks observed on DSC thermograms of the model drug, 
unloaded and 5-FU loaded polymer samples at 15°C for 4 hours in aqueous 
medium. 
 
Sample Peak 1 Peak 2 Peak 3 Peak 4 
Polymer Unloaded 75 215 367 - 
Polymer loaded at 500 mg/L 74 227 388 444 
Polymer loaded at 2000 mg/L 76 225 396 447 
Polymer loaded at 3500 mg/L 74 226 396 449 
Drug (5 FU) - 288 318 - 
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Figure 5.51. DSC thermograms of 4 arm PMMA-b-PAA (a) unloaded, (b) loaded at 500 
mg/L polymer concentration, (c) loaded at 2000 mg/L polymer 
concentration, (d) loaded at 3500 mg/L polymer concentration and (e) of 
5FU. 
 
 
Differential Thermal Gravimetry and Thermal Gravimetric Analysis of loaded 
and unloaded samples are shown in Figure 5.52. In DTG thermograms of loaded 
samples any peak due to degradation of drug could not be detected at 288°C and 340°C. 
Weight fractions after degradation shows that fraction of residue after degradation of 
polymer increased with increasing polymer concentrations during loading. The drug 
shows a distinct degradation at 350°C and at 18% of initial quantity remains at 600°C. 
The difference in residue fractions of loaded polymer samples may have originated 
from degradation of varying drug contents of the samples. Although we cannot make a 
quantitative determination of drug contents of polymer samples from differences, it has 
(a) 
(b) 
(c) 
(d) 
(e) 
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been obvious that loading efficiency has increased with increasing polymer and drug 
concentrations of loading. 
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Figure 5.52. Comparison of DTG and TGA thermograms of 4 arm PMMA-b-PAA 
(MW 4900/18000) loaded at different polymer concentrations with that of 
model drug (5FU). 
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5.6. Drug Release 
 
 Prior to achievement of drug release experiments certain assumptions related to  
theory of drug release performed in a diffusion cell under continuous flow of fresh 
buffer solution, and criterion involved by determination of released amount of drug 
through UV-measurements has to be verified by experimental methods. The first 
prerequisite to determine amount of drug is zero absorbance of neat polymer which is 
defined with the term ‘control’. UV-absorbance of receptor compartment versus time 
was measured as described in Chapter 4.9 for the two cases called ‘control’ and ‘blank’. 
When neat polymer was placed in donor compartment for control experiment no 
absorbance throughout experiment was observed.  Permeation of neat drug (5FU) 
solution put in donor compartment was also monitored to compare kinetics of drug 
release from loaded polymer particles with that of blank. Release profiles of both 
control and blank experiments are given in Figure 5.53. 
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Figure 5.53.  Drug release profiles of neat polymer (control) and neat drug (blank) 
determined by UV-spectroscopy from receptor compartment of diffusion 
cell. 
 
 
 Effect of temperature of medium on UV-absorbance of drug that permeated from 
donor compartment of diffusion cell to the receptor compartment through membrane 
that separates the two compartments was observed as in Figure 5.54. Experiments 
performed at 22°C and 37°C indicate that permeation increases at higher temperatures.  
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Figure 5.54. Release profiles of neat drug passed through membrane of diffusion cell at 
different medium temperatures. 
 
  
 Measurements of UV-absorbance were performed with 1 ml/min flowrate of 
fresh PBS passing through receptor compartment of diffusion cell for all experiments 
performed to validate assumptions employed to describe mass transfer system. It was 
the maximum flowrate at which amount of release could be detected. At higher 
flowrates concentration of drug was too low to be detected by UV-spectrometry.  
One last parameter that could have an effect on mass transfer rate was rate of 
mixing in donor and receptor compartments. Theoretical model proposed in Chapter 3 
assumes homogeneous drug concentrations in both donor and receptor compartments 
which require continuous mixing. Same model assumes that mass transfer through 
membrane depends on concentration difference only.  Effect of mixing in compartments 
of diffusion cell were observed by employing no mixing, mixing in donor compartment 
only and mixing in both compartments when a known amount of neat drug was placed 
in donor compartment and PBS passed through receptor compartment at 1 ml/min 
flowrate. Amount of drug permeated through membrane was monitored for each 
condition as shown in Figure 5.55. The three profiles did not exhibit significant 
variations especially within the initial interval of experiment which confirms that the 
only driving force is concentration difference at the two sides of membrane. However, 
when donor compartment was not mixed, permeation profile was more linear since the 
drug solubility was poor. Probably drug precipitated at the upper side of membrane 
providing an approximately constant flux.  
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Figure 5.55. Effect of mixing in donor and receptor compartments of diffusion cell. 
 
 
Permeation profiles in cases of mixing exhibited similar mass transfer behavior; 
until 40% of the total drug placed in donor compartment permeated through membrane, 
profile was linear with a constant mass transfer coefficient. Then, depending on the 
decrease in drug concentration in donor compartment, mass transfer rate decreased. 
However, since mass fluxes in initial interval are identical, effect of mixing rate has no 
effect on mass transfer rate (dM/dt) and it is a function of concentration difference only. 
The experiment indicates that mixing in donor compartment is essential since 
concentration difference at the two sides of membrane cannot represent average 
concentrations of donor and receptor compartments if there is no mixing. Homogeneity 
of the receptor compartment is also necessary to eliminate effect of variations in 
flowrate that passes through receptor compartment. Therefore, both compartments are 
well mixed in drug release experiments in order to provide homogeneous drug 
concentrations at both sides of the membrane.  
Drug release experiments from 5FU loaded 4 arm PMMA-b-PAA were 
performed for the samples with the highest drug loading contents. Figure 5.56 shows 
release profiles of 5FU from loaded 4 arm PMMA-b-PAA samples at two different 
flowrates. Data was collected continuously at 1 min intervals for 400 hours. Cumulative 
amount of released drug was determined from downstream at every 1000 minutes 
intervals. Experimental data of experiments have been given in Appendix B.  
Loading conditions of the sample can be reminded as 3500 mg/L polymer & 
drug concentration in 3 ml volume, being loaded for 4 hours at 15 °C and at pH=1.2. 
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Release of the loaded drug from particles occurred in donor compartment of the 
diffusion cell, then released amount was transferred to receptor compartment through 
semi-permeable membrane. Fresh PBS solution passed through receptor compartment 
of diffusion cell with 0.25 ml/min flow rate. But it was too hard to detect concentration 
of released drug when mass decreased.  The experiment was repeated with 0.025 
ml/min PBS flow rate and it was observed that results of the two experiments were 
consistent. 
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Figure 5.56. Drug release profiles of 4 arm PMMA-b-PAA loaded at 3500 mg/L 
polymer concentration at 15°C, 4 h. (a) Amount of drug released versus 
time; (○) series belong to the sample with DLC=13.6%, PBS flow 
rate=0.025 ml/min. (●) series belong to DLC=20.6%, PBS flow rate=0.25 
ml/min. Mt amounts were determined from collected 15 ml portions of 
downstream. 
 
 
 Concentration of drug in receptor compartment monitored by UV-spectroscopy  
was used to determine amount of released drug per unit time by using Equation 5.6. 
 
 
Mt = A266× 0.016456 (mg/ml) × flowrate (ml/min)× t (min) (5.6)
               
 
Since flowrate of PBS solution that received released amount of drug is quite 
small (0.025 ml/min) calculation of released drug per minute may only be 
approximately representative. In order to confirm the quantities calculated from 
continuous release data, samples of downstream collected for 600 minute intervals (15 
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ml) were separately analysed by UV-spectrophotometry. The data gathered that way for 
the two replicates of release experiments from 5FU loaded 4 arm PMMA-b-PAA, 
loaded at a polymer concentration of 3500 mg/L, are shown in Figure 5.57. 
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Figure 5.57.  Drug release profiles of 4 arm PMMA-b-PAA loaded at 3500 mg/L 
polymer concentration at 15°C, 4 h. (a) Released fraction of drug versus 
time, (b) Blank experiment of 5FU permeation through membrane (n=3). 
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Figure 5.58.  Graphical determination of 5FU permeability through membrane that 
separates donor and receptor compartments of diffusion cell.  
 
 
Permeability is calculated as P=0.005 from experimental data obtained by 
keeping drug concentration constant at donor compartment. Initial 5FU concentration 
introduced to donor compartment was 10 mg/ml. The slope of linear function given in 
Figure 5.58 provided permeability of the semi-permeable membrane that separated the 
two compartments of diffusion cell as derived in Chapter 3.3 (Equation 3.36). 
As long as permeability was known and it is the only mass transfer resistance 
that released drug confronts prior to measurement, all constants were available within 
the model derived in Chapter 3.2. Equation 3.30 was the general form of derived model 
based on assumption that drug release from particles would be expressed according to 
power law which can be declared by the mathematical expression ktn. Since the volume 
of donor compartment is 1 ml,  Cd = ktn was substituted to derive model equation which 
included the release rate constant (k) and power index (n) which constituted the degree 
of release kinetics. Eventually, the ultimate equation (Equation 3.31) had four 
unknowns the two (Cn and C) being integration constants as expressed in Equation 5.7: 
 
 
),,,()( nkCCftM nt =  (5.7)
 
 
 Solution of this equation was achieved by a trial and error approach, by using 
Solver tool (Microsoft Office Excel, 2007) to minimize sum of square errors (SSE) 
calculated from errors between theoretical and experimental Mt values. Solution of 
equation yields a zero order release behavior from particles within the donor 
compartment. The only constraint for the solution was non-negativity of n. For this case 
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k and Cn values were estimated as k=9.78×10-4 and Cn=0.217.  C is zero since initial 
condition claims that drug concentration in donor compartment is zero at t=0.  SSE is 
0.0658. General equation can then be represented as in Equation 5.8. 
 
 
( ) tt eFFttM κκ −+×××= 217.0109.78109.78)( 4-4-  (5.8)
 
 
where concentration of the donor compartment is constant and Cd=ktn=9.78×10-4 mg/ml 
since n=0. Then mass transfer rate is to be constant throughout experiment and release 
process occurs at steady state. 
 Comparison of experimental and theoretical Mt and Mt/M values calculated from  
Equation 3.31 are shown on Figure 5.59. Here it can be observed that experimental data 
shows deviation from linearity. 
 Drug release systems may comply with more than one mechanisms and different 
release profiles at initial and proceeding stages of drug release is a very common issue. 
In order to decrease SSE and provide a better fit between theoretical model and 
experimental results, it is recommended to make a distinction between initial release 
profile up to where Mt/M<0.6 and late release profile where Mt/M>0.4 and analyze the 
two regions separately. The overlapping region may be explained by both mechanisms 
(Ho and Sirkar, 1992).  
The first interval starting from t=0 up to t=130 hour covers the first stage of drug 
release where 40% of the drug loaded to polymer sample was released. Then Equation 
3.31 was solved for each interval separately as shown in Appendix B. As a result SSE 
decreased to 0.016 and deviation from experimental data diminished as in Figure 5.60.  
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Figure 5.59. Experimental and theoretical values of (a) Mt and (b)Mt/M obtained from 
model that assumes Cd=ktn=9.78×10-4 mg/ml, for the drug release from 4 
arm PMMA-b-PAA nanoparticles. 
 
 
 Solution of equation yields an approximately zero order release behavior again. 
n1=0.0025 that is quite close to zero is the order of release rate for the initial interval 
and  n2=0 for the rest of the release process. As release rate is a bit higher in the initial 
region the main difference in two intervals originate from k values which are 
k1=1.35×10-3 and k2=7.59×10-4. The constraints for the solution were non-negativity of 
n values and C=0 for the initial interval of drug release. For this case Cn values were 
estimated as C1=0.12 and C2=-0.212 for the two intervals. C was nonzero for the second 
(b) 
(a) 
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interval and was estimated to be C3=0.118 as shown in Appendix B. The third, fourth 
and fifth terms of the alternating series that appear in Equation 3.31 were not significant 
although they were nonzero, therefore they were not considered for constitution of the 
general equation. 
Equation 3.31 for the solution of equation in two separate intervals that cover the 
first 130 hours and the rest of release process respectively, yields the two equations 
given in Equations 5.8 and 5.9. 
 
 
t
t e
FtFtM κκ
−+×−×= 12.0101.35
0025.1
101.35 0025..03-0025.1-3       ⎥⎦
⎤⎢⎣
⎡ ≤ 40.0
M
Mt  (5.8)
 
 
18.1212.01059.7107.59 4-4- +−×−×= − tt eFtFM κκ            ⎥⎦
⎤⎢⎣
⎡ > 40.0
M
Mt  (5.9)
 
 
where F is volumetric flow rate of PBS stream passing through receptor compartment 
(0.025 ml/min), κ=AP/Vr, Vr is volume of receptor compartment (0.47 ml), A is area of 
membrane (0.785 cm2) and P is permeability calculated previously (0.005 cm/min). 
Concentration of donor compartment (Cd) also has two conditions given by the 
mathematical expressions as in Equations 5.10 and 5.11. 
 
 
-3101.35×≅dC    mg/ml                  ⎥⎦
⎤⎢⎣
⎡ ≤ 40.0
M
Mt  (5.10)
 
 
-4107.59×=dC   mg/ml                    ⎥⎦
⎤⎢⎣
⎡ > 40.0
M
Mt  (5.11)
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Figure 5.60. Experimental and theoretical values of (a) Mt and (b)Mt/M obtained from 
model that assumes Cd=1.35×10-3 mg/ml (for the initial interval where 
Mt/M<40) and Cd=7.59×10-4 mg/ml (for the late interval where Mt/M>40), 
for the drug release from 4 arm PMMA-b-PAA nanoparticles. 
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5.7  Biodegradation 
 
Biodegradability of particles were evaluated in terms of particle sizes of 
degraded 4 arm PMMA-b-PAA samples at 37°C. For the particle size analysis with 
DLS polymer samples were degraded in standard PBS solution.  
Polymer samples prepared by simple equilibrium method were analyzed in 1 
hour to determine particle size of undegraded polymer particles. Initial particle size is 
about 20-30 nm as dissolved in aqueous medium at 25 ºC. Dissolved polymeric micelle 
samples were introduced into degradation temperature that was 37 ºC, then they start to 
agglomerate and reach an average particle size of 35 nm within 36 hours. Within 3 days 
particle size drops back to an average particle size of 25 nm, and below 10 nm in a 7 
days period of degradation. Variation of particle sizes for degraded polymer samples 
were shown in Figure 5.61.   
Volume average particles sizes shown in Figure 5.61 represent the dominant 
peak that constitutes more than 90% of total volume of particles. That peak also 
represents the smallest particle size interval. But presence of other peaks having a 
particle size between 50 nm and 150 nm indicate tendency of 4 arm PMMA-b-PAA 
particles to agglomerate.  
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Figure 5.61.  Volume average particle size analysis of 4 arm PMMA-b-PAA degraded 
in PBS solution at 37 ºC (n=3). Concentrations of polymer samples were 2 
mg/ml.  
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 The effect of polymer concentration on agglomeration and micelle forming 
behavior versus degradation has to be investigated. For this reason, polymer solutions at 
different concentrations (varying between 1-8 mg/ml) were degraded at 37°C and 
monitored in terms particle size.  
 Particle size distribution of undegraded 4 arm PMMA-b-PAA show that, average 
particle size does slightly increase with increasing polymer concentration, but average 
size of agglomerates which constitutes only a 10% of all particles by volume strongly 
depends on polymer concentration as can be observed from Figure 5.62. Then it can be 
declared that undegraded particles form unimolecular micelles with almost constant 
particle size about 20-30 nm that is virtually independent of polymer concentration. But 
agglomeration tendency increases drastically with increasing concentration of polymer 
in solution.  
After three days of degradation, micelle size remains constant, and dependency 
of agglomerate sizes on polymer concentration is not significant. Particle size still 
occurs in 20-30 nm, while agglomerates at every concentration were observed to be 
about 100-150 nm (Figure 5.63). This case is just identical to the initial particle size 
distributions observed at low polymer concentrations, only volumetric ratios of 
agglomerates to particles are smaller. Particle size distributions of the samples 
determined by zetasizer have been reported in Appendix C. 
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Figure 5.62. Variation of particle size with increasing polymer concentration of 4 arm 
PMMA-b-PAA nanoparticles before degradation. 
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Figure 5.63. Variation of particle size with increasing polymer concentration of 4 arm 
PMMA-b-PAA nanoparticles degraded for 3 days. 
 
  
At the seventh day of degradation, agglomerates were completely diminished 
and particle sizes were decreased down to below 10 nm as (Figure 5.64). Thereby the 
biodegradability of 4 arm PMMA-b-PAA with a PMMA core smaller than 5000 Da was 
substantiated.  A dependency of particle size on polymer concentration still holds but 
the polymer solution at this point has lost all its capability to produce a micellar 
structure that can entrap hydrophobic molecules. 
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Figure 5.64. Variation of particle size with increasing polymer concentration of 4 arm 
PMMA-b-PAA nanoparticles degraded for 7 days. 
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5FU loaded particles in dimethyl formamide and acetic acid solution were also 
investigated by DLS. Hydrodynamic radius of unloaded 4 arm PMMA-b-PAA  particles 
was 14 nm with a slight agglomeration (about 6.3 volume % agglomerates having 79 
nm size) as given in Table C.2. The polymer samples loaded in dimethyl formamide 
(DLC=7.3%) and 1% acetic acid solution (DLC=8.0%) yielded almost the same particle 
size as unloaded sample, and exhibited no agglomeration. Volume average particle sizes 
of 4 arm PMMA-b-PAA  particles were 11.3 nm (loaded in DMF) and 12.3 nm (loaded  
in 1% acetic acid). Detailed description of particle size distributions of the samples have 
been shown in Tables C.12-C.13. 
All the samples that were employed for the biodegradation experiments were 
loaded with pyrene (as described in Chaper 4.6) after the particle size analysis to check 
their loading capacity. Figure 5.65 shows the capability of 4 arm PMMA-b-PAA as 
dissolved in PBS solution at various polymer concentrations. UV absorbance of pyrene 
loaded samples show the increasing abilities of micelle forming and entrapping capacity 
of polymer samples with increasing polymer concentration. It is obvserved in Figure 
5.66 that biodegraded polymer samples have lost their capability to entrap and 
solubilize pyrene molecules. 
Particle sizes were also determined by AFM images in order to confirm particle 
size and particle size distribution data obtained by DLS. In order to observe single 
particles and agglomerates, dilute solutions (such as 5×10-3 mg/ml) were prepared 
(Demir and Erman 2002). Figure 5.67 and 5.68 show how agglomeration proceeds even 
within 1 hour of degradation at 37°C. 
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Figure 5.65. Entrapment efficiency of 4 arm PMMA-b-PAA in PBS solution having 
polymer concentrations 8,6,4,2,1 mg/ml (from top to bottom), before 
degradation. 
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Figure 5.66. Entrapment efficiency of 4 arm PMMA-b-PAA in PBS solution having 
polymer concentrations 6,4,2,1 mg/ml (from top to bottom), after 7 days of 
degradation. 
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Figure 5.67.  AFM micrograph of 4 arm PMMA-b-PAA (MW 4900/18000 Da) as 
dissolved in aqueous medium at 25 °C. 
 
 
Figure 5.68.  AFM micrograph of 4 arm PMMA-b-PAA (MW 4900/18000 Da) 
degraded for 1 hour in aqueous medium at 37 °C. 
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Figure 5.69.  AFM micrograph of 4 arm PMMA-b-PAA (MW 4900/18000 Da) as 
degraded for 7 days in aqueous medium at 37 °C. 
 
 
Figure 5.70.  AFM micrograph of 4 arm PMMA-b-PAA (MW 4900/18000 Da) as 
degraded for 10 days in aqueous medium at 37 °C. 
 
 
 
 107
 
 
 
 
 
Table 5.15. Particle size analysis of 4 arm PMMA-b-PAA (MW: 18000, fc:0.27). 
Degradation 
Time Count 
Average 
Particle Size 
(nm) 
Minimum 
Particle Size 
(nm) 
Minimum 
Particle Size 
(nm) 
σ 
5×5 µm2 
As dissolved 
 
88 
158 
26.0 
31.1 
11.0 
11.0 
150.3 
207.3 
25.4 
24.3 
1 hour 
 
161 
53 
35.2 
58.3 
11.0 
11.0 
305.8 
298.7 
44.1 
69.4 
1 day 38 42.9 11.0 122.7 28.3 
5 days 44 37.8 11.0 288.6 54.2 
7 days 382 36.3 11.0 342.7 46.7 
10 days 83 22.65 11.0 85.4 17.9 
2×2 µm2 
As dissolved 
 
53 
133 
14.2 
9.9 
4.4 
4.4 
78.0 
68.8 
13.4 
10.9 
1 hour 
 
55 
59 
12.4 
17.9 
4.4 
4.4 
64.8 
197.5 
12.8 
29.6 
1 day 55 16.13 4.4 93.1 21.0 
5 days 16 19.0 4.4 107.5 26.4 
7 days 107 13.12 4.4 189.2 19.8 
10 days 60 8.7 4.4 58.3 9.6 
 
 
 
 
Figure 5.71. Particle analysis of 4 arm PMMA-b-PAA (MW 4900/18000 Da) as 
degraded for 10 days in aqueous medium at 37 °C. 
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Particle sizes from 5×5 µm2 and 2×2 µm2 scans were determined by particle 
analysis and are given by Table 5.15. Particle analysis of 5×5 µm2 AFM scans can be 
examined in detailed from sketches and statistics given in Appendix D. In all samples 
exposed to particle analysis, threshold height was kept at 1±0.2 nm. σ values were given 
as a measure of variation of particle sizes indicating an evaluation of particle size 
distribution. 
Agglomerates remaining at 7th day of degradation can be observed in Figure 
5.69. They seem like accumulated particles when compared to solid agglomerates 
observed previously. By the 10th day of degradation, agglomerates significantly 
decreased both in number and particle size (Figures 5.70 & 5.71).   
AFM images and particle analysis cannot yield definite results for particle size 
and distribution analysis since samples can never be perfectly representative. Besides 
agglomerates observed from micrographs might have occurred via drying process. But 
when AFM micrographs were compared with particle size determinations achieved by 
DLS, it was observed that results were comparative after all. 
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CHAPTER 6 
 
CONCLUSIONS 
 
3 arm, 4 arm and 6 arm PMMA-b-PAA copolymers having molecular weights 
between 18kDa-80kDa and hydrophobic core ratios varying from 0.1 to 0.45 were 
synthesized by ATRP method. 
Brominated 3 arm, 4 arm and 6 arm initiators of first stage of ATRP reaction 
were synthesized from 1,3,5-trihydroxybenzene, pentaerythritol and dipentaerythritol 
with 94.5, 76.3 and 67.3% conversions. Pentaerythritol tetrakis (2-bromoisobutyrate) 
from pentaerythritol and dipentaerythritol hexakis (2-bromoisobutyrate) from 
dipentaerythritol were synthesized with 100% purity while attained purity of 1,3,5- (2-
bromo-2-methyl propionate) benzene from 1,3,5-trihydroxybenzene was 82 %.  
Sythesis of PMMA cores were achieved in anisole by using PMDETA as ligand 
and CuCl as catalyst in stoichiometric ratio. Monomer to initiator molar ratio was kept 
250 for each arm. Reactions were carried at 60-70°C for 10-12 minutes to obtain 
PMMA-Br macroinitiators at 5000 Da molecular weights and with acceptable 
polydispersity indexes. Molecular weights were tried to be kept about 5000 Da for 
providing particle sizes of degraded polymers under 5 nm after biodegradation at 37 °C 
following administration into body for therapeutically purposes. This is an important 
requirement for biodegradable polymers to be used for drug delivery for only the 
particles smaller than 5 nm can be removed from circulatory system by renal route. 
3 arm PMMA-b-PtBA synthesis from PMMA-Br macroinitiators were also 
carried in anisole by using PMDETA as ligand. CuBr was used as catalyst with 10% 
excess and monomer to initiator molar ratio varied about 500-600 for each arm. 
Reaction times changing from 5 hours to 20 hours determined molecular weights of 
PMMA-b-PtBA copolymers. Synthesized PMMA-b-PtBA copolymers were reacted 
into PMMA-b-PAA copolymers by selective hydrolysis reaction of tBA chains by 
trifluoroacetic acid. 
Critical micelle concentrations and maximum loading capacities of polymer 
samples were determined by fluorescence method. Pyrene was used as a fluorescent 
probe and critical micelle concentration was determined by both comparing ratio of first 
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and third bands in emission spectra and detecting the shift in I336 band in excitation 
spectra of pyrene loaded polymer samples at different concentrations. Critical micelle 
concentration was observed to increase with increasing molecular weight and maximum 
loading capacity was observed to increase with increasing hydrophobic core ratio. 
Therefore an optimum PMMA-b-PAA copolymer was proposed to have 20000 Da 
molecular weight and 0.25 hydrophobic core ratio in order to provide a minimum 
critical micelle concentration and maximum loading capacity for hydrophobic drugs. 
Drug loading method was optimized with 4 arm PMMA-b-PAA having 30 kDa 
molecular weight and 0.23 hydrophobic core ratio and indomethacin as model drug. 
Drug and polymer was easily loaded at high loading content (24.8%) with 1 hour of 
mixing at room temperature following dissolution in a strong solvent which was 
dimethylformamide. Removal of solvent and excess drug was achieved by dialysis. 
Dialysis method yielded excellent loading performance when compared to salting out 
and solvent deposition methods which constitute alternatives for drug loading.  
Drug loading contents of synthesized PMMA-b-PAA samples with 4 and 6 arms 
were very poor when they were tried to be loaded with the anticancer drug 5 
Fluorouracyl at the same conditions. Therefore determination of ideal loading 
conditions were required. 6 arm PMMA-b-PAA  having molecular weight of 34 kDa 
with hydrophobic core PMMA of 5400 Da, and 4 arm PMMA-b-PAA having molecular 
weight of 18000 Da with hydrophobic core PMMA of 4900 Da), were used for 
determination of ideal drug loading conditions for 5FU loading. The polymers were 
characterized by FTIR to confirm they were completely hydrolyzed and contained 
neither monomer nor solvent residue.    
 Drug loading conditions were optimized as 4 hours of loading at 15°C, within 
aqueous medium with pH value of 1.0-1.5. Polymer samples were dissolved in minute 
amounts of ethanol and drug samples at equal quantities were dissolved in 1% HCl. 
Effect of polymer concentration on loading performance was investigated and it was 
observed that higher polymer concentrations yielded higher drug loading contents. 
Three polymer concentrations (500, 2000 and 3500 mg/L) yielded 8.8 %, 17.7% and 
17.1% drug contents (average drug contents of two replicates), respectively. In FTIR 
spectra of loaded polymer samples, asymmetric stretching of COO- bands appeared due 
to interaction of carboxyl groups of the polymer with 5FU. In DSC and DTG 
thermograms specific degradation peaks of 5FU could not be observed and TGA 
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thermograms indicated an improvement in thermal stability of the polymer probably due 
to interaction with 5FU molecules. 
 Although drug loading contents determined from concentration analysis of 
dialysis media of samples by UV-spectroscopy were very close, TGA thermogram of 4 
arm PMMA-b-PAA loaded at a polymer concentration of 3500 mg/L exhibited 
relatively low residue depicting relatively higher drug content. Therefore 4 arm PMMA-
b-PAA loaded at a polymer concentration of 3500 mg/L samples were tested for their 
drug release performances. 
 Drug release from 4 arm PMMA-b-PAA loaded at a polymer concentration of 
3500 mg/L, at 15°C for four hours were determined by a continuous system equipped 
by a Franz diffusion cell, a syringe pump and a flow cell continuously monitored by UV 
spectroscopy. Absorbance of PBS solution passed through receptor compartment at 
37°C was analyzed with one minute intervals. To confirm continuous measurement, 15 
ml samples of downstream were separately analyzed to calculate released amount of 
drug versus time. The experiment was repeated at two different flow rates, 0.25 ml/min 
and 0.025 ml/min, which yielded comparable amounts of drug released. Release profile 
from particles has been estimated by considering continuous mass transfer of released 
drug to the receptor compartment of diffusion cell through a semipermeable membrane. 
Concentration of PBS flow passing through receptor compartment was monitored 
throughout release process and release profile was modelled following determination of 
permeability as 0.005 cm/min which constituted the mass transfer coefficient of overall 
system. 
Drug release from 4 arm PMMA-b-PAA was modeled separately for the initial 
and proceeding intervals of release process. Solution of parameters (n, k and integration 
constants) by trial and error indicated that release from polymer particles approached 
zero order kinetics with negligibly small n for the initial interval and constant release 
for the rest of the process. Therefore drug release mechanism was dominated by k 
constants which were determined as 1.35×10-3 and 7.59×10-4 for the initial and late 
intervals of drug release, respectively. Precise values of coefficient (k) and degree (n) of 
release  kinetics within donor compartment provided by the solutions has been tabulated 
in Table 6.1. They show the release behavior from PMMA-b-PAA nanoparticles 
according to the mathematical model derived by assuming drug concentration in donor 
compartment to be time dependent obeying the power low equation which was 
represented by the  mathematical expression, ktn. 
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Table 6.1.  Constants of release kinetics equation from 5FU loaded PMMA-b-PAA 
nanoparticles. 
 
 
Release Profiles for the 
Initial and Late Periods 
(SSE=0.016) 
 
 
 
Release Profile 
Along the Whole 
Release Period 
(SSE=0.066) 
⎥⎦
⎤⎢⎣
⎡ ≤ 40.0
M
M t  ⎥⎦
⎤⎢⎣
⎡ > 40.0
M
M t  
k n k1 n1 k2 n2 
9.78×10-4 0 1.35×10-3 0.0025 7.59×10-4 0 
 
 
 Biodegradation profiles of 4 arm PMMA-b-PAA were consistent with release 
profiles which indicated erosion of polymeric particles. 4 arm PMMA-b-PAA particles 
exposed to buffer solution of 7.4 pH and body temperature tended to agglomerate for 
the first day of degradation. This behavior explains 6 hours of delay in release profile, 
when agglomeration was severe. Then agglomerates slowly reduced in seven days when 
drug release appeared almost with a constant rate.  
 Average particle size of  4 arm PMMA-b-PAA having a PMMA core of 5000 
Da molecular weight and 0.25±0.05 hydrophobic core ratio was 20-30 nm as dissoleved 
in aqueous medium. Due to agglomeration, particle size could rise up to 150 nm, but 
agglomerates were rather few (<10 v%). compared to small particles After 10 days of 
degradation average particle size were smaller than 10 nm, dilute samples resulting in 5 
nm. AFM micrographs confirmed these results.  
 For a final word, amphiphilic 4 arm PMMA-b-PAA nanoparticles have been 
proved promising drug carriers especially for hydrophobic anticancer drugs. They 
exhibit substantial drug loading content (14 % for 5FU and 22% for indomethacin) and 
provided controlled release for 18 days. All polymer samples studied for their release 
performance exhibited sustained release with a 4-6 hours of delay prior to beginning of 
drug release. This delay is attributed beneficial for the application of release system in 
cancer therapy since sustained delivery permits carrier particles accumulate in tumors. 
Agglomerated particles not exceeding 100 nm particle size provides another benefit for 
cancer therapy ensuring passive tumor targeting. On the other hand further 
agglomeration of particles within the first few hours of administration may cause 
problems in reticuloendothelial system. A surface modification of 4 arm PMMA-b-PAA 
nanoparticles may be necessary to prevent severe agglomeration for parenteral 
applications of drugs carried by 4 arm PMMA-b-PAA nanoparticles. 
 113
REFERENCES 
 
Aguiar, J.; Carpena, P.; Molina-Bolívar, J. A.; Carnero, R. C. On the Determination of 
the Critical Micelle Concentration by the Pyrene 1:3 Ratio Method. J. Colloid 
Interf. Sci. 2003, 258, 116–122. 
 
 
Allen, C.; Maysinger, D.; Eisenberg, A. Nano-Engineering Block Copolymer 
Aggregates for Drug Delivery. Colloid Surface B. 1999, 16, 3–27.  
 
 
Arias, J. L.; Ruiz, M. A.; López-Viota, M.; Delgado, Á. V.; Poly(Alkylcyanoacrylate) 
Colloidal Particles as Vehicles for Antitumour Drug Delivery: A Comparative 
Study. Colloids and Surface B. 2008, 62, 64–70. 
 
 
Asthana, A.; Chauhan, A. S.; Diwan, P.V.; Jain, N.K. Poly(Amidoamine) (PAMAM) 
Dendritic Nanostructures for  Controlled Site-Specific Delivery of Acidic Anti-
Inflammatory Active Ingredient. AAPS Pharm.Sci. 2005, 6, 536-542.  
 
 
Aulenta, F.; Hayes, W.; Rannard, S. Dendrimers: A New Class of Nanoscopic 
Containers and Delivery Devices. Eur. Polym. J. 2003, 39, 1741–1771. 
 
 
Babu, V. R.; Sairam, M.; Hosamani, K. M.; Aminabhavi, T. M. Development of 5-
Fluorouracil Loaded Poly(Acrylamide-co-Methylmethacrylate) Novel Core-
Shell Microspheres: In Vitro Release Studies. Int. J. Pharm. 2006, 325, 55–62. 
 
 
Bartolozzi, I.; Solaro, R.; Schacht, E.; Chiellini, E. Hydroxyl End-Capped Macromers 
of N-Vinyl-2-Pyrrolidinone as Precursors of Amphiphilic Block Copolymers. 
Eur. Polym. J. 2007, 43, 4628–4638. 
 
 
Bontha, S.; Kabanov, A. V.; Bronich, T. K. Polymer Micelles With Cross-Linked Ionic 
Cores for Delivery Of Anticancer Drugs. J. Control. Release. 2006, 114, 163-
174. 
 
 
Brannon-Peppas L.; Blanchette J. O. Nanoparticle and Targeted Systems for Cancer 
Therapy. Adv. Drug Deliver. Rev. 2004, 56, 1649– 1659. 
 
 
Brannon-Peppas L. Polymers in Controlled Drug Delivery. Medical Plastics And 
Biomaterials Magazine. 1997, 4, 34-44. 
 
 
 114
Brar, A. S.; Saini, T. Atom Transfer Radical Polymerization of 2-Methoxy Ethyl 
Acrylate and Its Block Copolymerization with Acrylonitrile. Eur. Polym. J. 
2007, 43, 1046–1054. 
 
 
Braunecker, W. A.; Matyjaszewski K. Controlled/Living Radical Polymerization: 
Features, Developments and  Perspectives. Prog. Polym. Sci. 2007, 32, 93-146 
 
 
Breitenbach, A.; Li, Y. X.; Kissel, T. Branched Biodegradable Polyesters for Parenteral 
Drug Delivery Systems. J. Control. Release. 2000, 64, 167–178.  
 
 
Burguière, C., Chassenieux, C., Charleux, B. Characterization of Aqueous Micellar 
Solutions of Amphiphilic Block Copolymers of Poly(Acrylic Acid) And 
Polystyrene Prepared via ATRP. Toward the Control of the Number of Particles 
in Emulsion Polymerization. Polymer. 2003, 44, 509–518. 
 
 
Candau, F.; Ottewill, R. H. Scientific Methods for the Study of Polymer Colloids and 
their Applications ; Kluwer : Strasbourg, 1988, pp 311-314. 
 
 
Castelli, F.; Messina, C.; Sarpietro, M. G.; Pignatello, R.; Puglisi, G. Eudragit as 
Controlled Release System for Anti-Inflammatory Drugs. A Comparison 
between DSC and Dialysis Experiments. Thermochim. Acta.  2003, 400, 227–
234.  
 
 
Castelli, F.; Conti, B.; Maccarrone, D.; Lacamera, O.; Conte, U. Indomethacin-
Dipalmitoylphosphatidylcholine Interaction. A Calorimetric Study of Drug 
Release From Poly(Lactide-co-Glycolide) Microspheres into Multilamellar 
Vesicles. Drug Deliv. 1997, 4, 273-279.  
 
 
Celik, C.; Hızal, G.; Tunca, U. Synthesis of Miktoarm Star and Miktoarm Star Block 
Copolymers via a  Combination of Atom Transfer Radical Polymerization and 
Stable Free-Radical Polymerization. J. Polym. Sci. Pol. Chem. 2003, 41, 2542–
2548.  
 
 
Chatterjee, U.; Jewrajka, S. K.; Mandal, B. M. The Amphiphilic Block Copolymers of 
2-(Dimethylamino)Ethyl Methacrylate and Methyl Methacrylate: Synthesis by 
Atom Transfer Radical Polymerization and Solution Properties. Polymer. 2005, 
46, 10699–10708.  
 
 
Cheng, Y.; Xu, T. The Effect of Dendrimers on the Pharmacodynamic and 
Pharmacokinetic Behaviors of Non-Covalently or Covalently Attached Drugs. 
Eur. J. Med. Chem. 2008, 43, 2291-2297.  
 115
Chu, J.; Chen, J.; Zhang K. N,N,N,N,N-Penta(Methyl Acrylate)Diethylenetriamine: A 
Novel Ligand for Atom Transfer Radical Polymerization of Methyl 
Methacrylate. J. Polym. Sci. Pol. Chem. 2004, 42, 1963–1969. 
 
 
Chytil, P.; Etrych, T.; Koňák, Č.; Šírová, M.; Mrkvan, T.; Říhová, B.; Ulbrich, K. 
Properties of HPMA Copolymer–Doxorubicin Conjugates with pH-Controlled 
Activation: Effect of Polymer Chain Modification. J. Control. Release. 2006, 
115, 26–36. 
 
 
Coessens, V.; Pintauer, T.; Matyjaszewski K. Functional Polymers by Atom Transfer 
Radical Polymerization. Prog. Polym. Sci. 2001, 26, 337-377. 
 
 
Crank J. The Mathematics of Diffusion; Clarendon Pres: Oxford, 1975; pp 89-91. 
 
 
Demir, M. M.; Erman, B. Dimensions of Polystyrene Particles Deposited on Mica from 
Dilute Cyclohexane Solution at Different Temperatures. Macromolecules, 2002, 
35, 7986-7992. 
 
  
Deng, G.; Ma, D.; Xu, Z. Synthesis of ABC-Type Miktoarm Star Polymers By ‘‘Click’’ 
Chemistry, ATRP and ROP. Eur. Polym. J. 2007, 43, 1179–1187.  
 
 
Djordjevic, J.; Michniak, B.; Uhrich, K. E. Amphiphilic Star-Like Macromolecules as 
Novel Carriers for Topical Delivery of Nonsteroidal Anti-Inflammatory Drugs. 
AAPS Pharm.Sci. 2003, 5, Article 26, 1-12. 
 
 
Dodova, M. G.; Calis, S.; Crcarevska, M. S.; Geskovski, N.; Petrovska, V.; Goracinova, 
K.; Wheat Germ Agglutinin-Conjugated Chitosan–Ca–Alginate Microparticles 
for Local Colon Delivery of 5-FU: Development and in vitro Characterization. 
Int. J. Pharm. 2009, 381, 166–175. 
 
 
Eerikäinen, H.; Peltonen, L.; Raula, J.; Hirvonen, J.; Kauppinen, E. I. Nanoparticles 
Containing Ketoprofen and Acrylic Polymers Prepared by an Aerosol Flow 
Reactor Method. AAPS Pharm. Sci. 2004, 5, Article 68, 1-9.  
 
 
Erdoğan, T.; Ozyürek, Z.; Hızal G.; Tunca U. Facile Synthesis Of AB2-Type Miktoarm 
Star Polymers Through the Combination of Atom Transfer Radical 
Polymerization and Ring-Opening Polymerization. J. Polym. Sci. Pol. Chem. 
2004, 42, 2313–2320. 
 
 
 116
Even, M.; Haddleton, D. M.; Kukulj, D. Synthesis and Characterization of Amphiphilic 
Triblock Polymers by Copper Mediated Living Radical Polymerization. Eur. 
Polym. J. 2003, 39, 633–639.  
 
 
Faisant, N.; Akiki, J.; Siepmann, F.; Benoit, J.P.; Siepmann, J. Effects of the Type of 
Release Medium on Drug Release From PLGA-Based Microparticles: 
Experiment and Theory. Int. J. Pharm. 2006, 314, 189–197. 
 
 
Faisant, N.; Siepmann, J.; Richard, J.; Benoit, J.P. Mathematical Modeling of Drug 
Release from Bioerodible Microparticles: Effect of Gamma-Irradiation. Eur. J. 
Pharm. Biopharm. 2003, 56, 271–279. 
 
 
Gast, A. P. Polymeric Micelles. Curr Opin Colloid In. 1997, 2, 258-263. 
 
 
Ganguly, M. Controlled Polymerization of Alkyl Methacrylates. Ph.D. Dissertation, 
University Of Pune, Pune, India. December 2002. 
 
 
Gao, H.; Gu, Y.; Ping, Q. The Implantable 5-Fluorouracil-Loaded Poly(L-Lactic Acid) 
Fibers Prepared by Wet-Spinning from Suspension. J. Control. Release. 2007, 
118, 325–332. 
 
 
Gaucher, G.; Dufresne, M. H.; Sant, V. P.; Kang, N.; Maysinger D.; Leroux J. C. Block 
Copolymer Micelles: Preparation, Characterization and Application in Drug 
Delivery. J. Control. Release. 2005, 109, 169–188. 
 
 
Gillies, E. R., Fréchet, J. M. J. Development of Acid-Sensitive Copolymer Micelles for 
Drug Delivery. Pure Appl. Chem. 2004, 76, 1295–1307. 
 
 
Grayson, S. M.; Fréchet, J. M. J. Convergent Dendrons and Dendrimers: from Synthesis 
to Applications. Chem. Rev. 2001, 101, 3819-3868. 
 
 
Gudasi, K. B.; Vadavi, R. S.; Shelke, N. B.; Sairam, M.; Aminahbavi, T. M. Synthesis 
and Characterization of Novel Polyorganophosphazenes Substituted with 4-
Methoxybenzylamine and 4-Methoxyphenethylamine for in vitro Release of 
Indomethacin and 5-Fluorouracil. React. Funct. Polym. 2006, 66, 1149–1157. 
 
 
Gupte, A.; Ciftci, K. Formulation and Characterization of Paclitaxel, 5-FU and 
Paclitaxel + 5-Fu Microspheres. Int. J. Pharm. 2004, 276, 93–106. 
 
 117
Haddleton, D. M.; Clark, A. J.; Crossman, M. C.; Duncalf, D. J.; Heming, A. M.; 
Morsley,  S. R.;  Shooter, A. J. Atom Transfer Radical Polymerisation (ATRP) 
Of Methyl Methacrylate in the Presence of Radical Inhibitors. Chem. Commun. 
1997, 1173-1174. 
 
 
Heng, P. W. S.; Chan, L. W.; Easterbrook, M. G.; Li, X. Investigation of the Influence 
of Mean HPMC Particle Size and Number of Polymer Particles on The Release 
of Aspirin from Swellable Hydrophilic Matrix Tablets. J. Control. Release. 
2001, 76, 39–49. 
 
 
Ho, W. S. W.; Sirkar, K. K. Membrane Handbook; Van Nostrand Reinhold; New York, 
1992; pp 915-931. 
 
 
Ibrahim, K. Studies on Atom Transfer Radical Polymerization of Acrylates and 
Styrenes with Controlled Polymeric Block Structures. Ph.D. Dissertation, 
Helsinki University Of Technology, Helsinki, Finland, June 2006.  
 
 
Ishizu, K.; Furukawa, T.; Yamada, H. Silver Nanoparticles Dispersed within 
Amphiphilic Star-Block Copolymers as Templates for Plasmon Band Materials. 
Eur. Polym. J. 2005, 41, 2853–2860.  
 
 
Ishizu, K.; Uchida, S. Synthesis and Microphase-Separated Structures of Star-Block 
Copolymers.  Prog. Polym. Sci. 1999, 24, 1439–1480. 
 
 
Jain, A.; Jain, S. K. In vitro and Cell Uptake Studies for Targeting of Ligand Anchored 
Nanoparticles for Colon Tumors. Eur. J. Pharm. Sci. 2008, 35, 404–416. 
 
 
Jankova, K.; Bednarek, M.; Hvilsted, S. Star Polymers by ATRP of Styrene and 
Acrylates Employing Multifunctional Initiators. J. Polym. Sci. Pol. Chem. 2005, 
43, 3748–3759. 
 
 
Jie, P.; Venkatraman, S. S.; Min, F.; Freddy, B. Y. C.; Huat, G. L. Micelle-Like 
Nanoparticles of Star-Branched PEO–PLA Copolymers as Chemotherapeutic 
Carrier. J. Control. Release. 2005, 110,  20– 33. 
 
 
Jones, M. C.; Hui, G.; Leroux, J. C. Reverse Polymeric Micelles for Pharmaceutical 
Applications. J. Control. Release. 2008, 132, 208-215.  
 
 
Kakizawa, Y.; Kataoka, K. Block Copolymer Micelles for Delivery of Gene and 
Related Compounds. Adv. Drug Deliver. Rev. 2002, 54, 203–222. 
 118
Kang, B. K.; Chon, S. K.; Kim, S. H.; Jeong, S. Y.; Kim, M. S.; Cho, S. H.; Lee, H. B.; 
Khang, G. Controlled Release of Paclitaxel from Microemulsion Containing 
PLGA and Evaluation of Anti-Tumor Activity in vitro and in vivo. Int. J. Pharm. 
2004, 286,147–156. 
 
 
Kang, H.; Liu, W.; He, B.; Shen, D.; Ma, L.; Huang, Y. Synthesis of Amphiphilic Ethyl 
Cellulose Grafting Poly(Acrylic Acid) Copolymers and Their Self-Assembly 
Morphologies in Water. Polymer. 2006, 47, 7927-7934. 
 
 
Kang, N.; Leroux, J. C. Triblock and Star-Block Copolymers of N-(2-Hydroxypropyl) 
Methacrylamide or N-Vinyl-2-Pyrrolidone and D,L-Lactide: Synthesis and Self-
Assembling Properties in Water. Polymer. 2004, 45, 8967–8980. 
 
 
Kang, Y.;  Wu, J.;  Yin, G.;  Huang, Z.;  Yao, Y.;  Liao, X.;  Chen, A.; Pu, X.;  Liao, L. 
Preparation, Characterization and in vitro Cytotoxicity of Indomethacin-Loaded 
PLLA/PLGA Microparticles Using Supercritical CO2 Technique. Eur. J. 
Pharm.Biopharm. 2008, 70, 85-97. 
 
 
Kilian, L. Synthesis and Characterization of Responsive Poly(Alkyl Methacrylate) 
Topologies. Ph. D. Dissertation, Virginia Polytechnic Institute and State 
University, Virginia, USA, July 2004. 
 
 
Klose, D.; Siepmann, F.; Elkharraz, K.; Siepmann, J. PLGA-Based Drug Delivery 
Systems: Importance of the Type of Drug and Device Geometry. Int. J. Pharm. 
2008, 354, 95–103. 
 
 
Krishnan, R. K.; Srinivasan, S. V. Homo and Block Copolymers of tert-Butyl 
Methacrylate by Atom Transfer Radical Polymerization. Eur. Polym. J. 2004, 
40, 2269–2276. 
 
 
Langer, R. S.; Peppas, N. A. Present and Future Applications of Biomaterials in 
Controlled Drug Delivery Systems. Biomaterials. 1981, 2, 201-214. 
 
 
Lele, B. S.; Leroux, J. C. Synthesis of Novel Amphiphilic Star-Shaped Poly(L-
Caprolactone)-block-Poly(N-(2-Hydroxypropyl) Methacrylamide) by 
Combination of Ring-Opening And Chain Transfer Polymerization. Polymer. 
2002, 43, 5595–5606. 
 
 
Leroux, J. C.; Ranger, M. Water-Soluble Amphiphilic Nanocarriers – Applications in 
Drug Delivery, Drug Delivery Companies Report, Autumn-Winter, 2002. 
 
 119
Li, S.; Wang, A.; Jiang, W.; Guan, Z. Pharmacokinetic Characteristics and Anticancer 
Effects of 5-Fluorouracil Loaded Nanoparticles. BMC Cancer. 2008, 8, 103-112. 
 
 
Limer, A. J.; Rullay, A. K.; Sanmiguel V.; Peinado, C.; Keely, S.; Fitzpatrick, E.; 
Carrington, S. D.; Brayden, D.; Haddleton, D. M. Fluorescently Tagged Star 
Polymers by Living Radical Polymerisation for Mucoadhesion and Bioadhesion. 
React. Funct. Polym. 2006, 66, 51–64. 
 
 
Lin, C. C.; Fu, C. H. Controlled Release Study of 5-Fluorouracil-Loaded 
Chitosan/Polyethylene Glycol Microparticles. Drug Deliv. 2009, 16, 274–279.  
 
 
Liu, M.; Kono, K.; Fréchet J. M. J. Water-Soluble Dendritic Unimolecular Micelles: 
Their Potential as Drug Delivery Agents. J. Control. Release.  2000, 65, 121–
131.  
 
 
Liu, Z.; Rimmer, S. Synthesis and Release of 5-Fluorouracil from Poly(N-
Vinylpyrrolidinone) Bearing 5-Fluorouracil Derivatives. J. Control. Release. 
2002, 81, 91–99. 
 
 
Lópezdíaz, D.; Velázquez, M. M. Variation of the Critical Micelle Concentration with 
Surfactant Structure: A Simple Method to Analyze the Role of Attractive–
Repulsive Forces on Micellar Association. Chem. Educ. 2007, 12, 327-330. 
 
 
Lowman, A. M.; Peppas, N. A. Hydrogels, Encyclopedia of Controlled Drug Delivery; 
Wiley; New York, 1999; pp 397-418. 
 
 
Lukyanov, A. N.; V. P. Torchilin. Micelles from Lipid Derivatives of Water-Soluble 
Polymers as Delivery Systems for Poorly Soluble Drugs, Adv. Drug Deliver. 
Rev. 2004, 56, 1273– 1289. 
 
 
Malinowska, A.; Vlček, P.; Kříž, J.; Toman, L.; Látalová, P.; Janata, M.; Masař, B. 
ATRP of (Meth)Acrylates Initiated with a Bifunctional Initiator Bearing 
Trichloromethyl Functional Groups and Structural Analysis Of The Formed 
Polymer. Polymer. 2005, 46, 5–14.  
 
 
Manocha, B.; Margaritis, A. Production and Characterization of  γ -Polyglutamic Acid 
Nanoparticles For Controlled Anticancer Drug Release. Crit. Rev. Biotechnol. 
2008, 28, 83–99. 
 
 
 120
Mao, B. W.; Gan, L. H.; Gan, Y. Y.; Tam, K. C.; Tan, O. K. Controlled One-Pot 
Synthesis of pH-Sensitive Self-Assembled Diblock Copolymers and Their 
Aggregation Behavior. Polymer. 2005, 46, 10045–10055. 
 
 
Marion, S. C.; Okano, T.; Kataoka, K. Functional and Site-Specific Macromolecular 
Micelles as High Potential Drug Carriers. Colloid. Surface. B. 1999, 16, 207–
215. 
 
 
McCarron, P. A.; Hall, M. Incorporation of Novel L-Alkylcarbonyloxymethyl Prodrugs 
Of 5-Fluorouracil into Poly(Lactide-co-Glycolide)  Nanoparticles. Int. J. Pharm. 
2008, 348, 115–124. 
 
 
Musumeci, T.; Ventura, C. A.; Giannone, I.; Ruozi, B.; Montenegro, L.; Pignatello, R.; 
Puglisi, G. PLA/PLGA Nanoparticles for Sustained Release of Docetaxel. Int. J. 
Pharm. 2006, 325, 172–179. 
 
 
Narrainen, A. P.; Pascual, S.; Haddleton, D. M. Amphiphilic Diblock, Triblock, and 
Star Block Copolymers by Living Radical Polymerization: Synthesis and 
Aggregation Behavior. J. Polym. Sci. Pol. Chem. 2002, 40, 439-450. 
 
 
Ning, F.; Jiang, M.; Mu, M.; Duan, H.; Xie, J. Synthesis of Amphiphilic Block–Graft 
Copolymers [Poly(Styrene-b-Ethylene-co-Butylene-b-Styrene)-G-Poly(Acrylic 
Acid)] and Their Aggregation in Water. J. Polym. Sci. Pol. Chem. 2002, 40, 
1253–1266. 
 
 
Nishiyama, N.; Kataoka, K. Current State, Achievements, and Future Prospects of 
Polymeric Micelles as Nanocarriers for Drug and Gene Delivery. Pharmacol. 
Therapeut.  2006, 112, 630-648.  
 
 
Nurmi, L.; Holappa, S.; Mikkonen, H.; Seppälä, J. Controlled Grafting of Acetylated 
Starch by Atom Transfer Radical Polymerization Of MMA. Eur. Polym. J. 
2007, 43, 1372–1382.  
 
 
Pascu, M. L.; Carstocea, B.; Brezeanu1, M.; Gazdaru, D.; Voicu, L.; Smarandache, A. 
Studies On Activated Fluorouracil with Optical Beams, for Use in The Eye 
Tumours Treatment. Romanian Reports In Physics. 2003, 55, 270-274. 
 
 
Patri, A. K.; Kukowska-Latallo, J. F.; Baker, J. R. Jr.  Targeted Drug Delivery with 
Dendrimers: Comparison of the Release Kinetics of Covalently Conjugated 
Drug and Non-Covalent Drug Inclusion Complex. Adv. Drug Deliver. Rev.  
2005, 57, 2203–2214. 
 121
Prabakaran, D.; Singh, P.; Kanaujia, P.; Vyas, S. P.; Effect of Hydrophilic Polymers on 
the Release of Diltiazem Hydrochloride from Elementary Osmotic Pumps. Int. J. 
Pharm. 2003, 259, 173–179.  
 
 
Qiu, L. Y.; Bae, Y. H.; Polymer Architecture And Drug Delivery. Pharmaceut. Res. 
2006, 23, 1-30. 
 
 
Quaglia, F.; Ostacolo, L.; Derosa, G.; Larotonda, M.; Ammendolab, M.; Nese, G; 
Maglio, G.; Palumbo, R.; Vauthier, C. Nanoscopic Core-Shell Drug Carriers 
Made of Amphiphilic Triblock and Star-Diblock Copolymers. Int. J. Pharm. 
2006, 324, 56–66.  
 
 
Radhakumary, C.; Prabha, D. N .; Mathew, S.; Nair C. P. R. Biopolymer Composite of 
Chitosan and Methyl Methacrylate for Medical Applications. Trends Biomater. 
Artif. Organs. 2005, 18, 117-124. 
 
 
Ritger, P. L.; Peppas, N. A. A Simple Equation for Description of Solute Release I. 
Fickian and Non-Fickian Release from Non-Swellable Devices in the Form of 
Slabs, Spheres, Cylinders or Discs. J. Control. Release. 1987, 5, 23-36. 
 
 
Rösler, A.; Vandermeulen, G. W. M.; Klok, H. A. Advanced Drug Delivery Devices via 
Self-Assembly of Amphiphilic Block Copolymers. Adv. Drug Deliver. Rev. 
2001, 53, 95–108. 
 
 
Sahoo, S. K.; Labhasetwar, V. Nanotech Approaches to Drug Delivery and Imaging. 
Drug Discov. Today.  2003, 8, 1112-1120. 
 
 
Sairam, M.; Babu R., Krishna, V.; Rao, K. S. V.; Aminabhavi, T. M. 
Poly(Methylmethacrylate)-Poly(Vinyl Pyrrolidone) Microspheres as Drug 
Delivery Systems: Indomethacin/Cefadroxil Loading and in vitro Release Study. 
J. Appl. Polym. Sci. 2007, 104, 1860–1865. 
 
Salaam, L. E.; Dean, D.; Bray, T. L. In vitro Degradation Behavior of Biodegradable 4-
Star Micelles. Polymer. 2006, 47, 310–318. 
 
 
Sanmiguel, V.; Limer, A. J.; Haddleton, D. M.; Catalina, F.; Peinado, C. Biodegradable 
and Thermoresponsive Micelles of Triblock Copolymers Based on 2-(N,N-
Dimethylamino)Ethyl Methacrylate and E-Caprolactone for Controlled Drug 
Delivery. Eur. Polym. J. 2008, 44, 3853–3863.  
 
      
 122
Sant, V. P.; Smith, D.; Leroux, J. C. Enhancement of Oral  Bioavailability of Poorly 
Water-Soluble Drugs by Poly(Ethylene Glycol)-block-Poly(Alkyl Acrylate-co-
Methacrylic Acid) Self-Assemblies. J. Control. Release.  2005, 104, 289–300.  
 
 
Santos, C.; Martins, M. A.; Franke, R. P.; Almeida, M. M.; Costa, M. E. V. Calcium 
Phosphate Granules for Use as a 5-Fluorouracil Delivery System. Ceram. Int. 
2009, 35, 1587–1594. 
 
. 
Sezgin, Z.; Yüksel, N.; Baykara, T. Preparation and Characterization of Polymeric 
Micelles for Solubilization of Poorly Soluble Anticancer Drugs. Eur. J. Phar. 
Biopharm. 2006, 64, 261–268. 
 
 
Shim, W. S.; Kim, S. W.; Choi, E.-K.; Park, H.- J.; Kim, J.-S.; Lee D. S. Novel pH 
Sensitive Block Copolymer Micelles for Solvent Free Drug Loading. Macromol. 
Biosci. 2006, 6, 179–186. 
 
 
Silverstein, R. M., Webster, F. X., Kiemle, D. J. Spectrometric Identification of Organic 
Compounds, 7th  ed.; John Wiley & Sons Inc, 2005; Chapters 2-4. 
 
 
Storey, R. F.; Scheuer, A. D.; Achord, B. C. Amphiphilic Poly(Acrylic Acid-b-Styrene-
b-Isobutylene-b-Styrene-b-Acrylic Acid) Pentablock Copolymers from a 
Combination of Quasiliving Carbocationic and Atom Transfer Radical 
Polymerization. Polymer, 2005, 46, 2141–2152. 
 
 
Sun, X.; Zheng, H.; Huang, X.; Wang, X.; Zhou, Q.-F. Synthesis of Poly(Ethylene 
Oxide)-block-Poly(Methyl Methacrylate)-block-Polystyrene Triblock 
Copolymers by Two Step Atom Transfer Radical Polymerization. Polymer. 
2005, 46, 5251-5257.  
 
 
Svenson, S.; Tomalia, D. A. Dendrimers in Biomedical Applications. Adv. Drug 
Deliver. Rev.  2005, 57, 2106– 2129. 
 
 
Tao, L.; Uhric, K. E. Novel Amphiphilic Macromolecules and Their in vitro 
Characterization as Stabilized Micellar Drug Delivery Systems. J. Colloid Interf. 
Sci. 2006, 298, 102–110 . 
 
 
Tomalia, D. A. Dendrimers: Key Properties of Importance to Nanomedicine. 
Nanomedicine. 2006, 2, 269–312. 
 
 
 123
Tomalia, D. A.; Fréchet, J. M. J. Introduction to Dendrimers and Dendritic Polymers. 
Prog. Polym. Sci. 2005, 30, 217-219. 
 
 
Tuma, J. J. Engineering Mathematics Handbook, 3rd ed.; McGraw Hill, 1987; p.368. 
 
 
Tunca, U.; Erdoğan, T.; Hızal, G. Synthesis and Characterization of Well-Defined 
ABC-Type Triblock Copolymers via Atom Transfer Radical Polymerization and 
Stable Free-Radical Polymerization. J. Polym. Sci. Pol. Chem. 2002, 40, 2025–
2032.  
 
 
Ulbrich, K.; Pechar, M.; Etrych, T.; Jelínková, M.; Kováø, M.; Øíhová, B.; Polymer 
Carriers for Targeted Drug Delivery and Controlled Drug Release. Materials 
Structure. 2003, 10, 3-5. 
 
  
Wang, G.; Henselwood, F.; Liu, G. Water-Soluble Poly(2-Cinnamoylethyl 
Methacrylate)-block-Poly(Acrylic Acid) Nanospheres as Traps for Perylene. 
Langmuir.  1998, 14, 1554-1559. 
 
 
Wei, H.; Zhang, X.; Cheng, C.; Cheng, S. X.; Zhuo, R. X. Self-Assembled, 
Thermosensitive Micelles of a Star Block Copolymer Based on PMMA and 
PNIPAAM for Controlled Drug Delivery. Biomaterials. 2007, 28, 99–107. 
 
 
Xie, D.; Yang, Y.; Zhao, J.; Park, J. G.; Zhang, J. T. A Novel Comonomer-Free Light-
Cured Glass-Ionomer Cement for Reduced Cytotoxicity and Enhanced 
Mechanical Strength. Dent. Mater. 2006, 23, 994-1003. 
 
 
Yang, H. C.; Hon, M. H. The Effect of the Molecular Weight of Chitosan Nanoparticles 
and Its Application on Drug Delivery. Microchem. J. 2009, 92, 87–91. 
 
 
Yang, Z.; Liu, J.; Huang, Z.; Shi, W. Crystallization Behavior and Micelle Formation of 
Star-Shaped Amphiphilic Block Copolymer Based on Dendritic Poly(Ether-
Amide). Eur. Polym. J. 2007, 43, 2298–2307. 
 
 
Yin, M.; Habichera, W. D.; Voit, B.; Preparation of Functional Poly(Acrylates and 
Methacrylates) and Block Copolymers Formation Based on Polystyrene 
Macroinitiator by ATRP. Polymer. 2005, 46, 3215–3222. 
 
 
Yin, N.; Chen, K.; Kang, W. Preparation of BA/ST/AM Nano Particles by Ultrasonic 
Emulsifier-Free Emulsion Polymerization. Ultrason. Sonochem. 2006, 13, 345–
351. 
 124
Yu, H.; Peng, J.; Zhai, M.; Li, J.; Wei, G.; Qiao, J. Synthesis and Characterization of 
Poly (n-Butyl Acrylate)-Poly(Methyl Methacrylate) Latex Interpenetrating 
Polymer Networks by Radiation-Induced Seeded Emulsion Polymerization. 
Radiat. Phys. Chem. 2006, 76, 1746–1750. 
 
 
Yu, Z.-Q.; Ni, P.-H.; Li, J.-A.; Zhu, X.-L. Miniemulsion Copolymerization of Methyl 
Methacrylate and Butyl Acrylate in the Presence of Vinyl Siloxane Rubber. 
Colloid Surfaces A, 2004, 242, 9–15. 
 
 
Yuan, W.; Yuan, J.; Zheng, S.; Hong, X. Synthesis, Characterization, and Controllable 
Drug Release of Dendritic Star-Block Copolymer by Ring-Opening 
Polymerization and Atom Transfer Radical Polymerization. Polymer. 2007, 48, 
2585-2594. 
 
 
Zhang, Z.; Zhang, Q.; Wang, J.; Shi, X.; Zhang, J.; Song, H.; Synthesis and Drug 
Release in vitro of Porphyran Carrying 5-Fluorouracil. Carbohyd. Polym. 2010, 
79, 628-632. 
 
 
Zhang, Y.; Jiang, M.; Zhao, J.; Chen, D. Thermo-Sensitive Core–Shell Nanoparticles as 
Potential Drug Carrier. Eur. Polym. J. 2007, 43, 4905-4915. 
 
 
Zhang, Z.; Grijpma, D. W.; Feijen, J. Poly(Trimethylene Carbonate) and Monomethoxy 
Poly(Ethylene Glycol)-block-Poly(Trimethylene Carbonate) nanoparticles for 
the controlled release of dexamethasone. J. Control. Release. 2006, 111, 263–
270. 
 
 
Zhang, Y.; Zhuo, R. X. Synthesis and Drug Release Behavior of Poly (Trimethylene 
Carbonate)–Poly(Ethyleneglycol)–Poly(Trimethylene Carbonate) Nanoparticles. 
Biomaterials. 2005a, 26, 2089–2094. 
 
 
Zhang, Y.; Zhuo, R. X. Synthesis, characterization, and in vitro 5-FU Release Behavior 
of Poly(2,2-Dimethyltrimethylene Carbonate)-Poly(Ethylene Glycol)-Poly(2,2-
DimethylTrimethylene Carbonate) Nanoparticles. J. Biomed. Mater. Res. 2005b, 
76, 674–680. 
 
 
Zhao, Y. L.; Gong, A. J.; Jiang, J.; Liu, H. W.; Chen, C. F.;  Xi, F. Synthesis of 
Dendritic-Linear Block Copolymers by Atom Transfer Radical Polymerization. 
Chinese Chem. Lett. 2001, 12, 595-596. 
 
 
Zheng, D.; Li, X.; Xu, H.; Lu, X.; Hu, Y.; Fan, W. Study on Docetaxel Loaded 
Nanoparticles with High Antitumor Efficiacy agains Malignant Melanoma. Acta 
Biochim. Biophys. Sin. 2009, 41, 578-587.  
 125
Zheng, Y.; Yang, W.; Wang, C.; Hu, J.; Fu, S.; Dong, L.; Wu, L.; Shen, X. 
Nanoparticles Based on the Complex of Chitosan and Polyaspartic Acid Sodium 
Salt: Preparation, Characterization and the Use for 5-Fluorouracil Delivery. Eur. 
J. Phar. Biopharm. 2007, 67, 621–631. 
 
 
Zhuo, R. X.; Du, B.; Lu, Z. R. In vitro Release of 5-Fluorouracil with Cyclic Core 
Dendritic Polymer, J. Control. Release. 1999, 57, 249–257. 
 
 
 
 126
APPENDIX A 
 
CRITICAL MICELLE CONCENTRATIONS 
 
 
 
 
 
 
 
 
 
 
 
 
Figure A.1.  CMC determination by fluorescence method for 3 arm PMMA-b-PAA with 
molecular weight of 22000 Da and hydrophobic core ratio of 0.26. 
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 Figure A.2. CMC determination by fluorescence method for 4 arm PMMA-b-PAA with 
molecular weight of 27000 Da and hydrophobic core ratio of 0.17. 
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Figure A.3.  CMC determination by fluorescence method for 4 arm PMMA-b-PAA with 
molecular weight of 30000 Da and hydrophobic core ratio of 0.23. 
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Figure A.4. CMC determination by fluorescence method for 4 arm PMMA-b-PAA with 
molecular weight of 33000 Da and hydrophobic core ratio of 0.19. 
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 Figure A.5. CMC determination by fluorescence method for 4 arm PMMA-b-PAA with 
molecular weight of 45000 Da and hydrophobic core ratio of 0.11. 
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 Figure A.6. CMC determination by fluorescence method for 6 arm PMMA-b-PAA with 
molecular weight of 77000 Da and hydrophobic core ratio of 0.11. 
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 Figure A.7. CMC determination by fluorescence method for 6 arm PMMA-b-PAA with 
molecular weight of 45000 Da and hydrophobic core ratio of 0.18. 
 
 130
APPENDIX B 
 
DRUG RELEASE DATA 
 
Table B.1. Assumptions, constants and constraints occupied in mathematical 
determination of theoretical model. 
  
ASSUMPTION: X(t)=kt^n 
Y(t)=i1+i2+i3+i4+i5+Cn/e^kt+C 
n=n1 and k=k1  in 0-40% release interval 
n=n2 and k=k2  in 40-100% release interval 
Cn=C1 in 0-40% release interval 
Cn=C2 in 40-100% release interval 
C =C3 
C3 =0 in 0-40% release interval 
 
A= 0.785 cm2 
P= 0.005 cm.min-1 
Vr= 0.471 cm3 
 
n1= 0.00256012 
k1= 1.35E-03 
n2= 0 
k2= 7.59E-04 
C1= 1.20E-01 
C2= -2.12E-01 
C3= 1.18E-01 
AP/Vr= 0.00833333  
F= 0.025 cm3min-1 
 
SSQ= 0.0016 
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 Table B.2. Determination of terms in theoretical model derived and given by Equation 
3.31 including the first 5 terms of the alternating series. 
 
time 
(min) i=1 i=2 i=3 i=4 i=5 Cn/e^kt+C 
420 0.01435 0.00411 3.0065E-06 -8.57E-07 4.8898E-07 3.63E-03
930 0.03184 0.00412 1.3606E-06 -1.75E-07 4.5131E-08 5.17205E-05
1290 0.0442 0.00412 9.8169E-07 -9.11E-08 1.6925E-08 2.57501E-06
1580 0.05416 0.00412 8.0192E-07 -6.07E-08 9.216E-09 2.29739E-07
2110 0.07239 0.00413 6.0094E-07 -3.41E-08 3.8725E-09 2.77396E-09
2660 0.09131 0.00413 4.7697E-07 -2.15E-08 1.934E-09 2.8352E-11
3200 0.1099 0.00413 3.9667E-07 -1.48E-08 1.1113E-09 3.14963E-13
3620 0.12436 0.00413 3.5075E-07 -1.16E-08 7.6791E-10 9.51105E-15
4220 0.14503 0.00413 3.01E-07 -8.54E-09 4.8492E-10 6.40849E-17
4785 0.1645 0.00414 2.6555E-07 -6.64E-09 3.3274E-10 5.78033E-19
5310 0.1826 0.00414 2.3936E-07 -5.40E-09 2.4354E-10 7.27636E-21
5700 0.19605 0.00414 2.2302E-07 -4.68E-09 1.9693E-10 2.82135E-22
6330 0.21777 0.00414 2.0088E-07 -3.80E-09 1.4383E-10 1.48051E-24
7820 0.26918 0.00414 1.6269E-07 -2.49E-09 7.6326E-11 5.99683E-30
8955 1.70E-01 0.00228 7.9916E-08 -1.07E-09 2.8591E-11 1.18E-01
10395 0.19714 0.00228 6.8872E-08 -7.93E-10 1.8286E-11 1.18E-01
11095 0.21042 0.00228 6.4537E-08 -6.96E-10 1.5041E-11 1.18E-01
11685 0.22161 0.00228 6.1287E-08 -6.28E-10 1.2878E-11 1.18E-01
12825 0.24323 0.00228 5.5852E-08 -5.21E-10 9.742E-12 1.18E-01
13245 0.2512 0.00228 5.4086E-08 -4.89E-10 8.8451E-12 1.18E-01
13965 0.26485 0.00228 5.1304E-08 -4.40E-10 7.5473E-12 1.18E-01
14685 0.27851 0.00228 4.8795E-08 -3.98E-10 6.4916E-12 1.18E-01
15405 0.29216 0.00228 4.652E-08 -3.61E-10 5.6239E-12 1.18E-01
16125 0.30582 0.00228 4.4448E-08 -3.30E-10 4.9043E-12 1.18E-01
16275 0.30866 0.00228 4.404E-08 -3.24E-10 4.7701E-12 1.18E-01
17145 0.32516 0.00228 4.181E-08 -2.92E-10 4.0807E-12 1.18E-01
17565 0.33313 0.00228 4.0813E-08 -2.78E-10 3.7951E-12 1.18E-01
18225 0.34564 0.00228 3.9339E-08 -2.58E-10 3.3979E-12 1.18E-01
18885 0.35816 0.00228 3.7967E-08 -2.41E-10 3.0542E-12 1.18E-01
19125 0.36271 0.00228 3.7492E-08 -2.35E-10 2.9408E-12 1.18E-01
20685 0.3923 0.00228 3.4672E-08 -2.01E-10 2.3248E-12 1.18E-01
21405 0.40595 0.00228 3.3508E-08 -1.87E-10 2.0982E-12 1.18E-01
21675 0.41107 0.00228 3.3092E-08 -1.83E-10 2.0208E-12 1.18E-01
22395 0.42473 0.00228 3.2031E-08 -1.71E-10 1.8323E-12 1.18E-01
22765 0.43174 0.00228 3.1511E-08 -1.66E-10 1.7444E-12 1.18E-01
23085 0.43781 0.00228 3.1076E-08 -1.61E-10 1.673E-12 1.18E-01
23145 0.43895 0.00228 3.0995E-08 -1.60E-10 1.66E-12 1.18E-01
(Cont. on next page) 
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Table B.2. (cont.) 
time 
(min) i=1 i=2 i=3 i=4 i=5 C1/e^Kt+C3 
24375 0.46228 0.00228 2.9435E-08 -1.45E-10 1.4214E-12 1.18E-01
24885 0.47195 0.00228 2.8834E-08 -1.39E-10 1.3358E-12 1.18E-01
25665 0.48674 0.00228 2.7959E-08 -1.30E-10 1.2178E-12 1.18E-01
26115 0.49528 0.00228 2.7479E-08 -1.26E-10 1.156E-12 1.18E-01
27105 0.51405 0.00228 2.6478E-08 -1.17E-10 1.034E-12 1.18E-01
27265 0.51709 0.00228 2.6323E-08 -1.16E-10 1.0159E-12 1.18E-01
27375 0.51917 0.00228 2.6217E-08 -1.15E-10 1.0037E-12 1.18E-01
27395 0.51955 0.00228 2.6198E-08 -1.14E-10 1.0015E-12 1.18E-01
27585 0.52316 0.00228 2.6018E-08 -1.13E-10 9.8097E-13 1.18E-01
27585 0.52316 0.00228 2.6018E-08 -1.13E-10 9.8097E-13 1.18E-01
28835 0.54686 0.00228 2.4893E-08 -1.03E-10 8.5894E-13 1.18E-01
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 Table B.3. Calculation of theoretical values of Mt and Mt/M. 
 
time (h) 
time 
(min) Mt exp Mt theo Error 
Square 
Error Mt/M exp Mt/M theo 
7.0 420 0.01385 0.01387 0.0000 0.0000 0.0221 0.0217
15.5 930 0.02808 0.02777 0.0003 0.0000 0.0447 0.0435
21.5 1290 0.0383 0.0401 -0.0017 0.0000 0.0611 0.0628
26.3 1580 0.0455 0.0500 -0.0045 0.0000 0.0725 0.0784
35.2 2110 0.0626 0.0683 -0.0057 0.0000 0.0997 0.1069
44.3 2660 0.0897 0.0872 0.0025 0.0000 0.1429 0.1365
53.3 3200 0.1093 0.1058 0.0035 0.0000 0.1741 0.1656
60.3 3620 0.1229 0.1202 0.0027 0.0000 0.1958 0.1883
70.3 4220 0.1367 0.1409 -0.0042 0.0000 0.2177 0.2207
79.8 4785 0.1566 0.1604 -0.0038 0.0000 0.2494 0.2511
88.5 5310 0.1772 0.1785 -0.0013 0.0000 0.2823 0.2795
95.0 5700 0.2044 0.1919 0.0125 0.0002 0.3256 0.3005
105.5 6330 0.2187 0.2136 0.0050 0.0000 0.3484 0.3346
130.3 7820 0.2565 0.2650 -0.0086 0.0001 0.4086 0.4151
149.3 8955 0.2787 0.2852 -0.0066 0.0000 0.4439 0.4467
173.3 10395 0.3160 0.3125 0.0035 0.0000 0.5035 0.4894
184.9 11095 0.3254 0.3258 -0.0005 0.0000 0.5183 0.5102
194.8 11685 0.3328 0.3370 -0.0042 0.0000 0.5302 0.5278
213.8 12825 0.3533 0.3586 -0.0053 0.0000 0.5629 0.5616
220.8 13245 0.3611 0.3666 -0.0055 0.0000 0.5752 0.5741
232.8 13965 0.3772 0.3802 -0.0030 0.0000 0.6009 0.5955
244.8 14685 0.3943 0.3939 0.0004 0.0000 0.6282 0.6169
256.8 15405 0.4135 0.4075 0.0060 0.0000 0.6588 0.6382
268.8 16125 0.4227 0.4212 0.0015 0.0000 0.6734 0.6596
271.3 16275 0.4314 0.4240 0.0073 0.0001 0.6872 0.6641
285.8 17145 0.4408 0.4405 0.0003 0.0000 0.7023 0.6899
292.8 17565 0.4483 0.4485 -0.0002 0.0000 0.7142 0.7024
303.8 18225 0.4594 0.4610 -0.0016 0.0000 0.7319 0.7220
314.8 18885 0.4712 0.4735 -0.0024 0.0000 0.7506 0.7416
318.8 19125 0.4853 0.4781 0.0072 0.0001 0.7732 0.7487
344.8 20685 0.5052 0.5077 -0.0025 0.0000 0.8048 0.7951
356.8 21405 0.5182 0.5213 -0.0031 0.0000 0.8256 0.8164
361.3 21675 0.5267 0.5265 0.0002 0.0000 0.8391 0.8245
373.3 22395 0.5363 0.5401 -0.0038 0.0000 0.8544 0.8459
379.4 22765 0.5498 0.5471 0.0027 0.0000 0.8760 0.8568
384.8 23085 0.5678 0.5532 0.0146 0.0002 0.9045 0.8663
385.8 23145 0.5694 0.5543 0.0151 0.0002 0.9072 0.8681
406.3 24375 0.5844 0.5777 0.0067 0.0000 0.9310 0.9047
(Cont. on next page) 
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Table B.3. (cont.) 
time (h) 
time 
(min) Mt exp Mt theo Error 
Square 
Error Mt/M exp Mt/M theo 
414.8 24885 0.5949 0.5873 0.0076 0.0001 0.9478 0.9198
427.8 25665 0.6030 0.6021 0.0008 0.0000 0.9606 0.9430
435.3 26115 0.6151 0.6107 0.0044 0.0000 0.9799 0.9563
451.8 27105 0.6227 0.6294 -0.0067 0.0000 0.9921 0.9857
454.4 27265 0.6257 0.6325 -0.0068 0.0000 0.9968 0.9905
456.3 27375 0.6267 0.6346 -0.0079 0.0001 0.9984 0.9938
456.6 27395 0.6277 0.6349 -0.0073 0.0001 1.0000 0.9944
459.8 27585 0.6277 0.6385 -0.0109 0.0001 1.0000 1.0000
459.8 27585 0.6277 0.6385 -0.0109 0.0001 1.0000 1.0000
480.6 28835 0.6277 0.6623 -0.0346 0.0012 1.0000 1.0000
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APPENDIX C 
 
PARTICLE SIZE ANALSIS BY ZETASIZER 
 
 TABLE C.1. Particle size analysis of 4 arm PMMA-b-PAA having 1mg/ml  
concentration in PBS 
 
 Size(nm) Intensity Volume Number    
 
7.5  0.0 0.0 0.0   
8.6  0.0 0.0 0.0  
9.9  0.0 0.0 0.0   
11.4  0.0 0.0 0.0  
13.1  0.0 0.0 0.0  
15.1  0.0 22.6 25.0  
17.4  12.7 45.2 49.9   
20.0  0.0 22.6 25.0  
 23.0  0.0 0.0 16.4     
26.4  0.0 0.0 0.0   
30.4  0.0 0.0 0.0  
34.9  0.0 0.0 0.0  
40.2  0.0 0.0 0.0   
46.2  0.0 0.0 0.0   
53.2  0.0 0.0 0.0  
61.2  0.0 2.3 0.0  
70.3  79.1 4.7 0.1  
80.9  7.8 2.5 0.0  
93.1  0.0 0.1 0.0  
107.0 0.0 0.0 0.0  
123.1 0.0 0.0 0.0  
141.6 0.0 0.0 0.0  
162.9 0.4 0.0 0.0  
 
Peak Analysis by intensity 
 
Peak Area Mean Width  
1 12.7 17.4 2.4 
2 86.9 71.3 10.5 
 
Peak Analysis by volume  
 
Peak Area Mean Width  
1 90.4 17.4 4.9 
2 9.6 71.3 20.6 
 
Peak Analysis by number  
 
Peak Area Mean Width  
1 99.8 17.4 4.9 
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 TABLE C.2. Particle size analysis of 4 arm PMMA-b-PAA having 2 mg/ml  
concentration in PBS. 
 
 
 Size(nm) Intensity Volume Number    
 
6.4  0.0 0.0 0.0   
8.1  0.0 0.0 0.0  
10.2  0.0 16.5 20.7   
12.8  4.3 39.9 45.6  
16.2  3.6 30.3 29.3  
20.3  0.0 6.9 4.3  
25.6  0.0 0.0 0.0   
32.2  0.0 0.0 0.0  
 40.6  0.0 0.0 0.0    
51.1  0.0 0.5 0.0   
64.4  14.9 2.0 0.0  
81.0  61.3 2.6 0.0  
102.0 15.8 1.3 0.0   
128.5 0.0 0.1 0.0   
161.7 0.0 0.0 0.0  
203.7 0.0 0.0 0.0  
256.4 0.0 0.0 0.0  
322.8 0.0 0.0 0.0  
406.5 0.0 0.0 0.0  
511.8 0.0 0.0 0.0  
644.3 0.0 0.0 0.0  
811.2 0.0 0.0 0.0  
1021.4 0.0 0.0 0.0  
1286.0 0.0 0.0 0.0  
 
 
Peak Analysis by intensity 
 
Peak Area Mean Width  
1 8.0 14.3 6.3 
2 92.0 81.9 25.2 
 
Peak Analysis by volume  
 
Peak Area Mean Width  
1 93.5 14.0 7.4 
2 6.5 79.0 42.9 
 
Peak Analysis by number  
 
Peak Area Mean Width  
1 100.0 13.6 6.8 
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 TABLE C.3. Particle size analysis of 4 arm PMMA-b-PAA having 4 mg/ml  
concentration in PBS. 
 
 
Size(nm) Intensity Volume Number    
 
5.1  0.0 0.0 0.0   
6.5  0.0 0.0 0.0  
8.2  0.0 0.0 0.0   
10.3  0.0 0.0 0.0  
12.9  0.0 0.0 0.0  
16.3  0.0 24.3 25.0  
20.5  19.9 48.6 50.0  
25.8  0.0 24.3 25.0  
32.5 0.0 0.0 0.0     
40.9 0.0 0.0 0.0   
51.5 0.0 0.0 0.0  
64.8 0.0 0.0 0.0  
81.6 0.0 0.3 0.0   
102.8 23.0 0.8 0.0   
129.4 50.1 0.9 0.0  
162.9 0.0 0.3 0.0  
205.1 0.6 0.0 0.0  
258.3 0.0 0.0 0.0  
325.2 0.0 0.0 0.0  
409.4 0.0 0.0 0.0  
515.5 0.0 0.0 0.0  
649.0 3.9 0.1 0.0  
817.1 3.2 0.2 0.0  
1028.8 0.0 0.1 0.0  
 
 
Peak Analysis by intensity 
 
Peak Area Mean Width  
1 19.9 20.5 4.8  
2 73.0 121.0 41.3 
3 7.1 725.6 320.2 
 
Peak Analysis by volume  
 
Peak Area Mean Width  
1 97.3 20.8 9.5 
2 2.3 118.9 66.9 
 
Peak Analysis by number  
 
Peak Area Mean Width  
1 100.0 20.8 9.5 
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 TABLE C.4. Particle size analysis of 4 arm PMMA-b-PAA having 6 mg/ml  
concentration in PBS. 
 
 
Size(nm) Intensity Volume Number    
 
11.1  0.0 0.0 0.0   
13.9  0.0 14.3 18.5  
17.5  3.6 38.6 43.5   
22.1  5.0 34.3 31.5  
27.8  0.0 10.0 6.5  
35.0  0.0 0.0 0.0  
44.1  0.0 0.0 0.0   
55.5  0.0 0.0 0.0  
69.9  0.0 0.0 0.0     
88.0  0.0 0.0 0.0   
110.7 0.0 0.3 0.0  
139.4 25.0 0.5 0.0  
175.5 0.0 0.3 0.0   
221.0 0.0 0.1 0.0   
278.3 29.0 0.6 0.0  
350.3 37.4 0.7 0.0  
441.1 0.0 0.3 0.0  
555.3 0.0 0.0 0.0  
699.2 0.0 0.0 0.0  
880.3 0.0 0.0 0.0  
1108.3 0.0 0.0 0.0  
1395.4 0.0 0.0 0.0  
1756.9 0.0 0.0 0.0  
2212.0 0.0 0.0 0.0  
 
 
Peak Analysis by intensity 
 
Peak Area Mean Width  
1 8.6 20.2 8.5  
2 25.0 139.4 32.4 
3 66.4 318.8 137.8 
 
Peak Analysis by volume  
 
Peak Area Mean Width  
1 97.1 19.7 10.9 
2 1.2 150.0 64.8 
3 1.7 333.1 175.0 
 
Peak Analysis by number  
 
Peak Area Mean Width  
1 100.0 19.0 9.9 
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 TABLE C.5. Particle size analysis of 4 arm PMMA-b-PAA having 1 mg/ml 
concentration in PBS after three days of degradation. 
 
 
Size(nm) Intensity Volume Number    
 
5.7  0.0 0.0 0.0   
7.2  0.0 0.0 0.0  
9.1  0.0 0.0 0.0   
11.4  0.0 0.0 0.0  
14.4  0.0 0.0 0.0  
18.1  0.0 5.7 10.7  
22.8  1.7 24.1 33.6   
28.7  7.8 35.7 37.1  
36.2  5.4 21.8 16.4     
45.6  0.0 4.5 0.0   
57.4  0.0 0.0 0.0  
72.2  0.0 0.2 0.0  
91.0  3.5 1.4 0.0   
114.5 33.9 3.1 0.0   
144.2 43.3 2.6 0.0  
181.5 4.4 0.9 0.0  
228.5 0.6 0.0 0.0  
287.7 0.0 0.0 0.0  
362.3 0.0 0.0 0.0  
456.1 0.0 0.0 0.0  
574.3 0.6 0.0 0.0  
723.1 3.5 0.0 0.0  
910.4 8.0 0.0 0.0  
1146.2 0.0 0.0 0.0  
 
 
Peak Analysis by intensity 
 
Peak Area Mean Width  
1 15.0 30.8 22.0  
2 85.0 132.1 55.1 
 
Peak Analysis by volume  
 
Peak Area Mean Width  
1 91.8 29.1 17.1 
2 8.2 126.4 75.1 
 
Peak Analysis by number  
 
Peak Area Mean Width  
1 99.9 27.2 15.7 
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 TABLE C.6. Particle size analysis of 4 arm PMMA-b-PAA having 2 mg/ml  
concentration in PBS after 3 days of degradation. 
 
 
Size(nm) Intensity Volume Number    
 
4.6  0.0 0.0 0.0   
5.8  0.0 0.0 0.0  
7.3  0.0 0.0 0.0   
9.2  0.0 0.0 0.0  
11.6  0.0 15.2 19.5  
14.6  6.6 38.6 44.3  
18.3  7.1 32.3 30.2   
23.1  1.2 9.6 5.7  
29.1  0.0 0.7 0.2     
36.6  0.0 4.5 0.0   
46.1  2.5 0.2 0.0  
58.0  6.9 0.6 0.0  
73.1  9.4 0.9 0.0   
92.0  10.7 0.7 0.0   
115.8 14.3 0.5 0.0  
145.9 18.6 0.3 0.0  
183.6 16.4 0.2 0.0  
231.2 6.4 0.1 0.0  
291.1 0.0 0.1 0.0  
366.5 0.0 0.0 0.0  
461.5 0.0 0.0 0.0  
581.0 0.0 0.0 0.0  
731.5 0.0 0.0 0.0  
921.0 0.0 0.0 0.0  
 
 
Peak Analysis by intensity 
 
Peak Area Mean Width  
1 14.9 17.1 8.0  
2 85.1 129.6 144.6 
 
Peak Analysis by volume  
 
Peak Area Mean Width  
1 96.3 16.4 9.0 
2 3.7 80.4 55.2 
 
Peak Analysis by number  
 
Peak Area Mean Width  
1 99.9 15.7 8.0 
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 TABLE C.7. Particle size analysis of 4 arm PMMA-b-PAA having 4 mg/ml  
concentration in PBS after 3 days of degradation. 
 
 
Size(nm) Intensity Volume Number    
 
5.2  0.0 0.0 0.0   
6.1  0.0 0.0 0.0  
7.3  0.0 0.0 0.0   
8.6  0.0 0.0 0.0  
10.2  0.0 0.0 0.0  
12.1  0.0 0.0 0.0  
14.4  0.0 2.7 5.3   
17.1  2.5 16.0 23.0  
20.2  15.8 32.7 36.2     
24.0  22.2 30.9 25.9   
28.4  10.7 14.0 8.4  
33.7  0.0 2.6 1.1  
39.9  0.0 0.0 0.0   
47.3  0.0 0.0 0.0   
56.1  0.0 0.0 0.0  
66.5  0.0 0.0 0.0  
78.8  0.7 0.1 0.0  
93.4  17.3 0.4 0.0  
110.7 22.8 0.4 0.0  
131.3 7.9 0.2 0.0  
155.6 0.0 0.0 0.0  
184.5 0.0 0.0 0.0  
218.7 0.0 0.0 0.0  
259.2 0.0 0.0 0.0  
 
 
Peak Analysis by intensity 
 
Peak Area Mean Width  
1 51.2 23.4 9.1  
2 48.8 107.5 38.2 
 
Peak Analysis by volume  
 
Peak Area Mean Width  
1 98.9 22.2 10.7 
2 1.1 104.0 46.9 
 
Peak Analysis by number  
 
Peak Area Mean Width  
1 100.0 21.0 9.6 
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 TABLE C.8. Particle size analysis of 4 arm PMMA-b-PAA having 6 mg/ml  
concentration in PBS after 3 days of degradation. 
 
 
 
Size(nm) Intensity Volume Number    
 
4.3  0.0 0.0 0.0   
5.1  0.0 0.0 0.0  
6.0  0.0 0.0 0.0   
7.1  0.0 0.0 0.0  
8.4  0.0 0.0 0.0  
10.0  0.0 0.0 0.0 
11.8  0.0 0.0 0.0  
14.0  0.0 0.0 0.0  
16.6  0.0 3.8 5.8     
19.7  7.6 28.8 30.8   
23.4  70.1 46.1 44.2  
27.7  0.0 21.1 19.2  
32.9  0.0 0.0 0.0   
38.9  0.0 0.0 0.0   
46.2  0.0 0.0 0.0  
54.7  0.0 0.0 0.0  
64.9  0.0 0.0 0.0  
76.9  0.0 0.0 0.0  
91.2  0.0 0.0 0.0  
108.1 0.0 0.0 0.0  
128.1 4.8 0.0 0.0  
151.9 17.6 0.1 0.0  
180.0 0.0 0.0 0.0  
213.4 0.0 0.0 0.0  
 
 
Peak Analysis by intensity 
 
Peak Area Mean Width  
1 77.7 23.0 4.2  
2 22.3 146.8 30.4 
 
Peak Analysis by volume  
 
Peak Area Mean Width  
1 99.8 23.0 8.4 
 
Peak Analysis by number  
 
Peak Area Mean Width  
1 100.0 22.7 8.6 
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 TABLE C.9. Particle size analysis of 4 arm PMMA-b-PAA having 1 mg/ml  
concentration in PBS after 7 days of degradation. 
 
 
 
Size(nm) Intensity Volume Number   
 
1.1  0.0 0.0 0.0   
1.4  0.0 0.0 0.0   
1.8  0.0 0.0 0.0   
2.2  0.0 5.5 13.8  
2.8  1.1 16.3 34.2   
3.5  2.1 20.7 30.0  
4.4  3.6 18.0 13.5  
5.6  5.5 14.2 5.5   
7.0  7.9 10.3 2.1  
8.8  10.2 6.8 0.7   
11.1  12.1 4.1 0.2  
14.0  13.0 2.3 0.1  
17.6  12.3 1.1 0.0   
22.2  10.0 0.5 0.0  
27.9  6.6 0.2 0.0  
35.2  2.9 0.0 0.0  
44.3  0.6 0.0 0.0  
55.8  0.0 0.0 0.0  
70.2  0.0 0.0 0.0  
88.4  0.0 0.0 0.0  
111.3 0.6 0.0 0.0  
140.2 3.5 0.0 0.0  
176.5 8.0 0.0 0.0  
222.2 0.0 0.0 0.0  
 
 
Peak Analysis by intensity 
 
Peak Area Mean Width  
1 87.8 14.5 22.0 
2 12.2 162.6 55.1 
 
Peak Analysis by volume  
 
Peak Area Mean Width 
1 100.0 5.4 4.5 
 
Peak Analysis by number  
 
Peak Area Mean Width  
1 100.0 3.5 1.9 
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 TABLE C.10. Particle size analysis of 4 arm PMMA-b-PAA having 2 mg/ml  
concentration in PBS. 
 
 
 
Size(nm) Intensity Volume Number   
 
1.2  0.0 0.0 0.0  
1.5  0.0 0.0 0.0   
1.8  0.0 0.0 0.0  
2.3  0.0 0.0 0.0  
2.9  0.0 0.0 0.0   
3.7  0.0 5.5 12.7  
4.6  2.1 17.7 33.0   
5.8  5.0 24.3 31.2    
7.3  8.3 21.5 15.2  
9.2  11.2 15.2 5.7   
11.6  12.4 8.9 1.8  
14.6  11.4 4.4 0.5   
18.3  8.5 1.8 0.1    
23.1  4.5 0.6 0.0  
29.1  1.4 0.1 0.0  
36.6  0.0 0.0 0.0  
46.1  0.0 0.0 0.0  
58.0  1.2 0.0 0.0  
73.0  3.9 0.0 0.0  
91.9  7.2 0.0 0.0  
115.7 9.2 0.0 0.0  
145.7 8.6 0.0 0.0  
183.5 5.1 0.0 0.0  
231.0 0.0 0.0 0.0  
 
 
Peak Analysis by intensity 
 
Peak Area Mean Width  
1 64.7 12.5 14.7 
2 35.3 121.3 111.2  
 
Peak Analysis by volume  
 
Peak Area Mean Width 
1 100.0 7.6 6.2 
 
Peak Analysis by number  
 
Peak Area Mean Width  
1 100.0 5.7 3.3
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TABLE C.11. Particle size analysis of 4 arm PMMA-b-PAA having 4 mg/ml 
concentration in PBS after 7 days of degradation. 
 
 
Size(nm) Intensity Volume Number   
 
1.2  0.0 0.0 0.0   
1.5  0.0 0.0 0.0    
1.9  0.0 0.0 0.0   
2.4  0.0 0.0 0.0  
3.0  0.0 0.0 0.0   
3.8  0.0 0.0 0.0  
4.8  0.0 0.0 0.0   
6.0  0.0 6.3 12.5    
7.6  5.5 21.2 33.5  
9.5  14.8 29.8 32.7   
12.0  21.6 24.2 15.5  
15.1  20.7 13.1 4.7   
19.1  10.8 4.6 0.9   
24.0  0.0 0.8 0.1  
30.2  0.0 0.0 0.0  
38.0  0.0 0.0 0.0  
47.9  0.0 0.0 0.0  
60.3  0.0 0.0 0.0  
75.9  0.0 0.0 0.0  
95.6  6.2 0.0 0.0  
120.3 11.5 0.0 0.0  
151.5 8.9 0.0 0.0  
190.8 0.0 0.0 0.0  
240.2 0.0 0.0 0.0  
 
 
Peak Analysis by intensity 
 
Peak Area Mean Width  
1 73.4 13.1 10.3 
2 26.6 125.0 71.0  
 
 
Peak Analysis by volume  
 
Peak Area Mean Width 
1 100.0 10.8 7.7 
 
Peak Analysis by number  
 
Peak Area Mean Width  
1 100.0 9.2 5.5
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 TABLE C.12. Particle size analysis of 4 arm PMMA-b-PAA having 6 mg/ml  
concentration in PBS after 7 days of degradation. 
 
 
Size(nm) Intensity Volume Number   
 
1.9  0.0 0.0 0.0  
2.3  0.0 0.0 0.0    
2.8  0.0 0.0 0.0    
3.4  0.0 0.0 0.0  
4.2  0.0 0.0 0.0   
5.1  0.0 0.0 0.0  
6.2  0.0 0.0 0.0  
7.6  0.0 0.0 0.0   
9.2  0.0 9.7 14.1  
11.3  14.7 30.9 37.5   
13.8  32.2 36.6 34.3  
16.9  19.0 19.1 12.5   
20.6  0.0 3.7 1.6    
25.2  0.0 0.0 0.0  
30.7  0.0 0.0 0.0  
37.6  0.0 0.0 0.0  
45.9  0.0 0.0 0.0  
56.0  0.0 0.0 0.0  
68.5  0.0 0.0 0.0  
83.7  0.6 0.0 0.0  
102.2 22.5 0.0 0.0  
124.9 11.0 0.0 0.0  
152.5 0.0 0.0 0.0  
186.3 0.0 0.0 0.0  
 
 
Peak Analysis by intensity 
 
Peak Area Mean Width  
1 65.9 14.1 5.9 
2 34.1 109.2 31.7 
 
Peak Analysis by volume  
 
Peak Area Mean Width 
1 99.9 13.4 7.0  
 
Peak Analysis by number  
 
Peak Area Mean Width  
1 100.0 12.7 6.3 
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 TABLE C.13.  Particle size analysis of 5-FU loaded (in dimethyl formamide) 4 arm 
PMMA-b-PAA having 2 mg/ml concentration in PBS. 
 
 
Size(nm) Intensity Volume Number   
 
4.6  0.0 0.0 0.0  
5.7  0.0 6.7 14.1    
7.2  1.5 20.1 35.1    
9.1  2.9 25.2 30.7  
11.4  4.5 20.5 13.3   
14.4  5.9 13.9 4.8  
18.1  6.3 7.9 1.4  
22.9  5.4 3.7 0.4   
28.8  3.3 1.3 0.1  
36.2  1.0 0.3 0.0   
45.6  0.0 0.0 0.0  
57.4  0.0 0.0 0.0   
72.3  0.0 0.0 0.0    
91.0  0.9 0.0 0.0  
114.6 4.3 0.0 0.0  
144.3 9.9 0.0 0.0  
181.7 15.2 0.0 0.0  
228.7 17.4 0.0 0.0  
288.0 14.1 0.0 0.0  
362.6 6.7 0.0 0.0  
456.5 0.7 0.1 0.0  
574.8 0.0 0.0 0.0  
723.7 0.0 0.0 0.0  
911.2 0.0 0.0 0.0  
 
 
Peak Analysis by intensity 
 
Peak Area Mean Width  
1 30.8 17.7 19.8 
2 69.2 224.8 205.1 
 
Peak Analysis by volume  
 
Peak Area Mean Width 
1 99.7 11.3 8.9  
 
Peak Analysis by number  
 
Peak Area Mean Width  
1 100.0 8.7 4.9 
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 TABLE C.14.   Particle size analysis of 5-FU loaded (in 1% acetic acid solution) 4 arm 
PMMA-b-PAA having 2 mg/ml concentration in PBS. 
 
 
Size(nm) Intensity Volume Number   
 
2.3  0.0 0.0 0.0  
2.9  0.0 0.0 0.0    
3.6  0.0 0.0 0.0    
4.6  0.0 0.0 0.0  
5.7  0.0 4.4 11.3   
7.2  1.2 14.9 30.5  
9.1  3.5 22.6 31.0  
11.4  6.7 22.3 17.0   
14.4  9.8 17.2 7.1  
18.1  11.5 10.6 2.3   
22.8  10.4 5.3 0.6  
28.8  6.6 2.0 0.1   
36.2  2.4 0.5 0.0    
45.6  0.0 0.1 0.0  
57.4  0.0 0.0 0.0  
72.3  0.0 0.0 0.0  
91.0  0.8 0.0 0.0  
114.6 4.9 0.0 0.0  
144.3 11.8 0.0 0.0  
181.6 16.2 0.0 0.0  
228.7 11.9 0.0 0.0  
287.9 2.2 0.0 0.0  
362.5 0.0 0.0 0.0  
456.4 0.0 0.0 0.0  
 
 
Peak Analysis by intensity 
 
Peak Area Mean Width  
1 52.2 18.8 19.5 
2 47.8 180.7 123 
 
Peak Analysis by volume  
 
Peak Area Mean Width 
1 99.9 12.3 11.1  
 
Peak Analysis by number  
 
Peak Area Mean Width  
1 100.0 9.2 5.8 
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APPENDIX  D 
 
PARTICLE SIZE ANALYSIS BY AFM 
 
 
 
 
Appendix C.1. 4 arm PMMA-b-PAA (MW:4900/18000) dissolved in water at 25°C . 
Figure D.1.  4 arm PMMA-b-PAA (MW:4900/18000) dissolved in water at 25°C  
(n=2). 
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Appendix C.3. 4 arm PMMA-b-PAA (MW:4900/18000) degraded in water at 
37°C for 1 hour. 
Figure D.2.  4 arm PMMA-b-PAA (MW:4900/18000) degraded in water at 37°C 
for 1 hour (n=2). 
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Figure D.3.  4 arm PMMA-b-PAA (MW:4900/18000) degraded in water at 37°C 
for 1 day. 
 .  
 
Figure D.4.  4 arm PMMA-b-PAA (MW:4900/18000) degraded in water at 37°C 
for 5 days. 
 .  
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Figure D.6.  4 arm PMMA-b-PAA (MW:4900/18000) degraded in water at 37°C 
for 10 days. 
  
 
Figure D.5.  4 arm PMMA-b-PAA (MW:4900/18000) degraded in water at 37°C 
for 7 days. 
 .  
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